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Abstract
Indigenous plant species historically used for their medicinal properties are a
tremendous source for bringing newer and safer drugs to the market. A concerted
effort is needed to characterize their medicinal potential and identify new molecules
that could be exploited in modern medicine. The current study was undertaken to
study the anticancer properties of several indigenous plants that are used by the local
population of the Arabian Peninsula and beyond for various medicinal purposes.
Towards this end, we acquired different plant extracts from five plants, namely
Boswellia sacra (BS), Cleome droserifolia (CD), Teucrium muscatensis (TM),
Orchadenus arabicus (OA), and Acredocarpus orientalis (AO) that were screened
for their anticancer properties and mechanism of action. Of these, only the essential
oil from Boswellia sacra has recently been shown to have anticancer activity.
Thirty-two different organic extracts were obtained from these native plants.
Essential oil from Boswellia sacra was used as a control as well as to expand upon
its anticancer activity profile. Initially, the essential oil and the extracts were
screened for their anti-proliferation potential in two different human cancer cell lines,
MCF-7 and HeLa, to ensure that their anticancer potential was not missed. The cell
proliferation assay, MTT (3-(4, 5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium
bromide]), was used to study the effect of the oil and various extracts on cell viability
in a time and dose-dependent manner. Once all the extracts had been screened, a
select group of effective extracts were chosen from each plant for a more in-depth
analysis in a full panel of human breast cancer cell lines comprising of MCF-7 and
MDA-MB-231 and their normal counterpart, MCF-10A, as well as the prototypic
human cervical cancer cell line, HeLa. MCF-7 represents a hormone-responsive
breast cancer cell line, while MDA-MB-231 represents a non-hormone responsive
(triple receptor negative) breast cancer cell line.

The mechanism of cell death

induced by these extracts was explored by testing the activities of various caspase
enzymes induced during apoptosis, a major pathway of programmed cell death, using
caspase-specific glo assays and western blot analysis.

Finally, a few isolated

compounds and their derivatives obtained from these extracts were acquired from our
collaborators and tested to determine whether they could demonstrate the anti-

viii
proliferative effects observed using the crude extracts and if so, whether it was due to
apoptosis.
Test of the extracts using these assays revealed that some of the extracts
exhibited anti-proliferative activity against the targeted cancer cell lines. The antiproliferative effects of some of these extracts were found to be selectively more
active against breast cancer cell line than HeLa cells. The ATP-dependent CellTiterGlo® Luminescent Cell Viability Assay further confirmed the effect of the extracts
on cell viability. Test of the activity of different caspase enzymes revealed that some
of the effective extracts had the capability of inducing apoptosis. Western blotting
was used to confirm the role of various caspases in the activation of apoptosis.
Finally, isolated compounds from these extracts and their derivatives were screened
with the MTT assay for their effect on cell viability.

One of these isolated

compounds has shown promising anti-proliferative activity and could induce a
specific caspase, suggesting activation of caspase-dependent apoptosis. Thus,
analyses from these multi-pronged approaches have resulted in the identification and
characterization of extracts having anticancer potential from five indigenous plant
species. We are further characterizing their mechanism(s) of action as well as
exploring other cell death pathways that may be induced. Overall, our results
demonstrate that traditional medicinal plants can provide an excellent source of
natural raw material to isolate novel anticancer agents, enlarging the arsenal of new
molecules available to fight cancer.

Keywords: Indigenous medicinal plants, Arabian Peninsula, Boswellia sacra,
Cleome droserifolia, Teucrium muscatensis, Orchadenus arabicus, Acredocarpus
orientalis, anticancer, anti-proliferation, apoptosis, caspases, anticancer drugs.
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)Title and Abstract (in Arabic

تعريف و توصيف إمكانية مكافحة السرطان باستخدام النباتات الطبية المحلية في شبه
الجزيرة العربية
الملخص

عرفت عبر التاريخ األنواع المختلفة من النباتات المحلية باستخداماتها الطبية و تعتبر
هذه النباتات مصدراً غنيا ً يجب استثماره لتحضير أدوية جديدة تكون آمنة طبياً .في الدراسة
الحالية تم جلب خمس من النباتات المحلية المستخدمة طبيا في شبه الجزيرة العربية أال و هي:
اللبان ( ،)Boswellia sacraالعفين () ،)Cleome droserifolia (CDالجُعدة
() ،)Teucrium muscatensis (TMالسحلبية ()،)Orchadenus arabicus (OA
القفص (( 23 .)Acredocarpus orientalis (AOمستخلصا ً استخلص من هذه نباتات و
استخدم في التجارب بغرض تحديد ما إن كانت هذه المستخلصات ذات خصائص مكافحة
للسرطان ،باإلضافة إلى زيت اللبان الذي يعرف بخصائصه المكافحة للسرطان و الذي أضيف
إلى الدراسة لتأكيد و تفصيل تأثيره على الخاليا السرطانية.
فعالية هذه المستخلصات في مكافحة السرطان تم اختبارها على نوعين من الخاليا
السرطانية MCF-7 :و  HeLaللتأكد من أن مفعولها المضاد للسرطان .باستخدام اختبار تكاثر
الخاليا ( )MTTمع تغيير جرعات هذه المستخلصات و وقت التعرض لها تمت دراسة تأثيرها
على تكاثر الخاليا السرطانية .بعد التحقق من جميع المستخلصات تم اختيار مجموعة
مستخلصات من كل نبتة و دراستها بعمق في أنواع مختلفة من خاليا الثدي السرطانية MCF-7
و MDA-MB-231و نظيرها خاليا  MCF-10Aالطبيعية و خاليا المهبل السرطانية
 .HeLaخاليا الثدي السرطانية  MCF-7تعبر نموذجا يستجيب للعالج بالهرمونات بينما
 MDA-MB-231ال تستجيب للعالج بالهرمونات .خالل هذه الدراسة استخدمت تقنيات متعددة
لتحديد تأثير هذه المستخلصات على نمو و تكاثر الخاليا السرطانية إضافة إلى آليات عملها.
أخيرا ،تم استخراج بعض المركبات الفعالة و مشتقاتها من هذه المستخلصات بواسطة
المتعاونين معنا لتحديد المكون المسؤول عن التأثير الذي لوحظ على تكاثر الخاليا السرطانية و
ما إن كان له عالقة بموت الخاليا المبرمج.
نتائج هذه الدراسة أظهرت أن بعض المستخلصات أثرت على تكاثر و نمو الخاليا
السرطانية و تسببت بخفض أعداد الخاليا .كما و أن قوة التأثير اختلفت من مستخلص آلخر،

x

حيث أن بعضها كان له تأثير أقوى على خاليا الثدي السرطانية بينما البعض اآلخر كان تأثيره
أقوى على خاليا المهبل السرطانية .تبين من دراستنا أن هذه المستخلصات تعمل على تفعيل
بروتينات الكاسبيز المسؤولة عن تنشيط عملية الموت المبرمج للخاليا مسببة تباطؤاً في عملية
تكاثر الخاليا السرطانية .أيضا أظهرت دراسة المركبات الفعالة الستخرجة من المستخلصات
مركبا ً واعداً كان له تأثير على تكاثر الخاليا السرطانية من خالل تحفيز إفراز بروتين كاسبيز
معين مما يجعلنا نقترح أن آلية عمله هي من خالل تنشيط موت الخاليا المبرمج بواسطة
بروتينات الكاسبيز .ختاماً ،نتائجنا أظهرت أن النباتات المستخدمة في الطب الشعبي هي مصدر
طبيعي و غني الستخراج مواد لها مفعول مكافح للسرطان ،موفرة بذلك آفاقا ً و موارد جديدة
لمحاربة مرض السرطان.
مفاهيم البحث الرئيسية :نباتات طبية محلية ،شبه الجزيرة العربية ،اللبان ،العفين ،الجُعدة،
السحلبية ،القفص ،مكافح للسرطان ،تباطؤ في التكاثر ،موت الخاليا المبرمج ،بروتينات
الكاسبيز ،أدوية مضادة للسرطان.
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Chapter 1: Introduction
1.1 Herbal Medicine
Ethnomedicine, or more precisely “ethnobotanic medicine” is defined as the
use of plants by humans as medicines [1, 2]. Ethnopharmacology, on the other hand,
is transformation from using plants as medicine to drug discovery involving the
observation, description, and experimental investigation of drugs and their biological
activities [3]. This approach is dependent on botany, chemistry, biochemistry,
pharmacology, and other factors such as anthropology, archaeology, history, and
linguistics which have led to establishing the biological activity of natural products
[4]. Humans have used plants as medicine since the earliest signs of civilization can
be traced. For centuries, use of natural products with therapeutic properties has been
recorded as medicine in almost all ancient civilizations, including Chinese, Indians,
and North Africans, providing evidence of utilizing plants as a treatment of different
diseases [5, 6].
Greeks were the first to classify and describe plants in order to identify them.
Europe played an important role in the production of medicinal plants used to heal
pain [7]. The 19th century saw the beginning of scientific investigation and isolation
of active compounds from medicinal plants, for example, discovery of quinine from
Cinchona bark by the French scientists Caventou and Pelletier [7]. This discovery
opened the interest to find other plants from the New World in jungles and forests for
new medicines. Explorers searched for a long time looking for new natural resources,
while the well-equipped phytochemistry laboratory of Harbonney became the center
for isolation of active principles of medicinal plants from the globe [7]. Numerous
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flavonoids were isolated and expanded rapidly by pharmaceutical companies later
on.
Many natural products isolated from plants before World War II (WWII) are
still in clinical use today for example, morphine and codeine from opium poppy,
digoxin from Digitalis leaves, atropine from hyoscyamine and hyoscine from
Solanaceae.

During and after WWII, many antibiotics were isolated from

Penicillium, Cephalosporium, and Streptomyces. After WWII, other drug discoveries
were made, such as reserpine from Rauwolfia (a pain-killer) and also vinblastine and
vincristine from Catharanthus roseus, which were effective in cancer chemotherapy
[7]. Later on, a lot of successful clinical agents were transferred from research teams
to pharmacologists and synthetic chemists. For example, use of atenolol which is a
beta-blocker and captopril (ACE-inhibitor) used for the treatment of hypertension,
salbutamol (adrenergic receptor stimulant) used for asthma, and benzodiazepines
(hypnotics and anxiolytics) used for insomnia and anxiety attacks [7].
Thus, plants have enormous medicinal properties, which make them a
valuable source of new medicines. According to the World Health Organization
(WHO), almost 65% of world population uses traditional medicines as a source of
therapeutic agents for their healthcare [8]. Plants can be a source of bioactive
compounds for direct use as drugs, as described above. Another importance of plants
is to produce bioactive compounds of novel or known structures, leading to the
synthesis of compounds which have high activity and lower toxicity. For example,
metformin, nabilone, oxycodone, taxotere, teniposide, verapamil, and amiodarone
are derived from plants [9]. Also the whole plant or part of it can be used as cure in
our diet such as cranberry, echinacea, feverfew, garlic, etc. The numbers of plants on
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the planet are estimated to be around 250,000 [10]. Only 6% of these plants have
been screened for their biological activity and 15% evaluated for their phytochemical
composition [11]. With advanced screening methods, the number of plants screened
should change.
The importance of obtaining different therapies from nature used for different
diseases cannot be underestimated. Around 25% of our current drugs come from
plants. From 252 drugs considered basic and important by WHO, 11% are of plant
origin. A majority of these drugs are obtained from plants. Natural compounds are
the leading therapeutic agents, allowing the design and rational planning for new
drug discovery, synthesis development, and discovery of new therapeutic properties
not connected to known compounds [12]. Considering that in 1991 in the US, of
every 10,000 pure compounds biologically evaluated, only 20 were tested in animal
models, of those only 10 were evaluated clinically, and only one reached the US
Food and Drug Administration (FDA) for approval for marketing through 10 years
costing US $231 million [13], it is critical that new compounds should be
continuously isolated and screened from plants.
1.2 Cancer Overview
Cancer is an uncontrolled growth of abnormal cells which results from
alterations in DNA. These alterations change the genetic information and prevent the
proper function of normal cells, leading them to divide without stopping and spread
to surrounding tissues. All types of cancer can start anywhere in the human body
made up of trillions of cells. It is one of the most common causes of morbidity and
mortality worldwide [14]. Globally, the National Cancer Institute (NCI) reports that
in 2012, there were 14 million new cases and 8.2 million deaths worldwide [15]. It is
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expected to rise to 22 million new cases within the two next decades. In the US,
between the years 2008 and 2012, there were about 454.8 cases and 171.2 deaths per
100,000 men and women per year. In 2015, there were ~1,658,370 new cases of
cancer in the US and it is estimated that 589,430 will die from the disease [16]. By
2024, the new cases are expected to be around 19 million in numbers [16-18].
In the UAE, the most common cancers in men are colon and rectum cancers,
while breast cancer is the most common in women. The overall incidence of cancer
in men was 89.8, while the mortality was 76.1 per 100,000 population. On the other
hand, the incidence of cancer in women was ~111.6-139.9 and mortality was 69.2
per 100,000 populations [19].
1.2.1 Causes of cancer
Cancer cells begin when the genes controlling basic cell function such as how
they grow and divide are altered or mutated. These genetic changes can be inherited
from the parents or modified by environmental factors such as tobacco smoke,
radiation, and ultraviolet rays from the sun. In addition, they affect three main groups
of genes, including proto-oncogenes, tumor suppressor genes, and DNA repair genes,
which are also called drivers of cancer [20]. Proto-oncogenes play an important role
in assuring regulated cell growth and division in normal cells, but in cancer cells they
are altered or activated to become cancer causing genes (oncogenes), allowing cells
to grow and survive when they should not. Tumor suppressor genes control cell
growth and division in normal cells, whereas in cancer cells these genes are mutated,
leading to dysregulated and uncontrolled cell division. DNA repair genes are
involved in the repair of damaged DNA in normal cells, but these genes are altered in
cancer, leading to the development of other mutations, ending up causing the cells to
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become cancerous. These genes are important in the fidelity of DNA replication,
assuring normal cell growth and division. Furthermore, cancer cells have biological
capabilities that are required for the successful development and complexity of
tumors in humans, including uncontrolled growth of cells, loss of cell differentiation,
ability to ignore signals involved in normal cell growth and death, and the capability
to influence normal cells, molecules, and blood vessels to supply the tumor with
oxygen and nutrients (microenvironment) [20]. Also, they can evade the immune
system that protects the body in order to hide from it or use the immune system to
prevent it from killing the cancer cells. All of these factors make cancer a very
successful disease.
1.2.2 Breast cancer
Breast cancer is the most common cancer in US women according to NCI
with124.8 diagnosed and 21.9 deaths per 100,000 women per year based on 20082012 data [16]. In 2012, there were 2,975,314 women living with breast cancer in the
US alone [17]. Around 12% of women will be diagnosed in their lifetime based on
2010-2012 data [17]. It is estimated that 231,840 women will be diagnosed and
40,290 deaths will occur in women in the US in 2015, while 1% accounts of the
breast cancer cases and deaths will occur in men [16-18]. In the UAE, the incidence
of breast cancer was 33.9-45.8 per 100,000 populations, accounting for 31-43% of all
cancer patients, while the breast cancer mortality was 10.1-13.1 per 100,000
populations, accounting for 8.2-12% of all cancer deaths in 2012 [19]. Recently,
breast cancer incidence has declined compared to the last decade as a result of the
development of better diagnostic techniques using mammography and treatment
strategies that have reduced the number of women using postmenopausal hormonal
therapy which had increased the incidence of invasive breast cancer as reported in
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the UK and the US [16-18].
Genetic mutations in BRCA1 and BRCA2 genes [21-25] and the family
history [26] are known as the most important risk factors for hereditary breast cancer.
However, there are other risk factors associated with the sporadic form of breast
cancer development such as increase in a women’s age (ranging from 45-54 years
[17], environmental factors [27, 28], hormonal therapy history [29], obesity [30, 31],
and alcohol intake [32].
Breast tumor development begins once a genetic mutation arises which
causes the mutated breast cell to divide and proliferate preferentially, leading to more
cells with the same mistake [20]. Then, the uncontrolled growth of cancer cells leads
to hyperplasia. After that, cancer cells proliferate too much as a result of further
damage, leading to further abnormalities (atypia). The cells loose a sense of
orientation and become blind to the surrounding cells and body’s signals to stop
proliferation, a process called dysplasia. The progression of breast cancer involves
pathological and clinical stages, starting with in situ carcinoma when cells become
more abnormal in growth and appearance, but have not broken around the tumor
through a boundary where the tumor is contained. Once the cancer cells break
through the boundary and invade nearby tissues, the cancer can be life threatening
and is called invasive cancer or primary tumor. Finally, when invasive cancer cells or
primary tumor gain the ability to enter the blood stream and travel to distant areas
(metastasize), it leads to secondary tumors (metastases) which is life threatening
[20].
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1.3 Cancer and Herbal Medicine
Many medicinal herbs have been used for the prevention and treatment of
cancer. Around 60% of anti-tumor and anti-infectious drugs on the market are from
natural origin under clinical trials and the number of new anticancer drugs are
increasing [33]. It is presumed that natural compounds are safer than synthetic
compounds as a result of their presence in diet, wide availability, and tolerability
[34]. The bioactive compounds isolated from medicinal plants can be developed as
anticancer agents. Many studies have demonstrated the anti-tumor properties of
products isolated from plant sources. For example, Camellia sinensis (green tea) is
the most popular beverage used in the world after water. It has a distinctive group of
polyphenols called catechins [34]. There are four major bioactive components in
green tea: epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin3-gallate (ECG), and epicatechin (EC). Green tea has been shown to suppress cell
growth and kill cancer after distinguishing tumor cells from normal cells [35]. Tea
consumption has inhibitory carcinogenic effect at many organ sites. Green tea has the
ability to inhibit the development of experimental rodent skin tumor [36], growth of
tumor cells [37], invasion and metastasis [38, 39], and angiogenesis [40, 41]. Many
studies suggest that people who drink more green tea have a lower risk of prostate
[42, 43] and breast cancers [44].
Curcuma longa (Curcumin) is the yellow pigment in turmeric. It is a wellknown spice in Southeast Asia [34]. Since the 1980s, curcumin has been shown as
the chemopreventive agent known to suppress many biological factors important for
proliferation of cancer cells [45-51]. Curcumin administration allows gradual decline
of the tumor growth rate and increases animal survival significantly [35]. In addition,
curcumin is able to suppress hemoglobin concentration in tumor cells, indicating

8
inhibition of angiogenesis. As a result of the poor absorption of curcumin in the
blood stream, researchers are looking at its derivatives which may have enhanced
bioavailability [52]. In a glioblastoma xenograft model system, curcumin has been
shown to inhibit tumor growth as well as angiogenesis [53]. Other studies have
shown that curcumin has an inhibitory effect on colon carcinogenesis as
demonstrated in rodent models [54, 55]. It also inhibits the initiation and promotion
of skin cancer [56]. Curcumin can inhibit the growth of cancer cells from multiple
organs sites in vitro, as tested in xenograft models by induction of cell cycle arrest
and apoptosis [57-60]. Synergistic anticancer activity of curcumin has been observed
with genistein [61], green tea [62], and embelin [63].
Vitis vinifera (red grape) is rich in resveratrol (3,4,5-trihyroxystilbene) which
is the bioactive anticancer agent found in red grapes, red wine, and mulberries [34].
Resveratrol can prevent cancer by inhibiting cyclooxygenase enzymes and
angiogenesis with modulation of drug metabolizing enzymes [35]. Experimentally, it
has been shown to have protective effects against carcinogenesis [64-65, 66]. It is
well known that it has antioxidant potential and anti-inflammatory activity [67]. It
seems to affect cell cycle and apoptosis pathways involved in the process of
preventing cancer [68]. In addition, it has affects against all stages of carcinogenesis
of skin cancer in mice [69]. Another advantage of resveratrol is that it can be applied
before or after UV exposure to decrease the incidence of skin cancer in mice [70].
The prophylactic use of reserveratol has been shown to reduce the number and size
of tumors in esophageal, intestinal, and colon cancers [70, 71]. In addition, it is
effective against cancer of other tissues such as liver, pancreas, gastrointestinal tract,
lung, and soft tissues [57, 72, 73].
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Other than these specific foods, daily consumption of vegetables develops the
immune system and fights diseases like cancer [35]. Generally vegetables have
sulforaphane and the flavonoid luteolin, especially in broccoli, celery, cabbage,
spinach, green pepper, and cauliflower [34]. Sulforaphane and luteolin both have
anti-inflammatory and anticancer activities [74]. Luteolin has been found to induce
cell cycle arrest and apoptosis in various cancer cells, including oral squamous [75],
esophageal [76], lung [77], colon [78], and liver [79]. In in vitro and in vivo studies,
it has been shown to inhibit cell growth and induce apoptosis in prostate cancer [80].
Other studies have shown that luteolin increases the efficacy of chemotherapy
(cisplatin) in gastric cancer [81]. It has the ability to decrease the development,
initiation, and post initiation stages of colon cancer in animal model systems [82].
Many other dietary and medicinal natural compounds are under investigation
for their anticancer activity [34]. These compounds include ellagic acid, some
triterpenes (such as lupeol, betulinic acid, ginsenosides, oleanolic acid) and ginkolide
B. Ellagic acid is an antioxidant polyphenol found in many fruits and vegetables like
grapes, strawberries, raspberries, pomegranate, and nuts [83, 84]. It has been shown
to have chemopreventive activity against skin, lung, esophageal, colon, bladder,
prostate, and breast cancers [83, 84]. Triterpenes, lupeol, and betulinic acid have
been tested in cell culture and animal models for their chemopreventive activities and
shown to have activity against multiple cancer types [85]. Ginkolide B from
Ginkobiloba extracts has also been tested for its chemopreventive activities against
many types of cancers [86, 87].
Many disorders such as atherosclerosis, arthritis, Alzheimer disease and
cancers are due to increased concentrations of free radicals in the body as well as
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from ultraviolet radiation and other environmental pollutants [88]. This results in
disequilibrium in the antioxidant pro-oxidant balance [89, 90]. Antioxidants isolated
from plants have well-known health promoting effects which donate an electron to
compromised molecules to bring them back to proper function [91]. For example,
many flavonoids (baicalein, baicalin, luteolin), monoterpenoids , triterpenoids
(oleanolic and ursolic acids), glycosides, and phenolic compounds (caffeic acid,
chlorogenic acid, ferulic acid, p-coumaric acid, and vanillic acid) in the plantago
species have been used for treating different diseases such as inflammation, disorders
of respiratory and digestive organs, reproductive system, blood circulation and
cancer due to their immunomodulatory activities [92].
Flavonoids and phenolic acids are metabolites from plants with polyphenolic
structure and high potential antioxidant effect. Flavonoids are classified into six
major subgroups: flavones (luteonin, apigenin, tangeritin), flavonols (quercetin,
kaemferol, myricetin, isorhamnetin, pachypodol), flavanones (hesteretin, naringenin,
eriodictyol), flavan-3-ols (catechins and epicatechins), isoflavones (genistein,
daidzein, glycitein), and anthocyanidins compounds (cyanidin, delphinidin, malvidin,
pelargonidin, peonidin, petunidin) [93]. Other flavonoid groups include aurones,
xanthones, and tannins. Flavonoids are available in our daily diet [94, 95]. Almost
6000 flavonoids have been identified in plants [96, 97]. Flavonoid components that
accumulate in the vacuoles of the plant cells are called glycosides. Differences in
glycosides are due to the number and type of sugars involved in glycosylation [98].
Flavonoids are known for their antioxidant activity important for oxidative stress
balance. Oxidative stress is involved in initiation and development of many
pathological conditions such as inflammation, autoimmune diseases, cataract, cancer,
Parkinson’s disease, arteriosclerosis, and aging [99]. Thus, consumption of high
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antioxidant rich fruits and vegetables should reduce the risk of many cancer types,
suggesting that antioxidants are effective agents for inhibiting cancer [100].
Polyphenols from different plants have been considered as anticancer agents
as well tested in many cancers cell lines at different stages of cancer growth. For
example, kaempferol, quercetin, anthocyanins coumaric acid, and ellagic acid
isolated from strawberry inhibit the growth of human cancers in breast (MCF-7), oral
(KB, CAL-27), colon (HT-29, HCT-116), and prostate cancer cell lines (LNCaP,
DU-145) [101,102]. Previous studies with similar effects have been reported from
isolated polyphenols such as resveratrol, quercetin, catechin, and epicatechin from
green tea polyphenols (epigallocatechin, epicatechin) [103].
It has been shown that flavonoids have anti-proliferative activity against
several cancer cell lines [104]. It is reported that citrus flavonoids inhibit the growth
of leukemia cells (HL-60) [105] and other cancer cell lines [106]. In addition, they
are promising agents due to their safety, low toxicity, and general acceptance [107,
108]. Kaempferol is also a type of flavonoid, which has shown inhibition of the
growth of ovarian cancer (91%) and breast cancer cell lines (94%) [109].
Epigallocatechin 3-gallate is an effective anti-angiogenic agent, inhibiting invasion
and proliferation of tumor cells [110]. It also has been shown to inhibit the growth of
bladder tumor cells and breast cancer cell lines [111]. Quercetin has antiinflammatory activity, which inhibits the inflammation processes directly [112]. In
addition, some tests have revealed anticancer properties of quercetin, including the
inhibition of proliferation and migration of cancer cells [113]. In addition, quercetin
is involved in mortality of prostate cancer showing 90% death within 48 hours and
no mortality on normal cells [114]. Gallic acid, caffeic acid, and ferulic acid also
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have been shown to have anticancer activities [115, 116]. Luteolin is a common
flavonoid in many types of plants, including fruits, vegetables, and medicinal herbs.
Studies have shown that luteolin has the potential for cancer prevention and therapy.
It induces apoptosis cell death in many kinds of cancers [117-120] inhibits cancer
cell proliferation [121-123], and suppresses angiogenesis of tumors [124].
Thus, phytochemicals isolated from the plants or natural compounds are
promising anticancer agents due to their multiple inhibitory activities, especially for
the various stages of cancer, including initiation, development, and angiogenesis.
1.4 Genes and Cancer
Human cancers are strongly linked to genetics. Approximately, 350 genes are
thought to be involved directly or indirectly to cancer [125].

Accordingly,

controlling genes could be a treatment or prevention of cancer. In order to improve
the drugs used in treating cancer, the pharmaceutical industry has moved from monotargeted to multi-targeted drugs, competing with natural compounds, which are
naturally a multi-targeted therapy.
NF-KB and STAT 3 transcription factors are involved in expression of more
than 400 genes crucial for prevention and treatment of cancer [126, 127]. They are
responsible for transformation to cancer cells, their survival, proliferation, invasion,
angiogenesis, and metastasis. Cancer cells are found to express the active forms of
these transcription factors [126, 127]. Other studies have shown that environmental
factors, high fat diet, stress, alcohol, and infections activate NF-B and most growth
factor receptors like EGFR, HER2, TNF also activate NF-B [128]. Aggarwal and
coworkers identified compounds from fruits and vegetables and other traditional
medicine, which can suppress these pathways and their downstream gene products.
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For example, curcumin can suppress both NF-B and STAT3 pathways in various
cancers, leading to inhibiting the survival of tumor cells, suppression of proliferation,
and invasion [129]. Other natural compounds that have shown similar effect using
cell culture and animal model systems, including capsaicin from red chili,
thymoqinone (TQ) from black cumin, anethole from fennel, eugenol from cloves,
and zerumbone from ginger. These natural compounds can activate the NF-B
signaling cascade, translocation of NF-B to the nucleus, DNA binding of the
dimers, or interactions with the basal transcriptional machinery. The inhibition of
NF-B results in inhibition of its target genes including Bcl-2, cyclin D1, matrix
metalloproteases, VEGF, and others [128].
The tumor suppresser gene p53 controls the cell cycle, apoptosis, genomic
integrity, and DNA repair [130, 131]. When p53 is activated, it binds to DNA
regulatory sequences, resulting in cell cycle inhibition, apoptosis, genetic stability
and inhibition of angiogenesis [132-134]. For example, EGCG in green tea induces
the expression of p53 and its targets p21 and BAX in prostate and breast cancer cells
[135, 136]. Induction of cell cycle arrest and apoptosis is observed by luteolinactivated p53 and its targets p21, BAX, and PUMA [81, 137]. The same effect has
been observed for curcumin [138, 132] and soy isoflavone genistein in glioma cells
[133].
Other regulatory elements can also be inhibited by phytochemicals such as
activator protein AP-1 that activates transcription and mediates gene activation [134].
The target genes for AP-1 are involved in survival, metastasis, angiogenesis,
proliferation, invasion, and differentiation [134]. Green tea (EGCG) [139],
resveratrol [140], and curcumin [141] have been shown to suppress AP-1 activation.
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Growth factors such as EGF, PDGF, FGF, tumor growth factor (TGF),
insulin-like growth factor (IGF), and colony stimulating factor (CSF) are also very
important in the development of cancer [141]. Once these factors are activated, they
result in increased cell growth, suppression of apoptosis, and invasion by cancer
cells. This activates the downstream signaling pathways such as PI3K-AKT and RasMAPK. Natural compounds have the ability to target these signaling pathways and
inhibit cancer development [140-141]. For example, curcumin inhibits the EGFR and
IGF receptor pathways and enhances the chemotherapeutic effects of oxaliplatin
[142, 143]. EGCG increases the efficacy of erlotinib in head and neck cancer by
inhibiting the activation of EGFR, AKT, and ERK [144, 145] and IGF-1 receptor in
colon cancer cells [146]. Luteolin inhibits the IGF-1-induced activation of IGF-1R
and AKT in prostate cancer cells and activates the suppression of EGFR and
MAPK/ERK signaling pathways [147].
Angiogenesis is a very crucial step for cancer development, progression, and
metastasis. It is also involved in the resistance to chemotherapy and radiation. EGCG
inhibits cell viability, capillary tube formation, and migration of human umbilical
vein endothelial cell (HUVEC), and in xenograft model of pancreatic cancer, inhibits
the expression of angiogenic and metastasis markers (von Willebrand factor, VEGF,
CD31, MMP-2, MMP-7, MMP-9, and MMP-12) [148]. Luotenol inhibits VEGFinduced angiogenesis and tumor growth in xenograft model [149]. The inhibition of
angiogenesis in different studies has been suggested by curcumin [150, 151],
genistein [152, 153], rutin, naringin, apigenin, and vitamin E [153].
Flavonoids have been shown to enhance several anticancer biological
activities at nontoxic concentrations [154]. Many studies have shown the importance
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of flavonoids in chemoprevention and chemotherapy. As mentioned earlier, they are
also involved in the inactivation of carcinogens, have anti-proliferative action, cause
cell cycle arrest, induce apoptosis and differentiation, inhibit angiogenesis, have antioxidative properties, and can reverse multidrug resistance or a combination of these
mechanisms [154]. This shows that natural compounds such as flavonoids are
promising agents in anticancer drug development [154].
1.5 Cancer Treatments
There are many types of cancer treatments. The type of treatment is
dependent upon the type and stage of cancer diagnosed for the patient. Some people
need only one type of treatment, while others may require a combination regimen to
get rid of cancer cells. For example, surgery can be used to remove the tumor from
the body along with chemotherapy (chemicals) to kill the cancer cells preferentially
or stop their proliferation and/or radiation therapy to kill cancer cells and shrink the
tumors. However, chemotherapy and radiation affect normal cells as well that are
fast growing. Thus, these treatments are quite toxic to healthy cells as well. Thus,
there are many new approaches being developed for treating cancer to specifically
reduce and/or circumvent the side effects of the chemotherapy/ radiation treatments
harming the healthy tissues and organs. Alternative treatments or targeted therapy
could be the solution to give the highest effect against cancer cells and reduce the
side effects of the traditional therapies, which can be discovered from nature [14].
1.5.1 Breast cancer treatment
Breast cancer treatment depends upon the type of tumor as well as the patient.
In order to overcome these differences, breast cancer treatment plan is based on the
patient’s overall health, biology of the tumor, and the stage of the tumor [14]. The
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effective treatment strategies are divided into two main areas, including the local and
systemic therapy. Local therapy aims to remove the cancer from its origin or local
area, helping to ensure that cancer will not come back to that area using surgery with
or without radiation therapy to the breast area.
Systemic therapy (adjuvant therapy) depends on many factors such as stage,
grade and molecular status of the tumor and whether the tumor is hormone receptor
positive [14]. Tumor cells can express estrogen (ER), progesterone (PR), or human
epidermal growth factor receptors (Her2/neu) alone or in combination. Thus, breast
cancer can be categorized based on hormone receptor positivity status. Some tumors
are completely devoid of these hormone receptors and are called “triple negative”.
These tumors are the most difficult to treat. Depending upon the type of receptors
expressed, the therapy is modified. Systemic treatment standards include
chemotherapy, hormone therapy, and targeted therapy, which are used in addition to
the basic local treatment (surgery with or without radiation) as a prevention to
diminish the risk for metastasis. Systemic therapy includes estrogen antagonist
tamoxifen,

aromatase

inhibitor

(AI),

ovarian

function

suppression,

and

chemotherapy, giving the best outcome to the patients [155-159].
The treatment strategies being currently used need improvement because of
serious side effects of radiation and chemotherapy. Radiation therapy is associated
with several toxic effects such as radiation pneumonitis, cardiac events, arm
lymphedema, brachial plexopathy, contralateral breast cancer, and risk of second
malignancy. The overall incidence of pneumonitis [160] and cardiac mortality [161,
162, 163] due to exposure at delivery has been minimized since the 1990s due to
modern radiation therapy techniques such as brachytherapy or Accelerated Partial
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Breast Irradiation (APBI).

Similarly, other modifications to radiotherapy has

reduced contralateral breast cancer incidence [164] and risk of second malignancy
[165]. According to NCI, it reduces local recurrence [166]. However, it is strongly
recommended to use whole breast radiation after surgery to reduce recurrence of the
cancer within the breast. Radiation therapy after surgery results in significant
reduction of recurrence in 10 year, (19% for radiation therapy after surgery compared
to 35% for surgery alone [167]. Chemotherapy has its own set of toxic effects that
includes nausea, myelosuppression, alopecia, mucositis, heart failure, and
thromboembolic events [168] as well as premature menopause [169]. Thus, it is
important to modify these treatments to have the highest effect and lowest side
effects for patient safety. In addition, searching for new targeted or alternative
therapies against cancer from nature is essential.
Other more innovative therapeutic approaches are also being tried to improve
treatment strategies for breast cancer such as “immunotherapy”. One such strategy is
the use of monoclonal antibodies alone or along with radiation and chemotherapy as
a guide to attack cancer cells [170]. The importance of these antibodies are based on
the immune system, which recognizes and looks for cancer cells like an invader to
fight off the cancer. For example, Trastuzumab is a monoclonal antibody against the
HER2/neu receptor and can target tumors expressing high levels of this antigen. This
FDA-approved “drug” is being used in combination with chemotherapy to improve
patient survival and progression of cancer [170]. Another treatment design used in
clinical trials is to reduce and block the proliferation and metastasis of cancer cells
by using anti-angiogenic drugs which block the growth of new blood vessels. Cancer
cells are capable of creating their own blood supply in order to grow and spread as in
metastatic breast cancers. Similarly, cancer vaccines are being designed from cancer
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cells or their parts to stimulate the immune system defenses to fight and kill cancer
cells. These are still in clinical trials [170].
Another way to improve treatment choices is to create tumor profiling using
the genes involved in causing cancer to predict the risk of recurrence in patients
[170]. Accordingly, tumors with high score require aggressive treatment
(chemotherapy along with hormonal therapy), but tumors with low scores may
require only chemotherapy. In addition, doctors can help guide treatment options by
predicting the response of the treatment. For example, circulating tumor cells of the
patient can be studied to determine whether they will respond to certain
chemotherapeutic drugs [170].
1.6 Herbal Extract Preparation
Natural products from medicinal plants, their extracts, or pure compounds
may provide uncountable opportunities for new drugs because of their chemical
diversity [171]. Many types of phytochemicals such as flavonoids and phenolics
have been approved to have significant impact on health and cancer prevention
[172]. Utilization of natural products from medicinal plants starts with pre-extraction
and extraction of the medicinal plant compounds. Recently, it has become one of the
main areas of research and development which is applied in the pharmaceutical,
nutraceutical, and dermocosmetic sectors.
Pre-extract preparation of plant samples aims to preserve the biomolecules in
the plants before the extraction. The samples are prepared fresh, dried, grounded or
powdered from different parts of the plant such as leaves, bark, roots, fruits and
flowers. Grinding and powdering methods are used to lower the size in order to
increase surface contact between samples and extraction solvents. It is crucial for
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high quality efficient extraction. Different preparation methods of plants affect the
preservation of phytochemicals in the final extracts [173].
Extraction is the separation of medicinal active portions of plant by using
selective solvents through known methods and procedures [174]. The aim of
extraction is to separate the soluble metabolites from insoluble residues left behind.
Crude extracts using these methods have complex mixtures of metabolites such as
alkaloids, glycosides, phenolics, terpenoids, and flavonoids. Conventionally, solvent
extraction and steam distillation are used for extraction of herbs in small research
setting levels. Significant advances have been made in extraction methods which aim
to increase the quality of outcome and lower the cost. These methods include
microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE), and
supercritical fluid extraction (SFE) [173].
MAE technology uses microwave energy to help in separating the analytes
from sample into the solvent [175]. Depending upon absorption by the material, the
energy of microwave is transferred to heat [176]. The radiation from microwave
interacts with polarizable materials in the solvents and sample, heating the surface
and transferring heat by conduction. MAE is simple, environment friendly,
economical, and it reduces the extraction time and solvent volume. However, heat
denaturation is expected if proper conditions are not used [177], resulting in drastic
decrease in phenolics and flavanones caused by oxidation [175]. This method is
considered as selective, favoring the small phenolic molecules.
UAE technology uses high intensity, high frequency sound wave interactions
with materials. It does not require complex instruments and has lower cost. UAE has
a lot of possible mechanisms for ultrasonic extraction, such as cell disruption,
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improved penetration, swelling enhancement, and capillary effect [178]. The main
advantage of this technology is that it uses shorter time, small amounts of material,
minimum volume of solvents, and has higher extraction outcome. The disadvantage
is the effect of the ultrasound energy on active compounds of medicinal plants,
which could lead to affecting the active molecules through free radical formation
[174].
SFE is considered a non-conventional technology of solvent extraction, but
the application took time to take off due to sophisticated and expensive high pressure
equipment required [179]. It is currently a well-known method of extraction using
primarily CO2 as a solvent because of its low toxicity and selective extraction
properties [180]. At a specific critical temperature and pressure, CO2 can adopt
properties in between a gas and a liquid. At this stage, it can be used as a solvent to
penetrate into a solid plant material efficiently and extract compounds in contrast to
other conventional organic solvent methods. High pressure equipment is used during
the extraction in batch or continuous manner, leading to selective extraction based on
varied pressure. The solvent is put in contact with the plant material according to
desirable separation of the product. For sample preparation, cylindrical extraction
vessels are used [174]. For processing, the solid is placed in the extraction vessel and
the solvent is fed in until the target extraction conditions are reached. An advantage
of this technique is that the extraction co-solvent can be removed easily. Also, CO2 is
inexpensive, noncorrosive, odorless, and a clean solvent without residue left in the
product. It is considered non-toxic and harmless, has high diffusivity, low viscosity
and surface tension in pharmaceuticals [174, 181]. Other solvents can be used for
SFE such as hexane, butane, and pentane. SFE can also be used for extracting
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volatile compounds like essential oils without loss or degradation since extraction
can be caused at ambient temperatures compared to other techniques mentioned.
Essential oil extraction can be through distillation, including water, water and
steam, and steam distillation (hydrodistillation). Distillation has been used since
ancient times (5000 years) [182]. During and beyond the middle ages, crude
distillation was used to make floral or aromatic waters which means that distillation
was used in perfumery, tonics, in cooking, and for trading. Nowadays, distillation is
the most common process for extracting essential oils from plants. This procedure
gives the ability to the volatile components to be distilled at lower temperatures,
lower than the boiling points for their constituents, to be easily separated from
condensed water. The plant material is placed inside a sill and then sealed once
inside. Next, steam or water is used to break the plant material, removing its volatile
components. The components then rise inside connecting pipes, leading into a
condenser which cools the rising vapor giving the liquid form which is collected in
vehicles below the condenser [183].
1.7 Cell Death Pathways
Cell death is a vital pathway in biological systems in order to maintain
cellular and immunological balance in our bodies. Its disruption is involved in
pathological conditions ranging from degenerative diseases to autoimmunity and
cancer [184, 185]. It is considered a genetic program which is important in
eliminating damaged or infected cells from the body to keep normal development
and maintenance of tissue homeostasis in check, and an active immune system in
place. There are three main pathways for cell death in humans, including necrosis,
apoptosis, and autophagy (Fig. 1). Cell death modes have been studied for a long
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time. The findings suggest that there is cross talk between apoptosis, necrosis, and
autophagy, sharing similar initiator and effector molecules regulated by the same
pathways [186]. These pathways depend on the cellular context of the death trigger,
with apoptosis and necrosis working together in networks that involve autophagy.
1.7.1 Necrosis
Necrosis is characterized by unregulated and passive cellular explosion in
response to trauma [187]. The morphological features of necrosis involve swelling of
organelles (endoplasmic reticulum, mitochondria), rupture of plasma membrane, and
lysis of the cell [187, 188] (Fig.1a). In contrast, in apoptosis, cells become distended
and intact, while necrotic death is followed by inflammatory reactions [189].
Necrotic cells release factors to enhance inflammatory response [190] and activate
proteins of inflammasome, leading to inflammasome activation and proinflammatory cytokine release. The activation of inflammasome is induced by ATP
produced from mitochondria that are released from damaged cells [191]. It mediates
cell death in response to damage or pathology but not through normal development
[192, 193].
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Figure 1: Types of cell death and their morphological hallmarks.
Diagrammatic classification of different types of cell death. Morphological features
of a) a healthy cell, b) a necrotic cell, c) an apoptotic cell, and d) an autophagic cell.
PCD: programmed cell death [184].
1.7.2 Apoptosis
Apoptosis is also known as programmed cell death (PCD). It has been studied
intensively and is considered as the main mechanism of regulated cell death [194]. It
is activated during cell damage or stress, normal development, and morphogenesis.
Apoptosis is triggered by extrinsic stimuli through cell surface death receptors such
as Tumor necrosis factor (TNF)-α, Fas, and Tumor Necrosis Factor-Alpha-Related
Apoptosis-Inducing Ligand (TRIAL), or by intrinsic stimuli through mitochondrial
signaling pathways [195, 196]. Both the intrinsic and extrinsic stimuli lead to the
activation of cysteine aspartyl proteases (caspases), which results in mitochondrial
membrane permeabilization, chromatin condensation, and DNA fragmentation,
ending in cellular destruction [197]. Thus, apoptosis is a caspase-dependent cell
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death pathway, unlike necrosis which is a caspase-independent form of cell death.
The morphological changes of apoptotic cells are shown in Fig. 1c involving cell
shrinkage, chromatin condensation, cytoplasmic blebbing, apoptotic bodies, and
vacuoles in cytoplasm.
1.7.3 Necroptosis
Necroptosis is an alternative programmed necrotic cell death pathway, which
is triggered by the same death signals that induce apoptosis. It is common in vivo
during physical trauma, neurodegeneration, and death caused by ischemia or
infection (Fig. 1). The term apoptosis-like PCD is used to describe necroptotic death
with apoptotic features; however, it activates cell death in a caspase-independent
manner [198]. This type is controlled by mitochondria and the mitochondrial effector
protein Apoptosis inducing factor (AIF) [199, 200]. AIF is considered as inducer of
apoptosis -like cell death in experimental models [198]. The activity of AIF cleavage
and transformation to a soluble form (tALF) is triggered by calpains or cathepsins,
which are released from mitochondria and translocated into the nucleus. Their
release is increased depending upon increased levels of intracellular calcium or
extensive DNA damage [198]. Increased intracellular calcium levels trigger
depolarization and loss of mitochondrial membrane, generation of reactive oxygen
species (ROS), and poly ADP ribose polymerase (PARP). Activation of PARP is
followed by activation and release of AIF from the mitochondria.
1.7.4 Autophagy
Autophagy (self-eating) is involved in self-engulfment of cytoplasmic
material and intracellular organelles within double-membraned vesicles called
autophagosomes (Fig.1d). When an autophagosome is formed, it is followed by
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fusion with lysosomes to create autolysosomes, where the degradation takes place by
acidic hydrolases [201]. Autophagy is considered as cytoprotective and cell deathpromoting during normal development [202] and in disease [203]. It is important in
the normal turnover of long-lived proteins and organelles which is crucial for
maintaining healthy cells. The hemostasis is critical in cells such as neurons and
cardiomyocytes. The activation of autophagy is dependent on many factors,
including nutrition deprivation, growth factors depletion, and hypoxia [204, 205].
Cytoplasmic degradation is enhanced in response to stress and therapy-promoting
survival.
1.8 Apoptosis
Since the 19th century, many observations have been made suggesting the role
of cell death during physiological processes [206, 207]. The phrase “programmed
cell death” was introduced in 1964, when cell death was proposed as not an
accidental phenomenon but followed by controlled steps, leading to cellular selfdestruction [208]. Apoptosis is from Greek origin, meaning “falling or dropping of”,
such as when the leaves fall off trees or dropping off flowers. It emphasizes that
death is necessary for the life cycle of organisms, required for the development of
multicellular organisms, and regulation and maintenance of cells in physiological and
pathological conditions. The term is based on the description of morphological
processes that leads to controlled cellular destruction [192].
Apoptotic cells have special morphological changes mentioned earlier,
including cells shrinkage, deformation and losing contact with neighboring cells,
chromatin condensation and margination at the nuclear membrane, blebbing or
budding of plasma membrane, and finally cell fragmentation into compact enclosed

26
structures called “apoptotic bodies” that contain cytosol, condensed chromatin, and
organelles [209]. The activation of proteolytic enzymes activates the cleavage of
DNA into oligonucleosomal fragments, while other specific proteins determine the
integrity and shape of cytoplasm or organelles. Macrophages engulf the apoptotic
bodies, which are removed from the tissues without causing inflammation [209].
The mechanism of apoptosis is highly complex and refined. Caspases are
expressed in an inactive form (procaspases) in most of the cells and when activated,
they can activate other procaspases, allowing initiation of a protease cascade [210].
Also, some procaspases can aggregate and activate automatically. This proteolytic
cascade allows one caspase to activate other caspases, which amplifies the apoptotic
signaling pathways, leading to rapid cell death [210]. Caspases are able to cleave
proteins at aspartic acid residues as a result of their proteolytic activity. They vary in
their ability to recognize different specificities of amino acids, and induce
irreversible commitment towards cell death. Caspases serve various roles such as
initiators (caspase 2, 8, 9, 10), executioners (caspase 3, 6, 7), and inflammatory
caspases (caspase 1, 4, 5) [211, 212]. Apoptotic cells have extensive protein crosslinking as well, which is achieved by the expression and activation of tissue
transglutaminase [213]. Also, DNA breakdown is induced by calcium and
magnesium endonucleases, resulting in DNA fragmentation [214].
Another feature of apoptosis is that the apoptotic cells express cell surface
markers required for phagocytic recognition by neighboring cells in order to permit
quick phagocytosis with minimal compromise to surrounding tissues (Fig. 2). This is
accomplished by the outward movement of the cytoplasmic phosphatidylserine (PS)
lipid of the plasma membrane to the outer layer of the lipid bilayer [216]. The
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externalization of phosphatidylserine is a recognition ligand for phagocytes on the
surface of apoptotic cells. Recently, studies have shown that other proteins may be
exposed on the cell surface during apoptosis, including Annexin I and calreticulin
[216]. Annexin V is a calcium-dependent phospholipid binding protein that interacts
with phosphatidylserine residues and is used for the detection of apoptosis [217].
Calreticulin is a protein bound to low density lipoprotein (LDL) receptor protein
related to engulfing apoptotic cells and cooperates with phosphatidylserine as a
signal for recognition. The two main pathways of apoptosis activation are described
below:

Figure 2: Receptors and adaptor molecules involved in apoptotic cell recognition and
engulfment.
Phosphatidylserine (PS) exposure enables the recognition of apoptotic cells by
phagocytes. PS can be directly bound by either specific PS-receptors, such as brainspecific angiogenesis inhibitor 1 (BAI1), stabilin-2, and the T-cell immunoglobulin
mucin (TIM) proteins (TIM1 and TIM4), or indirectly via bridging molecules like
annexin A1 (anx A1), β2-glycoprotein I (β2GPI), the growth arrest-specific 6 (gas6),
the milk-fat globule EGF-factor 8 (MFG-E8), and protein S (prot S) [215].
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1.8.1 The intrinsic pathway
Mitochondria

is the regulator of intrinsic apoptosis pathway. It plays a

central role in the integration and propagation of death signals from the inside of the
cell in response to DNA damage, oxidative stress, starvation, and chemotherapeutic
drugs [218, 219]. Once the disruption of mitochondrial inner transmembrane and
mitochondrial membrane permeability is initiated, the homeostasis of basic cell
metabolic function is lost, such as ATP synthesis, oxidation of redox molecules
(NADH, NADPH, and glutathione), increase in reactive oxygen species, etc. [220,
221]. Also, osmotic swelling of mitochondria is enhanced, leading to the rupture of
outer mitochondrial membrane and release of pro-apoptotic proteins from
mitochondria into the cytoplasm [222, 223] (Fig. 3). Cytochrome c is one of the
proteins released to activate the apoptosome, caspase cascade, and other factors such
as AIF (224), the endonuclease G (endoG) [225], Smac/Diablo [226], and Htr/Omi
[227]. Intrinsic apoptotic pathway involves procaspase 9 activation, which activates
downstream mitochondrial pro-apoptotic events at the apoptosome. It is a cytosolic
death signaling protein complex formed when cytochrome c is released from the
mitochondria [228]. Caspase 9 activation is dependent on the dimerization of the
procaspase 9 molecules at Apaf-1 scaffold [229]. When the initiator caspase 9 is
activated, the other effector proteolytic procaspases such as 3, 6, and 7 are activated
and accordingly cleave specific protein substrates, resulting in mediation and
amplification of death signal to execute the cell death with all the morphological
features mentioned earlier [230].
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Figure 3: Schematic illustration of the intrinsic and extrinsic pathways of apoptosis
[231].
1.8.2 The extrinsic pathway
The extrinsic apoptosis signaling is dependent upon the activation of death
receptors [231]. They are cell surface receptors which transmit the death signals after
ligation with specific ligands. Death receptors belong to tumor necrosis factor
receptor (TNFR) gene superfamily, including TNFR-1, Fas/CD95, and TRAIL
receptors DR-4 and DR-5 [232]. TNFR members contain extracellular subdomains
consisting of cysteines for specific recognition of ligands, leading to trimerization
and activation of death receptors [233].

The signaling is transmitted to the

cytoplasmic part of the death receptor, which has conserved sequences, the death
domain (DD). Adaptor molecules like FADD or TRADD also have a death domain
that binds the DD of the receptors, leading to the formation of death-inducing
signaling complex (DISC). The adapter molecules also contain death effector domain
(DED) that is unmasked upon its interaction with the receptor, leading to the
recruitment of procaspase 8 and 10 to the DISC. Recruitment of procaspases to the
DISC results in autocatalytic cleavage, resulting in release of active caspase 8 and 10
which then activate other effector caspases, leading to the activation of the caspase
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cascade and eventually cell death [234]. The caspase-dependent extrinsic apoptosis
pathway is classified as type 1 [234].
In type 2 extrinsic pathway, the signal coming from the activated receptor is
not sufficient for activating the caspase signaling cascade for inducing cell death
(Fig. 3). Thus, in type 2 extrinsic death signaling pathway, the signal is amplified
through a mitochondrial apoptotic pathway provided by a Bcl-2 family member, Bid,
that links it to the caspase signaling cascade. Bid is activated (cleaved) by caspase 8
and translocated into the mitochondria, where it acts with pro-apoptotic Bcl-2 family
members, Bax and Bak, to induce cytochrome c release and mitochondrial proapoptotic factors into the cytosol [235]. Cytochrome c bound to Apaf-1 induces
ATP-dependent changes to activate oligomerization of the apoptosome (a wheel
structure with 7-fold symmetry). The wheel structure triggers the activation of
procaspase 9 (initiator caspase) [236]. The activated caspase 9 then initiates the
activation of other effector caspases such as caspase 3, 6, and 7, resulting in cell
death [237].
1.9 Apoptosis and Cancer
Cancer is a result of dysregulated apoptosis. In the 1970s, pathologists
observed morphological features of apoptosis following radiation and chemotherapy
[238]. This suggested that anticancer agents induce apoptotic cell death after drugtarget interaction. This observation had crucial impact on the development of
anticancer agents [239-241]. Furthermore, the reduction of apoptosis or its resistance
correlated with carcinogenesis. Anticancer agents inducing apoptosis reduced the
treatment sensitivity [242]. Figure 4 shows the mechanisms by which apoptosis can
be dysregulated in cancer:
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1) defects in p53 tumor suppressor gene
2) imbalance of pro-apoptotic and anti-apoptotic proteins
3) reduced caspase function
4) increased expression of inhibitor apoptosis proteins (IAPs)
5) impaired death receptor signaling

Figure 4: Mechanisms contributing to evasion of apoptosis in carcinogenesis [243].
Anticancer agents primarily induce apoptosis through one of these
mechanisms, while mutations in apoptotic programs may enhance drug resistance
[239, 244]. For example, mutations in the tumor suppressor gene p53 reduced
therapy-induced apoptosis in murine tumors [245, 246]. On the other hand, reintroduction of normal p53 in p53-mutant tumors and xenografts resulted in the
induction of apoptosis and tumor regression during chemotherapy [247, 248].
Similarly, mutations in p53 have been linked to more than 50% of cancers [249]. P53
is required for drug-induced cell death through apoptosis, especially in tumors
independent of p53 [247]. P53 contribution to drug-induced apoptosis is affected by
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factors such as the chemical agent, the dose, tissue, and mutation in the tumor [247,
250, 251]. The degree of apoptosis contribution to treatment sensitivity in cancers is
not clear, but some studies show correlation between p53 mutations and poor
treatment response [242,252]. P53 knock-out mice exhibit reduced apoptosis
following radiation or chemotherapy [253-258].
The Bcl-2 family of proteins comprise of both pro- and anti-apoptotic
proteins important in regulating apoptosis (intrinsic pathway though the
mitochondria) [259]. When expression of the anti- or pro-apoptotic members of the
Bcl-2 family members are disrupted, this results in dysregulated apoptosis in the
affected cells [243]. Similarly, abnormalities in death signaling pathways can lead to
reduction of apoptosis through the extrinsic pathway of apoptosis. For example, a
reduction of membrane expression of death receptors or abnormal receptor
expression has been reported to be involved in death signaling pathways in cancers
[260]. There are different strategies targeting apoptosis in cancer treatment as new
treatment options, for example, targeting p53 for cancer treatment. They can be
classified as gene therapy, drug therapy, and immunotherapy. The p53-based drug
therapy has been investigated for targeting apoptosis through many mechanisms. For
example, Phikan 083 is a small molecule and derivative of carbazole that has been
predicted to bind and restore mutant p53 function in silico [261]. P53 vaccines
(immunization) called p53-based immunotherapy has been tested in clinical trials for
mice with advanced-stage cancer [262]. In another strategy, Bcl-2 antisense therapy
has been tested in clinical trials as a targeted agent. It has shown good
chemosensitization activity in combination with other conventional anticancer drugs,
improving the survival in cancer patients [263, 264]. Caspase-based drug and gene
therapy has also been used in inducing apoptosis. For example, apoptin and human
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caspase 3 gene therapy are being used as targeted treatments for cancer. Many other
gene-targeted therapies are in clinical trials to enhance the apoptotic pathways and
develop novel treatment strategies for cancer.
1.10 Aims and Objectives of the Project
This project aimed to screen the anticancer activities of several indigenous
medical plants of the Arabian Peninsula along with their mechanism of action.
Towards this end, four to six different types of extracts were obtained from five
indigenous medicinal plants made sequentially with various solvents.

We

hypothesized that since these plants have been used for their medicinal properties,
the probability of their having anticancer activity was high. Thus, these were first
screened in a breast cancer cell, MCF-7, and a cervical cancer cell line, HeLa, to
determine if they had any anti-proliferation activity against these cell lines. Once
screened, selected effective extracts from each plant were further tested in a more
expanded range of breast cancer cell lines, including MCF-7 and MDA-MB-231, and
a normal breast cell line, MCF-10A. The MTT cell viablity assay was used to study
the effect of the various extracts on the growth of the cancer cell lines in a dose-and
time-dependent manner and the mechanism of action of cell death was explored by
testing the activities of various caspase enzymes using Promega glo assays. Western
blotting was used to confirm the results. Our studies not only characterized the
anticancer potential of five indigenous medical plants, but they also characterized the
anticancer potential of several isolated compounds and derivatives from these
extracts. In future, we plan to characterize the anticancer potential of both the crude
and some of the pure components further in depth to hopefully enlarge the pool of
new molecules to fight cancer.
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1.11 Introduction to the Indigenous Medicinal Plants Studied in this Thesis
Five different plants were investigated for their anticancer potential during
the course of this thesis (Fig. 5). A brief introduction into the history and
background on these plants is given below:

Figure 5: Photographic images of the five plants used in this study.
These plants included: Boswellia sacra, Acredocarpus orientallus, Cleome
droserifolia, Teucrium muscatensis, and Orchadenus arabicus [339].
1.11.1 Boswellia sacra (BS)
Sacred Frankincense as it is called, Boswellia sacra is the source of the famous
aromatic resin obtained from the gums of genus Boswellia (Burseraceae family)
(Fig. 5).

Boswellia species includes Boswellia sacra from Oman and Yemen,

Boswellia carteri from Somalia, and Boswellia serrata from India and China [265].
The resins are used in incense, fumigants, and fixative in perfumes. The aromas from
the resins were valued for their qualities in religious customs since the ancient
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Egyptians [266]. Boswellia species resins are considered as having a wealth of
healing properties. They have been used as a treatment of rheumatoid arthritis [267]
and inflammatory diseases like Crohn’s disease [268]. Their anti-inflammatory
activity has been associated with the regulation of immune cytokine production
[269], and leukocyte infiltration [270, 271]. Extracts from Boswellia species have
been shown to have anti-bacterial, anti-fungal [272], anti-carcinogenic [273], and
anti-neoplastic properties [274, 275]. Extracts from Boswellia resins have been
shown to reduce the peritumoral edema in glioblastoma patients [274] and reverse
multiple brain metastases in breast cancer patients [276]. All the earlier mentioned
results suggested that the resins from Boswellia species include active ingredients
that modulate important biological and health activities.
Other than resin, essential oils are an important product of aromatic plants.
Essential oils are called volatile or ethereal oils which are present as secondary
metabolites in lower amounts in different parts of the plants. They are rich and
concentrated hydrophobic liquids with aroma produced by the aromatic plants [277].
Other biological properties of essential oils are dependent on their constituents.
These constituents are classified based on their chemical structures. The constituents
are considered as less effective than essential oils because they have synergistic and
selective effects [278]. The essential oil produced from Boswellia is characterized by
a high content of monoterpenes, including piene, dipentene, phellandrene, and
cadinene [279]. It includes acidic components among them boswellic acids, which
are triterpenic acids such as alpha and beta boswellic acids [280], 11-alpha-hydroxybeta-boswellic acid, 3-O-acetyl-11-hydroxy-beta-boswellic acid, and acetyl-11-ketobeta-boswellic acid (AKBA) [281]. Recent studies have identified ether-soluble gum
fractions of sesquiterpenes, alcohols, esters, and boswellic acids, while the ether-
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insoluble gum fractions include polysaccharides [282, 283]. The non-volatile
components include diterpenoids, while the volatile oil components include
monoterpenes as hydrocarbons, alcohols, and ketones, sesquiterpenes, and diterpenes
[284]. The composition of the Boswellia essential oil differs in different climate,
harvesting conditions, and geographical source. For example, boswellic acids
isolated are different from resins derived from Indian, Somalian and Arabian regions
[283-289].
Thus, since ancient times, essential oil from Boswellia and its components have
been used as perfumes and flavoring agents in food products as a result of their
specificity of aromas. In addition, they have been used in aromatherapy to improve
health because they have sedative and stimulant properties. For example, they have
traditionally been used for massages, baths, and for inhalation and relaxation [290].
Essential oils are described as antioxidants [291, 292], and antimicrobial [293]. They
have been used for the management of severe diseases such as cardiovascular disease
[294], diabetes [295], and Alzheimer’s disease [296].

For example, asthmatic

patients have used it traditionally as it eases their breathing and has a soothing action
in colds, cough, bronchitis, and laryngitis [297]. It can also remove scars and stretch
marks [298].
The pharmacological activities of Boswellia sacra as a crude extract or an
essential oil, or the isolated compounds have been shown to have anti-bacterial, antifungal, and immunomodulatory activities [285, 299-304]. Other studies have shown
that B.sacra has anti-inflammatory, anti-leukotriene, anti-acetylcholinesterase, and
anticancer activities, especially due to the boswellic acids derivatives [305-312].
Tetra and pentacyclic triterpene acids such as tircuallic, lupeolic, and roburic acids
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(boswellic acids) have anti-inflammatory activity as a result of microsomal
prostaglandin E2 synthase-1 inhibition ability [313]. AKBA has been considered as
an anti-inflammatory agent which blocks leukotriene synthesis by inhibiting activity
of lipoxygenase [309]. AKBA has a protective effect in an induced mouse colitis
model [314].
Essential oils from Boswellia species are reported to have anticancer
properties [291, 315, 265]. They can be used to improve chemotherapy and
radiotherapy when combined by decreasing the side effects of the drugs. As a result,
they are considered as a source of novel anticancer compounds since the nature of
the essential oils allows them to cross the membranes of the cells and reach inside the
cells. Clinical studies have shown that boswellic acids can inhibit the growth of
cancer cells in vivo and in vitro, indicating cytotoxicity on cancer cells by multiple
molecular mechanisms involving transcription factors, signal transducers, and
growth regulating genes [280]. It has been proposed that AKBA and boswellic acids
have anti-neoplastic activity via anti-proliferation and pro-apoptotic activities in
several human cancer cell lines, including meningioma [316], leukemia [310],
hepatoma [317], melanoma, fibrosarcoma [318], colon cancer [319], and prostate
cancer [320-322]. Triterpenoic acids such as ursolic and oleanolic acid can inhibit
tumor initiation and promotion [323]. In addition, they have anti-inflammatory,
hepato protection, analgesia, cardiotonic, sedative, and tonic effects. Purified
compounds of Boswellia sacra triterpenoids acids, especially boswellic acids (BAS),
are the bioactive ingredients, which are responsible for the anti-neoplastic activities.
These compounds have chemopreventive effects in prostate [321, 324], cervical
[322], breast [265], colorectal [325], pancreatic [326], and bladder cancer cell lines
[327]. Boswellia sacra essential oil has been studied in human breast cancer cell
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lines and it was able to induce tumor-specific apoptosis and suppress cancer cell
proliferation by inducing Akt and ERK1/2 activation, cyclin D1 and cdk4 expression,
and caspases activation. [265]. It has also been shown to have anti-proliferative
activity against basal cell carcinoma of the skin [328]. In addition, it induces human
pancreatic cancer cell death in a xenograft murine model [329].
1.11.2 Orchadenus arabicus (OA)
Orchadenus arabicus is a medicinal plant from the genus Orchadenus
belonging to family Resedaceae [330] (Fig. 5). It is found mostly in the desert and
dry regions from 0-2000 meters above sea level of Saudi Arabia, Oman, UAE, and
Yemen [331-333]. Plants of Orchadenus have complicated branching systems with
deciduous leaves and occasional polygamous flowers with or without ephemeral
corolla. These characteristics are crucial for the plants in order to adapt to the climate
[334]. Orchadenus arabicus has medicinal properties and traditionally has been used
as a therapy for different ailments as a result of its anti-inflammatory, antioxidant,
immune stimulating, and hypocholestrimic activities as well as its ability to reduce
the risk of getting cancer and heart disease because of the presence of bioactive
compounds within this plant [335].
Orchadenus arabicus has several bioactive compounds such as flavonoid
[336]. These phyto-constituents accumulate in the aerial parts of the plant affected by
the biotic and abiotic factors [336]. The constituents include quercetin-3-O-betaglucosyl

(1-2)-alpha-rhamnoside-7-O-alpha-rhamnoside,

quercetin

glycosides,

quercetin-3-O-p-coumaryl(1-6)-beta-glucosyl(1-6)-beta-glucoside-7-O-alpharhamnoside, quercetin-3-gentiobioside, isoquercitrin, and other known kaempferol
glycosides, afzelin and astragalin [337]. Analysis of the nutritional composition of
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Orchadenus arabicus has shown that the fruits and leaves have higher levels of
carbohydrates, crude fats, fibers, proteins, moisture, ash, and energy values than
other parts of the plant [338]. Antioxidant analysis of Orchadenus arabicus extracts
show higher total phenolic and flavonoid contents, resulting in higher radical
scavenging activity compared to ascorbic acid, which is known for free radical
scavenging properties [338]. These observations make Orchadenus arabicus a good
candidate for the search of new types of anticancer molecules.
1.11.3 Acridocarpus orientalis (AO)
Acridocarpus orientalis is a medicinal plant of the genus Acridocarpus and
the family Malpighiaceae (Fig. 5). Locally it is called qafas. It is located in the wadis
and mountain foothills of UAE [339] growing in rocky areas up to 1500 meters in
height [340]. It has been found in the foothills of the Jebel Hafeet Mountain between
Oman and UAE [341, 342]. It has also been found to grow in the northern and
southern mountains of Oman [342] especially surrounding Jabal Shams [343], and in
Somalia [339] at elevations between 100-700 meters [344]. Acridocarpus orientalis
is a small, highly branched shrub, having stems with hairy, and yellow flowers in
clusters [344, 339]. Its yellow flower petals are not joined to each other [344, 339].
The flowers are bisexual, including male and female reproductive organs [345].
Often, the leaves are evergreen [345]. The young leaves are covered in reddish
brown hair, which are lost upon growth, creating smooth leathery leaves with
prominent veins [344, 339]. It is used locally as a pain relief medicine. The crushed
seeds from a crude extract and the oil produced from this plant are massaged onto the
forehead and joints [339, 342] to relieve pain from chronic headaches, paralyzed
limbs, and for muscle and tendon pain [346]. The seeds are used as a source of
yellow dye in Oman [341], but the reddish hair of the young leaves are used as a
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tanning agent and to treat udder inflammation in cattle [339]. Many reports indicate
that several plant species in the genus Acridocarpus are used as a medicine in Africa
for gastro-intestinal disorders, paralysis, and skin blisters (pemphigus) [346-349]. In
Oman, it is used as a topical application for treating paralysis [347]. The oil is also
applied as a moisturizer on face and body to make the skin softer [350].
Acridocarpus genus species have several phytochemicals, including five
triterpenes: beta-sitosterol [351], stigmasterol [352], friedelin [348], oleanolic acid
[353], ursolic acid [354] and five falvonoids: apigenin [355], luteolin [356], vitexin
[349], kaempferol [357], and quercetin [358]. Extracts of Acridocarpus orientalis
have been analyzed and screened for their phytochemicals. Phytochemical screening
has revealed the availability of primary and secondary metabolites including:
carbohydrates, phenolic compounds and taninns, flavonoids, and saponins [359]. The
free radical scavenging activity estimated for Acridocarpus orientalis extracts has
shown that the antioxidant activity increases with increasing concentration of the
extract [360]. Antioxidant-based drugs are used for treating and preventing diseases
including atherosclerosis, stroke, diabetes, Alzheimer’s disease, Parkinson’s disease,
cancer, and other diseases [361, 362]. Thus, Acridocarpus has great potential as an
important drug for various illnesses, including cancer.
1.11.4 Cleome droserifolia (CD)
Cleome droserifolia is a medicinal plant of the genus Cleome and family
Cleomaceae (Fig. 5). Locally Cleome droserifolia is called samwa [363]. Other
terminologies include rem el bard, afeen, and mashta in Arabic, while frossk in
English [364]. In addition, it has other names like “spider flower” and “mountain bee
plant” [365]. All of the Cleome species grow at similar locations with different soil
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types. Moist places and rocky regions are favored for some species, while others
grow in black fertile soil and rainy season, regions with waste water, and some in
shaded areas in red soil which develops in worm,temperate, and moist climate during
rainy season [365]. It includes 150 species in tropical and subtropical countries in the
Old and New Worlds [366]. Cleomaceae family is also found in North Africa [367]
and India [365].
Cleome droserifolia is used traditionally for improving stomachics and
rubefacients, as well as treating many ailments like scabies, rheumatic fever,
inflammation, etc. [368].

It has antimicrobial, analgesic, antipyretic, and anti-

inflammatory activities [369]. It has immediate effect on abdominal and rheumatic
pain, diabetes, inflammation, and from snake and scorpion bites [364]. In addition, it
improves carbohydrate metabolism [370], fights obesity [371], and has
hypoglycemic effects or is antidiabetic for treating diabetes mellitus [363, 372-375].
It is reported that it also has antimalarial effect [374] and antioxidant activity in
diabetic rats [376-380]. Though not much is known about its anticancer potential, a
related species, Cleome gynandra, has been shown to be effective when injected in
Swiss albino mice using Ehlrich’s ascites carcinoma cells [381, 382].
Several bioactive constituents have been isolated from Cleome droserifolia,
including three sesquiterpenes (buchariol, teucladiol, daucosterol) [383] and a
flavonoid derivative [375]. Other studies of Cleome droserifolia indicate the
presence of glycosides, carbohydrates, cardenolides, saponins, sterols, triterpenes,
tannins, catechins, and falvonoids [365, 384] and several triterpenoids [385-387].
These constituents are thought to be responsible for the hypoglycemic effect of
Cleome in rats [388-392] as well as its liver-protective properties [393]. In addition,
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Cleome species contain 13 flavonoids glycosides [394, 395], kaempferol 3glucuronide from roots [396], new naringenin glycoside [397], and three new
coumarino lignoids from seeds [398]. Furthermore, Cleome species have antioxidant
properties [367]. Thus, a combination of antioxidant/phytonutrients present in
Cleome makes it an attractive candidate for further drug discovery [362].
1.11.5 Teucrium muscatensis (TM)
Teucrium muscatensis is a medicinal plant of the genus Teucrium belonging
to Lamiaceae or Labiatae family (Fig. 5) [399]. All of the Teucrium species grow in
rocky limestone areas, dry mountain meadows and pastures, and at the edge of sparse
oak and pine forests up to 1000 meters above sea level. The genus includes 300
species distributed in central Europe, the Mediterranean region, Western Asia and
North of Africa [400-402]. Members of Lamiaceae family are highly aromatic,
durable grass plants, have small fleshy leaves, and are multi-branched stems with
callous white exterior [402, 338]. Teucrium species have traditional medical uses
since the times of Socrates and Jalinous [402]. They have been used in traditional
and modern medicine because of their bioactive constituents [403-406]. Species of
Teucrium are rich in phenolic compounds with strong biological activities. The
medicinal properties of the Teucrium genus includes antibacterial, anti-inflammatory,
and antipyretic activities [400]. Other species from the same family in areas like
Sardinia and Baronia of Siniscola has been used for its antimalarial activities [407].
Also, other species are reported that have hypolipidemic activities [408]. Research
shows that Teucrium species have anti-diabetic, anti-spasmodic, anti-inflammatory,
analgesic, and antioxidant effects [409-415]. Other species of genus Teucrium in
Europe are used for the treatment of digestive disorders, abscesses, gout,
conjunctivitis, and stimulation of fat and cellulite breakdown [416, 417].

43
Teucrium muscatensis and Teucrium species in general are known to contain
diterpenoids and triterpenoids in the aerial parts of the plant such as [418-421]. The
secondary metabolites from Teucrium species are glycosides, terpenoids, steroids,
tannins, and phenolic compounds [422]. These metabolites have general protective
functions in the human body involving antioxidant, anti-allergic, antibiotic, and
hypoglycemic, effects [423-424].
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Chapter 2: Materials and Methods
2.1 Cell Lines and Tissue Culture
The hormone responsive human breast cancer cell line, MCF-7 and the triple
negative human breast cancer cell line, MDA-MB-231, were obtained from Prof.
Samir Attoub, Department of Pharmacology, College of Medicine and Health
Sciences, UAE University, Al Ain, UAE. The normal breast epithelial cell line,
MCF-10A, was obtained from ATCC (USA). The human cervical cancer cell line,
HeLa, was a gift of Prof. Tahir A. Rizvi, Department of Microbiology and
Immunology, College of Medicine and Health Sciences, UAE University, Al Ain,
UAE.
MCF-7 and MDA-MB-231 were grown in DMEM/high glucose medium
(Hyclone, USA) supplemented with 10% FBS (Hyclone), 10,000 units/ml
penicillin/streptomycin (Hyclone), and 50 µg/ml gentamicin (Hyclone). The HeLa
cell line was grown in DMEM/high glucose medium (Hyclone) supplemented with
7% fetal calf serum (FCS) (Hyclone), 10,000 units/ml penicillin-streptomycin
(Pen/Strep) (Hyclone), and gentamicin (Hyclone). The MCF-10A cell line was
grown in DMEM/F12 medium (Dulbecco’s Modified Eagles Medium/Hams nutrient
mixture) (Sigma, USA) and 5% Horse serum (Sigma) supplemented with 10,000
units/ml of Pen/Strep 10 μg/ml, Insulin (Sigma), 20 ng/ml epidermal growth factor
(EGF) (Sigma), 0.5 mg/ml hydrocortisone (Sigma), and 100 ng/m l cholera toxin
(Sigma). MCF-7 and MDA-MB-231 cells were maintained by removing the old
medium, washing with 7 ml phosphate buffered saline (PBS) (Hyclone), detaching
cells from the surface by adding 2 ml of 0.05% trypsin) (GIBCO), and adding 4 ml
of fresh DMEM complete medium (Hyclone). HeLa cells were maintained similarly
to MCF-7 and MDA-MB-231, but by using 0.025% trypsin instead of 0.05%. MCF-
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10A cells were maintained similarly, except that after trypsinization in 0.05%
trypsin, 2 ml of resuspension media (DMEM/F12 media supplemented with 20%
horse serum and 10,000 units/ml Pen/Strep) was added and cells were spun down at
1500 rpm for 5 minutes to remove the trypsin and resuspended in complete media
prepared freshly.

The other cancer cell lines were cultured in the ATCC-

recommended media as per ATCC instructions. All cells were maintained at 37⁰C in
a 5% CO2 incubator. For conducting experiments, cells were plated a day earlier
and seeded at the cell density mentioned in the experiments, depending upon the
plate and well size used for the experiment. All MTT assays were conducted in 96well plates using 5,000 cells per well, unless otherwise stated. This was followed by
treatment of the cell cultures with different concentrations of the tested extracts along
with appropriate dilutions of the control solvent (normally dimethyl sulfoxide
(DMSO).
2.2 Plant Extract Preparation
Plant extracts from the 5 different plants included those from Boswellia sacra
(BS), Cleome droserifolia (CD), Teucrium muscatensis TM), Orchadenus arabicus
(OA), and Acredocarpus orientalis (AO) were obtained.

These extracts were

prepared and supplied by our collaborators Profs. Ahmed Al Harrasi and Javid
Hussain, University of Nizwa, Sultanate of Oman. The extracts were solubilized in
DMSO or water to prepare stock solutions at 12.5 mg/ml, 25 mg/ml, and 50 mg/ml
concentrations, depending upon the form and solubility of each extract, then stored at
-20⁰C (Table 1).

From the stock solutions, different extract treatments were

prepared at twice the final concentration (50, 100, 250, and 500 mg/ml) in the media,
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depending upon the cell line used, since 100 µl of treatment was added to cells plated
in 100 µl media on the day of treatment.
Table 1: Description of the extracts, their stock concentrations, and solvent used for
solubilization
S.
No

Extract

1

Essential Oil (EO)

2

CH3Cl Extract (CH)

3

MTOH Extract (MT)

Plant

Concentration

Solvent

Pure distilled oil

DMSO

Boswellia
sacra

10 mg/ml
DMSO

(BS)
4

Hexane Extract (HX)

5
6
7

Aqueous Extract (AQ)
CD Butanol Extract (BT)
CD CH
CD Ethylacetate Extract
(ET)
CD HX
TM ET
TM MT
TM BT
TM HX
TM CH
TM AQ
OA CH
OA AQ
OA MT
OA ET
OA BT
OA HX
AO CH
AO MT
AO HX
AO AQ
AO ET
AO BT
AO BT
AO MT

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

DMSO prep
1 mg/ml

CD

50 mg/ml

H2O

DMSO

12.5 mg/ml

TM

50 mg/ml

DMSO

H2O

OA
(Whole)

50 mg/ml

DMSO

12.5 mg/ml
AO
(Leaves)

AO
(Leaves )
AO
(Stem)

50 mg/ml

DMSO

25 mg/ml
25 mg/ml

50% DMSO

50 mg/ml

DMSO

50 mg/ml
50 mg/ml

DMSO
DMSO
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30
31
32
33

AO ET
AO HX
AO CH
AO AQ

50 mg/ml
25 mg/ml
25 mg/ml
25 mg/ml

DMSO
DMSO
DMSO
50% DMSO

The DMSO control contained the same concentration of DMSO as present in the
tested extracts as a control for cell death induced by DMSO alone. The extracts were
prepared as shown in Table 2 to be tested in the MTT assay in 1 ml or 1.4 ml media,
depending upon the cell line used and the volume needed in the experiment.
Table 2: Recipes of the extract stock solution used in this study
12.5mg/ml Stock
25 µg/ml

DMSO/extract in 1ml media DMSO/extracts in 1.4 ml
media
4µl
5.6µl

50 µg/ml

8µl

11.2µl

125 µg/ml

20µl

28µl

250 µg/ml

40µl

56µl

25 µg/ml

2µl

2.8µl

50 µg/ml

4µl

5.6µl

125 µg/ml

10µl

14µl

250 µg/ml

20µl

28µl

25 µg/ml

1µl

1.4µl

50 µg/ml

2µl

2.8µl

125 µg/ml

5µl

7µl

250 µg/ml

10µl

14µl

25mg/ml Stock

50mg/ml Stock
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2.3 Essential Oil Preparation
The steam-distilled essential oil extracted from Boswellia sacra

was

solubilized using molecular biology grade DMSO at a 1:2 dilution which was used in
various experiments at different dilutions prepared in the appropriate media.
2.4 MTT Cell Viability Assay
MTT is a colorimetric assay for cell viability based on the cellular cleavage
of the yellow tetrazolium salt, [3-(4, 5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium
bromide] (MTT), into purple formazan crystals that is soluble in cell culture medium
and is measured at 560 nm using the plate reader directly in 96-well assay plates.
Absorbance is directly proportional to the number of living cells in the culture. The
reagents needed to conduct the MTT assay are listed in Table 3.
Table 3: List of reagents required for the MTT assay
Item

Company/Catalogue No

1

96 well plate for tissue culture
Nunc Microwell 96 wells w/lid Nunclon DSi

Thermo Scientific
Cat. No 167008

2

MTT Reagent
[3-(4, 5-dimethylthiazol-2-yl)-2-5diphenyltetrazolium bromide]
DMSO Dimethyl Sulfoxide (Molecular Biology
Grade), ˃ 99.9%

HiMedia
Cat. No MB186-1G

4

DMSO Dimethyl Sulfoxide ≥ 99.5%

Sigma-Aldrich Cat. No
D5879-1L

5

Plate Reader

Infinite M200 PRO TECAN

6

Plate Reader

Victor TM 2030 Multi-label
Reader Perkin Elmer

3

Sigma-Aldrich
Cat. No D8418-250ML

To conduct the assay, the MTT reagent was dissolved in 1 x PBS at a concentration
of 5 mg /ml PBS, depending on the number of plates, as shown below:
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No. of Plates
1
2
3
4

MTT
13 mg
26 mg
39 mg
52 mg

1 X PBS
2.6 ml
5.2 ml
7.8 ml
10.4 ml

After mixing (MTT + PBS) well using the vortex, the mixture was heated at
37⁰C water bath for 2 minutes to make sure that all the MTT particles were
dissolved, spun down at 1000 rpm for 1 minute in a table top centrifuge to collect the
contents, followed by filtration using a syringe and 0.2 µm filter, and spun down
again to be ready for adding to individual wells.
Cells were cultured in 96-well plates at a density of 5 x 10³ cells/well/100 µl
media. The cell number was determined empirically after testing the proliferation
capacity of MCF-7 and HeLa cells in MTT assays using increasing numbers of cells
(Fig. 1S in the appendix). Using this data, a cell number range was used which
provided a linear signal for either MCF-7 or HeLa cell lines. After 24 hours, cells
were treated with 100 µl of the different concentrations of the plant extracts, essential
oil, DMSO (as a negative control), or culture media alone for various time points.
Stock solution of MTT [3-(4, 5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium
bromide] (5 mg/ml) was added at 25 µl/well and the plates were incubated for 3-4
hours in a 37⁰C incubator. Culture media was decanted from the plates by a firm but
swift hand movement and residual liquid cleaned by wiping the plates on tissues.
The formazan crystals thus formed were dissolved by adding 200 µl of DMSO using
a multichannel pipette. Absorbance was measured at 560 nm using the plate reader
directly in the 96-well assay plates. Cell viability was calculated as a percentage of
cells treated with DMSO alone as a control using the same concentrations of DMSO
that were used to dissolve the extracts. This ranged from 0.2-1%. All experiments

50
were carried out at a minimum three times having all samples in triplicates or more.
Results were analyzed using MS Excel and GraphPad Prism v5 software.
2.5 Cell Titer-GLO Luminescent Cell Viability Assay
Appropriate cell lines were cultured in 96-well, opaque white well plates at a
density of 5 x 10³ cells/well/100 µl. After 24 hours, 50 µl of the cell culture was
removed and treated with 50 µl of the different extract concentrations at 37⁰C. After
48 hours, cells were assayed for cell viability using the Cell Titer-GLO Luminescent
Cell Viability Assay (Promega, USA) as per manufacturer’s directions. Briefly, the
substrate kit was thawed at room temperature. Fifty µl of the culture media was
removed from each well and 50 µl of the viability substrate was added. After that,
the plate was incubated for 10 minutes on a shaking platform (in the dark or covered
with aluminum foil) at room temperature. Luminescence was measured using the
Infinite M200 Pro Tecan plate reader. Details of the reagents used is provided in
Table 4.
Table 4: List of reagents required for Promega cell viability & caspase assays
Item
1
2
3
4
5
6

Company/Catalogue No

96 well opaque white plates for tissue Thermo Scientific
culture and luminometer
Cat. No 136101
Cell titer GLO cell viability assay kit 100ml Promega
Cat. No G7572
Caspase 3/7 GLO assay kit 10ml
Promega
Cat. No G8091
Caspase 8 GLO assay kit 10ml
Promega
Cat. No G8201
Caspase 9 GLO assay kit 10ml
Promega
Cat. No G8211
Plate Reader
Infinite M200 Pro Tecan
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Data were presented as percent cell viability of experimental groups
compared to DMSO-treated cells, the viability of which was taken as 100%. Each
sample was tested in triplicates. The essential oil and effectective extracts were
tested in two independent experiments except AO (S).
2.6 Caspase-GLO 3/7, 8 and 9 Assays
Appropriate cells were cultured in 96-well, opaque, white-well plates at a
density of 5 x 10³ cells/well/100 µl. After 24 hours, 50 µl of the supernatant was
removed from each well and then cells were treated with 50 µl different
concentrations of the desired extracts and incubated at 37⁰C incubator. After 48
hours, cells were assayed for the activity of different caspase enzymes using the
Promega caspase GLO assays as per manufacturer’s directions by thawing the kits at
room temperature. This was followed by removal of 50 µl of the culture media
which was replaced by 50 µl of the various caspases substrates. The plates were
incubated for 3 hours at room temperature with shaking in the dark (or covered with
aluminum foil). Luminescence was measured using the Infinite M200 Pro Tecan
plate reader. The data was reported as percentage of increase compared to control
and DMSO-treated cells. All samples were tested in triplicates for each extract
(treatment) and the experiments were repeated 2-3 times. A representative
experiement from these is shown in the results which were analysed by MS Excel
and GraphPad Prism 5 as a measure of mean ±SD and t-test. Details of the reagents
used are provided in Table 4.
2.7 Protein Extraction and Estimation
To determine the mechanism of cell death being utilized by the effective
extracts, western blot analyses were conducted of protein lysates. First, cells treated
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with various concentrations of the effective extracts were harvested by trypsinization
as described, washed with 1 x PBS, and lysed using 100 µl of RIPA lysis buffer (10
mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate,
0.1% SDS, 140 mM NaCl) per million cells supplemented with 50 µl of βmercaptoethanol/ml RIPA and 1 mM of the serine protease inhibitor,
phenylmethylsulfonyl fluoride (PMSF). Nuclei were separated from the lysed cells
by spinning at 14,000 rpm for 10 minutes at 4⁰C. The cell lysates were separated
from the pellets and either used immediately or stored at -80⁰C.
Protein amount in the cellular extracts was quantified using the Bio-Rad
Bradford colorimetric assay. A sample of the protein lysate was diluted in 50 mM
Tris-Cl, pH 8, to a final volume of 800 µl followed by addition of 200 µl of the dye
concentrate. A series of protein standards were made in parallel using bovine serum
albumin to estimate the amount of protein present in each sample by measuring
absorption at the visible wavelength of 595 nm using a spectrophotometer.
2.8 Western Blot Analysis
Total cellular protein lysates (40 µg per lane) were loaded onto 8-12% SDSpolyacrylamide mini gels (Bio-Rad) and blotted onto nitrocellulose membranes using
standard protocol. After wet transfer, the membranes were blocked with 5% low fat
dried milk in 1 x PBS and 0.1% Tween-20 (PBST) for 1 hour. The membranes were
then incubated at 40C overnight with the following primary antibodies in 1% milk in
PBST. Details of the antibodies used are provided in Table 5.
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Table 5: List of antibodies used in the western blot assays
S. No.

Antibody

1

PARP Antibody (1:1000)

2

Actin (1:1000)

3

Caspase 3 Antibody (1:1000)

4

Caspase 7 Antibody (1:1000)

5

Caspase 8 Antibody (1:1000)

6

Caspase 9 Antibody (1:1000)

7

Anti-mouse antibody (1:2000)

8

Anti-rabbit antibody (1:2000)

Company
Catalogue No
Cell Signaling Technology
Cat. No 9542
Sigma
Cat. No A-3854
Cell Signaling Technology
Cat. No 9668
Cell Signaling Technology
Cat. No 9492
Cell Signaling Technology
Cat. No 9746
Cell Signaling Technology
Cat. No 9502
Sigma
Cat. No A-0412
Sigma
Cat. No A-6154

The blots were then incubated with the appropriate secondary antibodies (anti-mouse
or anti-rabbit) for 1 hour and 30 minutes at room temperature followed by detection
using the Pierce™ ECL Plus Western Blotting Substrate and visualized using
Typhoon reader. Details of the reagents and instruments used in the western blot
procedure are provided in Table 6.
Table 6: List of reagents used in the western blot assays
S. No.

Reagent Name

Company/Catalogue No

1
2
3
4
5
6
7
8
9
10
11

Tris-Cl
Acrylamide 30%
SDS
Ammonium persulfate
TEMED
NaCl
KCl
Na2HPO4
KH2PO4
Tris-base
Glycine

Sigma/Cat. No T5941
Bio-Rad/Cat. No 161-0158
Bio-Rad/Cat. No 161-0302
Sigma/Cat. No A3678
Sigma/Cat. No T9281
Sigma/Cat. No S7653
Sigma/Cat. No P9541
Sigma/Cat. No S0876
Sigma/Cat. No P-0662
Sigma/Cat. No T6066
Sigma/Cat. No G8898
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12
13
14
15
16
17
18
19
20
21
20
21
22

Beta-mercaptoethanol
Glycerol
Bromophenol Blue
Tween 20
Methanol
PMSF serine protease inhibitor
Protran Nitrocellulose
membrane
Pierce™ ECL Plus Western
Blotting Substrate
Kaleidoscope markers
Blue Ray markers
Skimmed milk powder
Typhoon reader
Spectrophotometer

Sigma/Cat. No M-7154
Sigma/Cat. No G5516-500ml
Bio-Rad/Cat. No 161-0404
Bio-Rad/Cat. No 170-6531
Panreac/Cat. No 131091.1212
Sigma/Cat. No P7626
Whatman/Cat. No 10 401 196
Pierce/Cat. No 32132
Bio-Rad/Cat. No 161-0324
Jena Bioscience/Cat. No PS-103
Regilait
Typhoon FLA 9500
Milton Roy Spectonic 301

2.9 Morphological Studies
Cell cultures treated with different extracts were followed for morphological
changes by observation via an inverted light microscopic attached to a CCD camera.
The treated cells were compared with cells treated with similar DMSO
concentrations and untreated cells. Images were saved at various magnifications at
different times after treatment.
2.10 Purified Compounds and their Derivatives
Purified compounds from some of the crude extracts were made available by
our collaborator, Prof. Javid Hussain, University of Nizwa, Oman, and his team as
well as their derivatives. They were successful in isolating one compound from AO
(FTZ) and one from TM plant (IM-60) (Table 7). Three different derivatives were
also prepared from the FTZ compound. A description of the natural and synthetic
derivatives is provided in Table 7. Each of these were solubilized in DMSO and
tested for their anticancer activity using the MTT assay using the breast cancer cell
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line MCF-7. Effective compounds were further tested in the caspase assays to
determine if they could induce caspase enzymatic activity.
Table 7: List of purified compounds and synthetic derivatives tested in this study
S. No
1
2
3
4
5

Code
FTZ
F-OTF(1)
F-OTF-SS1
TZ-SM3
1M-60

Source (Plant or Synthetic)
Isolated from Acridocarpus orientalis
Synthetic derivative of FTZ
Synthetic derivative of FTZ
Synthetic derivative of FTZ
Isolated from Teucrium mascatensis

2.11 Statistical Analysis
Statistical analysis of the presented data was accomplished by using either
Microsoft Excel or Graphpad Prism v5 software. Average values were calculated for
each of the samples in replicates of three or more followed by calculation of their
standard deviations that were plotted as error bars on the column graphs. Paired,
two-tailed student’s t-test was used to determine significant differences between any
two groups. The extent of significance was shown as either one to three stars,
depending upon the value obtained (* = p <0.05; ** p <0.01; *** = p <0.001). The
dose- and time-dependent graphpad figures were generated by normalizing the
values obtained for the test groups with that of their DMSO control since a specific
DMSO control was used for each extract tested, whether it was the MTT assay or the
Promega glo assays.
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Chapter 3: Results
3.1 Description of Plant Extracts Tested
One essential oil and thirty-two different plant extracts were obtained from
our collaborators, Prof. Ahmed Al Harrasi and Dr. Javid Hussain, University of
Nizwa, Sultanate of Oman. The essential oil was prepared by steam distillation,
while the extracts were prepared using organic solvents based on their polarity from
low to high, as shown in the Figure 6.

Figure 6: Organic solvents used for plant extract preparation in the order of
increasing polarity.
The description of the extracts obtained from the five medicinal plants is given
below:
1. Boswellia sacra (BS). Steam-distilled essential oil, three resin extracts made
from hexane, chloroform, methanol, and the residual aqueous extract.
2. Cleome droserifolia (CD). Four extracts prepared by extraction with hexane,
chloroform, ethyl acetate, butanol.
3. Teucrium muscatensis (TM). Five extracts prepared by extraction with hexane,
chloroform, ethyl acetate, butanol, methanol and the residual aqueous extract.

57
4. Orchadenus arabicus (OA). Five whole plant extracts prepared by extraction
with hexane, chloroform, ethyl acetate, butanol, methanol, and the residual
aqueous extract.
5. Acridocarpus orientalis (AO).
a. Leaf (L). Five leaf extracts prepared by extraction with hexane, chloroform,
ethyl acetate, butanol, methanol, and the residual aqueous extract.
b. Stem (S). Five stem extracts prepared by extraction with hexane, chloroform,
ethyl acetate, butanol, methanol, and the residual aqueous extract.
The rationale of obtaining extracts made by different solvents was to ensure that
any bioactive compound that may be present in the plants being tested was not
missed due to the extraction procedure since some solvents may be better than others
in extracting the various biochemical activities found in plants.
A typical serial exhaustive extraction procedure used to prepare the extracts is
shown in Figure 7 [425]. It involves the use of sequential solvents with increasing
polarity to ensure that bioactive molecules of a wide polarity range are successfully
extracted from the crude plant material. Briefly, the process started with either the
whole plant or its parts that were dried in the dark, chopped and ground to a coarse
powder. The powdered plant material was extracted with methanol three times for
two weeks at room temperature. Then, the methanol extract was evaporated under
pressure, leaving a greenish syrup residue. The methanol extract was suspended in
water and then hexane was added with vigorous shaking in a separating funnel. The
mixture was allowed to separate into two layers; the hexane upper layer was removed
and the extraction with hexane was repeated twice. All hexane layers were combined
and evaporated on a rotary evaporator, resulting in the hexane fraction (Fig. 7).
Next, the other lower layers ware taken in a separating funnel where chloroform was
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added and separated as mentioned earlier. The chloroform lower layer was collected
and evaporated on a rotary evaporator, giving rise to the chloroform fraction. The
upper layer of chloroform was taken into a separating funnel and ethyl acetate was
added, separated and evaporated with rotary evaporator, giving rise to the ethyl
acetate fraction. The same procedure was applied for butanol, giving rise to the
butanol extract, while the remaining lower layer was collected and evaporated,
giving rise to the aqueous fraction.
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Ochradenus arabicus (28.4 kg)
Soaked in methanol
for two weeks and filtered
Methanol Extract (437.4 g)

n-hexane + water
Evaporated through Rotary
Crude Extract

Hexane Soluble Fraction
( 68.1g)

Extracted with
Chloroform
Extracted with
Ethyl Acetate
Crude Extract

Chloroform Fraction
(85.8g)

Evaporated through Rotary

Ethyl acetate (27.8 g)
Crude Extract

AquousFraction
(145.3 g)

n-butanol extract
(87.5 g)

Figure 7: Illustration of a typical extraction procedure used for preparing the extracts
tested in this study.
Figure courtesy of Dr. Javid Hassan, University of Nizwa, Oman.
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3.2 Experimental Design
To test the anticancer potential of the extracts described above, we started our
investigations with the Boswellia sacra essential oil, an oil that has already been
shown to have anti-proliferative effects in several cancer systems, including breast
cancer [265]. We wanted to confirm some of these observations using the steam
distilled oil preparation that was obtained from our collaborators. This was with the
intention to extend this observation to other cancer cell model systems to determine
the breadth and effectiveness of this oil as well as study its mechanism of action and
interaction with other chemotherapeutic drugs (not part of this thesis). This was
achieved by testing the oil in a human cancer cell model system that included a
breast and cervical cancer cell line. This also allowed us to establish the assays
needed to carry out the main aim of the thesis, to screen the Boswellia sacra and
other novel plant extracts for their anticancer potential in a more efficient manner.
Once established, the other plant extracts were then screened for their anticancer
potential. Due to the large number of extracts obtained, this screening was initially
limited to only two different cell lines: the breast cancer cell line MCF-7 and the
cervical cancer cell line, HeLa. Once the effective extracts from each plant were
short-listed for their effectiveness on cell proliferation, one representative extract
with anti-proliferative effects was chosen from each plant and characterized further
in a more expanded cancer model system that included the following cell lines:
1. MCF-10A. A normal human breast cell line used to test the extracts on
normal human cells [426].
2. MCF-7. A hormone-responsive human invasive breast ductal carcinoma cell
line that expresses estrogen and progesterone receptors (ER and PR), but no
HER2/neu gene amplification has been observed [427].
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3. MDA-MB-231. A triple negative human breast cancer cell line that does not
express any of the hormone receptors mentioned above [428].
4.

HeLa. A human cervical cancer cell line [429] chosen to determine the
breadth of anti-proliferation activity being observed.

Once the anti-proliferative activity of the chosen extracts had been confirmed,
their mechanism of action was explored using either the MCF-7 or HeLa cell lines
using various biochemical and cellular assays.
3.3 Test of Boswellia sacra Essential Oil on Human Cancer Cell Lines
We started our screening efforts with the essential oil from Boswellia sacra to
confirm the anti-proliferative effects being reported in literature [265], establish the
various cell assays, and determine the effective dose and time characteristics of the
oil obtained from our collaborators. Using the MTT assay, we screened the steam
distilled Boswellia sacra essential oil on the normal (MCF-10A) and three cancer
cell lines (MCF-7, MDA-MB-231, and HeLa) in a dose- and time-dependent manner.
The MTT assay is based on the cellular conversion of the tertazolium dye MTT into
purple formazan crystals by the mitochondrial NADPH-dependent oxido-reductase
enzymes that are easily detected using a 96-well plate reader. The ability to convert
the tetrazolium salt into the formazan product varies among different cell lines,
depending upon their metabolic capacity and the absorbance reading is directly
proportional to the number of living cells.
As can be seen from Figure 8, test of various dilutions of the Boswellia sacra
essential oil (1:500,1:800, 1:1000,1:1600, 1:2000, 1:3200, 1:4000) in individual cell
lines at 24 and 72 hours post treatment revealed that strong anti-proliferative effects
could be observed in these cell lines, including the normal cells. The column graphs
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in Figure 8, panels A-D show the dose- and time-dependent results of Boswellia
sacra treatment as a percent of control DMSO-treated cells. The essential oil was
solubilized in DMSO at a ratio of 1:1 and the same concentration of DMSO was used
in the DMSO control-treated cells to ensure that we were observing the effects of the
essential oil on cell viability and not the toxicity induced by DMSO alone. Our
results revealed that MCF-10A and MCF-7 cells were equally sensitive to 1:500 and
1:800 dilutions of the essential oil with cell viability decreasing by > 95% by 72
hours. Panels E-F show the same data but combined for all the cell lines in one
graph separately for the 24 and 72 hours, allowing easy comparison between the
effects of the oil on the different cell lines. As can be seen, the triple-negative MDAMB-231 cells were the most sensitive to killing and even a 1:1000 dilution led to
~80% killing by 72 hours. At this dilution, neither the MCF-10A or MCF-7 cells
were sensitive to killing, showing essentially 100% cell viability (Fig. 8, panels E
and F). HeLa were a lot less sensitive to the essential oil than the breast cancer cell
lines, killing ~ 50% of the cells at a dose of 1:500. Expanded versions of the MTT
column graphs A-D of Figure 8 are reproduced in Fig. 2S of the appendix for better
visualization.
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Figure 8: MDA-MB-231 is the most sensitive cell line to cell death by Boswellia
sacra essential oil.
Various dilutions of the essential oil were tested using the MTT assay on A) MCF10A, B) MCF-7, C) MDA-MB-231, and D) HeLa cells after 24 and 72 hours. Dosedependent effect of Boswellia sacra on cell viability as a percentage of untreated
cells for E) the 24 hour and F) 72 hour time points for all four cell lines tested. *
indicates statistically significant differences between the control and treated samples
(* = p<0.05; ** p<0.01; *** = p<0.001). The significance shown in panels A-D is
between the DMSO-control and essential oil-treated samples, while the significance
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shown in panel E-F is between the normal and cancer cell lines. This figure shows a
representative experiment of several experiments conducted using this oil in the four
cell lines. Expanded versions of the MTT column graphs A-D are reproduced in Fig.
2S of the appendix for better visualization.
Analysis of the time-dependent response of the essential oil in the individual
cell lines showed that the killing profiles for the various cell lines were identical at
24 and 72 hours (Fig. 9), suggesting that the oil was very efficient at killing cells,
accomplishing its cytopathic effects by 24 hours. Together, these data show that
Boswellia sacra essential oil can efficiently kill both breast cancer and cervical
cancer cells, though its effects on cell viability are more specific for breast cancer
than cervical cancer cells. Furthermore, these data show that the MDA-MB-231
cells are more sensitive to this oil than the normal cells, suggesting that Boswellia
sacra essential oil could be an option to treat triple negative breast cancer which
historically has been more difficult to treat, without much cytotoxicity for normal
cells at the same dose and time exposures. Suhail and colleagues also observed
cytotoxic effects of the essential oil on breast cancer cells, but much lower
cytotoxicity for normal MCF-10A cells than what we observed [265], which could be
due to difference in essential oil preparations used.
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Figure 9: Boswellia sacra essential oil has early kinetics of cell death induction in
human normal and cancer cell lines.
Time-dependent effect of Boswellia sacra essential oil different cell lines. A) MCF10A, B) MCF-7, C) MDA-MB231, and D) HeLa cells 24 and 72 hours post
treatment

3.4 Test of Boswellia sacra Extracts on Human Cancer Cell Lines
Next, we analyzed the extracts of Boswellia sacra to determine their antiproliferation potential using the MTT assay in comparison to the essential oil. This
was conducted to determine whether the anti-proliferation activity being observed
could be observed in the sequentially-prepared extracts or was it unique to the
essential oil. Figure 10 shows the results of the test of the different Boswellia sacra
extracts, including chloroform, methanol, and the remaining aqueous extract on
MCF-7 and HeLa cells at different concentrations (10, 100, 250, 500 µg/ml). Since
the hexane extract could not be weighed due to its sticky and semi-fluid nature, the
entire amount was solubilized in DMSO and was tested at two different dilutions
(1:200 and 1:400). As can be seen, all three organic extracts, but not the aqueous
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extract of Boswellia sacra resin, exhibited strong anti-proliferative activity against
the two tested cancer cell lines. Both methanol and chloroform extracts showed very
similar effects on the viability of MCF-7 and HeLa cells, inducing ~80% killing in
MCF-7 cells and about 90% in HeLa cells, all in a statistically significant manner
(Fig. 13, panels A and C). The hexane extract also showed very similar effects on
the two cell lines at 1:200 dilution killing > 80% of the cells; however, it lost the
cytotoxic effect on HeLa cells at the 1:400 dilution, while still killing the MCF-7
cells by ~75%, suggesting that MCF-7 cells were more sensitive to hexane extract
than HeLa cells (Fig. 13, panels B and D). Interestingly, the aqueous extract
enhanced the proliferation rates of the two cell lines tested rather than causing cell
killing or having no effect (Fig. 13, panels A and C), an observation that suggests
that the anti-proliferative compounds within the crude extracts keep the growth of
cells in check. Furthermore, it suggests that these compounds are soluble in the
organic solvents and have been successfully removed from the aqueous extracts by
the sequential extraction process.
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Figure 10: Effect of Boswellia sacra plant extracts on cancer cell viability.
Organic (chloroform, methanol, & hexane) and aqueous extracts of Boswellia sacra
were tested using MTT assay on A) & B) MCF-7 (72 hours), and C) & D) HeLa cells
(48 hours) post treatment. * indicates statistically significant differences between the
control and treated samples (* = p<0.05; ** p<0.01; *** = p<0.001)
3.5 Morphological Changes of Cell Treated with Boswellia sacra
Apoptotic cell death can be defined by various morphological changes that
distinguish it from other forms of cell death. To determine whether the organic
extracts of Boswellia sacra could cause apoptosis, we next analyzed the MCF-7 and
HeLa cells treated with different concentrations of chloroform extract of Boswellia
sacra for morphological changes compared with DMSO control. As shown in Figure
11, the most noticeable changes observed included cell shrinkage and rounding,
followed by detachment of the cells. These changes are characteristics of apoptotic
cell death, and were absent in the control DMSO-treated cells. The changes became
more remarkable with increasing time of treatment, suggesting that MCF-7 and HeLa
may be undergoing apoptosis post treatment.
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Figure 11: Morphological effects of Boswellia sacra on human cancer cell lines.
Photomicrographs of Boswellia sacra chloroform extract-treated MCF-7 and HeLa
cells at 14 hours post treatment at 100 and 250 μg/ml, respectively. The photographs
were taken at the same magnification for all the four panels (100X).
3.6 Boswellia sacra Induces DNA Fragmentation
Apoptotic cell death is also accompanied by various biochemical changes
unique to this form of cell death. One of the main features of apoptosis is DNA
fragmentation when the genomic DNA is cleaved by endonuclease, which breaks
apart the chromatin into nucleosomal-sized units that appear as a DNA ladder when
run on agarose gel [430, 431]. Thus, we tested the ability of Boswellia sacra
essential oil to fragment DNA of MCF-7 and HeLa cells at 24 and 48 hours post
treatment compared to media and DMSO control.

As apparent in Figure 12,

Boswellia sacra essential oil was able to induce DNA fragmentation within treated
cells, consistent with results obtained with the MTT assay and morphological
changes observed under the light microscope (Fig. 12).
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Figure 12: Boswellia sacra essential oil can induce DNA fragmentation in human
cancer cell lines.
Agarose gel electrophoresis showing DNA laddering of MCF-7 and HeLa cells after
treatment with Boswellia sacra essential oil (1:400) after 24 and 48 hours. The white
arrows point to the DNA ladders being observed in the gel, this experiment was
conducted once.
3.7 Boswellia sacra Activates Apoptosis
Next, we confirmed the ability of Boswellia sacra essential oil to induce
apoptosis by the activation of caspase enzymes, as has been reported earlier, but with
our preparation of the essential oil [265]. During apoptosis, a group of cysteine
aspartyl proteases, caspases, are activated in a cascade fashion, leading to the
activation of the initiator caspases (such as caspase-8 and 9) that cleave the
executioner caspases (such as caspase-3 and 7), enzymes that play a critical role in
programmed cell death. Activation of caspases results in mitochondrial membrane
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permeabilization, chromatin condensation, and DNA fragmentation, ending in cell
destruction.
Thus, the activation of the caspase enzymes was monitored using the
Promega Caspase-Glo assays for four different caspase enzymes, including caspase3/7, 8, and 9. These assays provide a pro-luminescent caspase substrate containing
caspase-specific tetrapeptide sequences that can be recognized and cleaved by the
targeted caspase enzymes, thus cleaving the substrate of luciferase and releasing a
glow-type light that can be captured and quantitated by the appropriate instruments.
These results were normalized to the viability of the cultures as assessed by the
Promega CellTiter-Glo® Luminescent Cell Viability Assay to ensure accurate results
were obtained reflective of the enzyme activation on a per cell basis. This assay is a
very sensitive and rapid method to assess the number of viable cells in culture based
on the quantitation of ATP as an indirect measure of metabolically active cells. It is
similar to MTT, but provides another independent measure of cell viability in a
quantitative manner.
As revealed by Figure 13, Boswellia sacra essential oil was able to induce the
activity of caspase enzymes in MCF-7 breast cancer cells in a statistically-significant
manner. Specifically, strong activation of caspase 7, 8, and 9 all could be observed,
suggesting that Boswellia sacra essential oil was inducing apoptosis in the breast
cancer cells through the activation of both the intrinsic and extrinsic pathways.
These results also confirmed the cytotoxic effect on breast cancer cells being induced
by the essential oil, as observed by the MTT assay.
Together, our results confirm the anticancer activity of Boswellia sacra
essential oil on breast cancer cells and extend it to cervical cancer cells. They also
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suggest that the essential oil and organic extracts of its resins have the ability to
induce apoptosis by the activation of both the intrinsic and extrinsic pathways.
Further studies are being conducted to determine how Boswellia sacra extracts can
be used to enhance the anticancer potential of other cancer chemotherapeutic drugs
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Figure 13: Boswellia sacra essential oil can induce activation of caspase enzymes.
Cell viability and caspase activity assay of Boswellia sacra essential oil (1:200
dilution) on MCF-7 at 48 hours treatment. * indicates statistically significant
differences between the DMSO control and Boswellia sacra-treated samples (* = p
<0.05; ** p <0.01; *** = p <0.001). This experiment was conducted once.
3.8 Screening of Medicinal Plant Extracts for Anticancer Activity
Next we proceeded with screening the other 28 extracts from the four
different shrubs Cleome droserifolia, Teucrium muscatensis, Orchadenus arabicus,
and Acredocarpus orientalis provided by our collaborators. As mentioned earlier,
these plants had been targeted for studying their anticancer activity due to their wellknown medicinal properties.
Due to the large number of extracts to be tested, we first performed an initial
screening of all the extracts using the MTT assay with the breast cancer cell line,
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MCF-7, and the cervical cancer cell line, HeLa in a dose- and time-dependent
manner. All extracts were tested at different concentrations (25, 50, 125, 250 µg/ml)
at two time points (24 and 72 hours) post treatment. Table 8 summarizes the results
obtained from the first screening.
As can be seen, all spectrum of anti-proliferative activities could be observed
in the tested extracts. Some could kill both cell lines (extracts shaded in green),
while some could not kill either of the cell lines (extracts not shaded and marked by
x). Interestingly, several extracts could selectively kill HeLa cells without killing
MCF-7 cells (extracts highlighted in blue and yellow), while none of the extracts was
found to kill MCF-7 specifically. However, there were some extracts that were more
“MCF-7-specific” and could kill these cells at lower doses and early on, while HeLa
cells only at higher doses and later on (for example, extracts shown in pink).
Overall, 11 out of 28 (39%) of the extracts showed anti-proliferative effects on the
two cancer cells, while 17 out of 28 (60.7%) extracts were ineffective in killing
either cell line. Interestingly, at least one effective extract was identified from each
of the plants screened. This is an important result and suggests that plants that have
been used for medicinal purposes historically provide a valuable source of raw
material for screening of anticancer compounds.
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Table 8: Summary of the first screening of plant extracts using the MTT assay

A closer look at Table 8 reveals that for each individual plant, only a few of
the extracts had effective cytotoxic activity and most were ineffective in killing the
cancer cells. A summary of effective extracts from each plant is listed below:
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CD 

CH only

TM 

CH, MT, HX

OA 

CH, ET (HeLa only)

AO (L) 

CH, ET (HeLa only)

AO (S) 

CH (HeLa only), BT (HeLa only)

As can be seen, the chloroform (CH) extracts were uniformly able to induce
cytotoxic effects in the cancer cell lines, although in one case (AO (S)), it was not
effective on MCF-7 cells. The remaining effective extracts were prepared by other
solvents that included two by ethyl acetate (ET), and one each by hexane (HX),
methanol (MT), and butanol (BT). None of the extracts aqueous extracts (AQ) were
found to be effective. These results suggest that chloroform may have the best
ability, among the solvents tested, to extract bioactive molecules that have anticancer
activity, though other solvents can extract such activities as well.
3.9 Cytotoxic Effect of Organic Solvents used for Extraction
It is possible that the cytotoxic activity of the extracts being observed was due
not to compounds within the extracts but due only to any remaining organic solvents
used for the extraction purposes. Therefore, we tested the cytotoxicity of the organic
solvents used for the extraction process using the MTT assay on the three cancer cell
lines used: MCF-7, MDA-MB-231, and HeLa.
As can be seen, testing of the pure solvents starting with a 1:500 dilution on
the three cell lines revealed that there was no cytotoxic effect of the organic solvents
on the cell lines tested (Fig. 14), confirming that any residual solvent that may have
remained in the extracts despite days of evaporation (sometimes over a month or
more) was not responsible for the anti-proliferative effects that were being observed.
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Furthermore, the extracts were tested by our collaborators directly using nuclear
magnetic resonance (NMR) at the University of Nizwa, Oman to determine whether
physical traces of the solvents could actually be detected. Their tests confirmed that
no residual organic solvents could be detected in the extracts (data not shown).
Next, five effective extracts from Table 8 were short-listed for further
analysis of their anticancer properties. At least one extract was chosen from each
plant or part thereof. For example, CD CH was chosen from Cleome droserifolia
since it represented a “more MCF-7-specific” extract. OA CH was chosen from
Orchadenus arabicus and TM CH from Teucrium muscatensis since they could kill
both MCF-7 and HeLa cancer cell lines, AO BT(S) and AO CH(L) were chosen from
Acredocarpus orientalis since AO BT(S) was HeLa-specific, while AO CH(L) from
the leaves could kill MCF-7 as well, though less efficiently.

These extracts were

tested in a more expanded series of cell lines, including MCF-10A, the normal breast
cell line and MDA-MB-231, the prototypic triple negative breast cancer cell line
along with MCF-7 and HeLa cells.
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Figure 14: Lack of cytotoxic effects of organic solvents used for plant extract
preparation.
Various organic solvents used for extract preparation were tested on MCF-7, MDAMB-231, and HeLa cells using the MTT assay at 24 and 72 hours post treatment, this
experiment was done once.
First, the MTT assay was repeated in all these cell lines in a dose-dependent
manner using three different concentrations (50, 125, 250) µg//ml) after 24, 48, and
72 hours treatment. This allowed us to compare the effects of the extracts in both the
normal and cancer cell lines at the same time in the same manner.
Figure 15 shows the results of the test of Cleome droserifolia extract on the
tested cell lines. As can be seen, this extract could induce cell death in all the three
breast cell lines in a comparable fashion in both a dose- and time- dependent manner.
MCF-10A and MCF-7 were equally sensitive to this extract, while MDA-MB-231
was slightly less sensitive as detected by the treatment with the lower doses (Fig. 15,

77
panel E). By 250 μg/ml dose, all three cell lines were equally sensitive, leading to >
90% death of the culture compared to cell growth in the presence of DMSO alone by
72 hours. When we compared all the four cell lines in a time-dependent manner,
HeLa cells were less sensitive to this extract in the beginning, but by 72 hours, had
nearly killed similar percentages of cells as the breast cells (Fig. 15, panel F). This
revealed that Cleome droserifolia crude extract affects cell proliferation of both
normal mammary and breast cancer cells equally, while the HeLa cells were
somewhat less sensitive to this extract. Expanded versions of the MTT column
graphs A-D of Figure 15 are reproduced in Fig. 3S of the appendix for better
visualization.
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Figure 15: Cleome droserifolia extracts can induce potent cell death in human
normal and cancer cell lines.
Cytotoxic effect of different concentration of Cleome droserifolia using MTT assay
on A) MCF-10A, B) MCF-7, C) MDA-MB-231, and D) HeLa cells after 24, 48, and
72 hours post treatmentPanel E) shows dose-dependent effect of Cleome droserifolia
on cell viability as a percentage of untreated cells for the 72 hour time point. Panel
F) shows the time-dependent effect of Cleome droserifolia on cell viability as a
percentage of untreated cells for the 250 µg/ml treatment. * indicates statistically
significant differences between the control and treated samples (* = p<0.05; **
p<0.01; *** = p<0.001). The significance shown in panels A-D is between the
DMSO-control and extract-treated groups, while the significance shown in panels E
and F is between the normal and cancer cell lines. This is a representative
experiment done two to three times. Expanded versions of the MTT column graphs
A-D are reproduced in Fig. 3S of the appendix for better visualization.
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Figure 16 reveals the results of Teucrium muscatensis on the normal and
cancerous cell lines. It could induce cytotoxic effects on the three cancer cell lines in
a statistically significant manner. However, the normal MCF-10A cells were the
most sensitive to this extract than the cancer cells. The MCF-7 and MDA-MB-231
cells showed quite comparable cytotoxicity profiles (Fig. 16, panel E), while like
CD, the HeLa cells were slightly less susceptible, as observed by the time course of
cell killing (Fig. 16, panel F). Thus, our results reveal that Teucrium muscatensis has
significant effect on not only breast and HeLa cancer cell viability, but also normal
breast cells. Since it can kill cancer cells effectively, though not specifically, it is still
worth to explore this extract further by isolating the active biomolecules to determine
if they may have more specific anticancer effects without affecting normal cells.
Expanded versions of the MTT column graphs A-D in Figure 16 are reproduced in
Fig. 4S of the appendix for better visualization.
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Figure 16: Teucrium muscatensis extracts can induce potent cell death in human
normal and cancer cell lines.
Cytotoxic effects of different concentration of Teucrium muscatensis using MTT
assay on A) MCF-10A, B) MCF-7, C) MDA-MB-231, and D) HeLa cells after 24,
48, and 72 hours post treatment. Panel E) shows dose-dependent effect of Teucrium
muscatensis on cell viability as a percentage of untreated cells for the 72 hour time
point. Panel F) shows the time-dependent effect of Teucrium muscatensis on cell
viability as a percentage of untreated cells for the 250 µg/ml treatment. * indicates
statistically significant differences between the control and treated samples (* =
p<0.05; ** p<0.01; *** = p<0.001). The significance shown in panels A-D is
between the DMSO-control and extract-treated groups, while the significance shown
in panels E and F is between the normal and cancer cell lines. This is a
representative experiment done two to three times. Expanded versions of the MTT
column graphs A-D are reproduced in Fig. 4S of the appendix for better
visualization.
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Figure 17 shows the results of effects of Orchadenus arabicus on the normal
and cancerous cell lines. The triple-negative breast cancer cell line, MDA-MB-231,
was the most sensitive to Orchadenus arabicus, causing > 90% cell death within 72
hours of treatment with 250 µg/ml extract (Fig. 17, panels E and F). The normal
cells, MCF-10A, and MCF-7 breast cancer cells were more intermediately affected
by this extract. HeLa cervical cancer cells were the least affected by this extract with
~80% of the cells still viable after treatment with 250 µg/ml for 72 hours. Thus, this
data suggests that the OA extract has specific anti-proliferative activity against breast
cancer cells, in particular the hormone non-responsive cells MDA-MB-231, that
could be exploited further for therapy. Expanded versions of the MTT column
graphs A-D of Figure 17 are reproduced in Fig. 5S of the appendix for better
visualization.
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Figure 17: Orchadenus arabicus extracts can induce cell death in human normal and
cancer cell lines.
Cytotoxic effect of different concentrations of Orchadenus arabicus using MTT
assay on A) MCF-10A, B) MCF-7, C) MDA-MB-231, and D) HeLa cells after 24,
48, and 72 hours post treatment. Panel E) shows dose-dependent effect of
Orchadenus arabicus on cell viability as a percentage of untreated cells for the 72
hour time point. Panel F) shows the time-dependent effect of Orchadenus arabicus
on cell viability as a percentage of untreated cells for the 250 µg/ml treatment. *
indicates statistically significant differences between the control and treated samples
(* = p<0.05; ** p<0.01; *** = p<0.001). The significance shown in panels A-D is
between the DMSO-control and extract-treated groups, while the significance shown
in panels E and F is between the normal and cancer cell lines. This is a
representative experiment done two to three times. Expanded versions of the MTT
column A-D are reproduced in Fig. 5S of the appendix for better visualization.
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Figures 18 and 19 shows the results of the test of Acredocarpus orientalis on
the normal and cancerous cell lines. For this plant, we had separate extracts available
from the leaves (AO (L)) and the stems (AO (S)). Test of AO (L) on the four cell
lines revealed that the leaf extract could efficiently kill all the four cell lines equally
well, including the normal breast and cervical cancer cells (Fig. 18). Thus, it could
kill > 75-80% of the four cell lines compared to DMSO control treated cells by 72
hours at the highest dose tested (250 µg/ml) (Fig. 18, panel E). This result suggests
that the leaf extract from Acredocarpus orientalis has strong cytotoxic activity and
may have a number of different bioactive components with individual characteristics
that could be explored further separately as specific anticancer agents. Expanded
versions of the MTT column graphs A-D of Figures 18 and 19 are reproduced in
Fig. 6S and 7S, respectively, of the appendix for better visualization.
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Figure 18: Acredocarpus orientalis (L) extracts can induce cell death in human
normal and cancer cell lines.
Cytotoxic effect of different concentrations of Acredocarpus orientalis (L) using
MTT assay on A) MCF-10A, B) MCF-7, C) MDA-MB-231, and D) HeLa cells after
24, 48, and 72 hours post treatment. Panel E) shows dose-dependent effect of
Acredocarpus orientalis (L) on cell viability as a percentage of untreated cells for the
72 hour time point. Panel F) shows the time-dependent effect of Acredocarpus
orientalis (L) on cell viability as a percentage of untreated cells for the 250 µg/ml
treatment. * indicates statistically significant differences between the control and
treated samples (* = p<0.05; ** p<0.01; *** = p<0.001). The significance shown in
panels A-D is between the DMSO-control and extract-treated groups, while the
significance shown in panels E and F is between the normal and cancer cell lines.
This is a representative experiment done two to three times. Expanded versions of
the MTT column graphs A-D are reproduced in Fig. 6S of the appendix for better
visualization.
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Test of Acredocarpus orientallis (S), the stem extract from AO plant, on the
other hand revelead a very different profile compared to the leaf extract and had only
imited anti-proliferative activity against the cell lines tested (Fig. 19). Whereas AO
(L) caused nearly 70-80% killing of the four cell lines tested by 72 hours, the
proliferation of the normal breast cells or the two breast cancer cell lines was not
affected at all by AO (S) (Fig. 19, panels A-C). In fact, statistically significant
proliferation of the treated normal breast cells (MCF-10A) and the two breast cancer
cell lines (MCF-7 and MDA-MB-231) was observed after 24 hours that persisted
with time for all except MCF-7 cells (Fig. 19, panel F). We believe that the increase
in conversion of the tetrazolium salt to formazan by the dehydrogenase enzymes is
due to increase in cell numbers and not enzyme per cell since we used cell numbers
in the range that reflects a linear increase in tetrazolium conversion with increasing
number of cells (Fig. 1S in the appendix).
HeLa cells, on the other hand, showed some anti-proliferative effect starting
48 hours post treatment (Fig. 19, panels D-F). This was very different from the
broadly-cytotoxic activity observed with the leaf extract from the same plant. These
results suggest that extracts from Acredocarpus orientalis have multiple activities
with the potential of providing variable anticancer activities. Thus, exploration of
isolated components from this plant would be valuable since it may lead to
compounds that could kill the cancer cells specifically over the normal cells, and lead
to the proliferation of normal cells at the same time.
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Figure 19: Acredocarpus orientallus (S) induces cell death in normal and human
cancer cell lines to a much lower extent.
Cytotoxic effect of different concentrations of Acredocarpus orientallus (S) using
MTT assay on A) MCF-10A, B) MCF-7, C) MDA-MB231, and D) HeLa cells after
24, 48, and 72 hours post treatment. Panel E) shows dose-dependent effect of
Acredocarpus orientallus (S) on cell viability as a percentage of untreated cells for
the 72 hour time point. Panel F) shows the time-dependent effect of Acredocarpus
orientallus (S) on cell viability as a percentage of untreated cells for the 250 µg/ml
treatment. * indicates statistically significant differences between the control and
treated samples (* = p<0.05; ** p<0.01; *** = p<0.001). The significance shown in
panels A-D is between the DMSO-control and extract-treated groups, while the
significance shown in panels E and F is between the normal and cancer cell lines.
This is a representative experiment done two to three times. Expanded versions of
the MTT column graphs A-D are reproduced in Fig. 7S of the appendix for better
visualization.
Next, we asked how effective were each of the five extracts in each cell line
individually in terms of their comparative ability to induce cell death. Thus, the
dose-and time-dependent effect of each extract on cell viability as a percentage of
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DMSO-control-treated cells was plotted for all extracts on each cell line separately
and is shown in Figures 20 and 21. Analysis of the effectiveness of the extracts in
MCF-10A normal cells revealed that CD and TM were the most cytopathic extracts
for normal mammary cells, killing over 90% of the cells by 72 hours (Figs. 20 and
21, panel A). This was followed by OA and AO (L) that showed intermediate levels
of cytotoxicity, leading to 70% cell death by 72 hours. This was in stark contrast to
AO (S) stem extract that was not cytotoxic for the normal cell at all, and in fact had a
proliferative effect on the growth of these normal cells in a dose-dependent manner
(Fig. 20, panel A).
A comparison of the effect of the five extracts on MCF-7 cells revealed that
all were effective at killing this cell line in a dose- and time-dependent manner,
leading to 70-90% death of these cells compared to the DMSO-control treated cells
(Figs. 20 and 21, panel B). CD and TM were more cytotoxic at lower doses than OA
and AO (L), while AO (S) could not kill these cells at the same dose and time. In
fact, it led to a proliferation of the MCF-7 early on at lower doses in a statistiacally
significant manner (Figs. 20 and 21, panel B).
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Figure 20: Comparative effect of different plant extracts on normal and cancerous
human cell lines with dose.
A) MCF-10A, B) MCF-7, C) MDA-MB231, and D) HeLa cell lines using the MTT
assay in a dose-dependent manner. * indicates statistically significant differences
between the control and treated samples (* = p<0.05; ** p<0.01; *** = p<0.001).
This figure shows replotting of data shown in Figs. 15-19.
Similar results were obtained for MDA-MB-231 where all the extracts could
kill > 75-90% of the cells at the highest dose tested at 72 hours, except for AO (S)
that once again led to a proliferation of these cancer cells at even low doses early on
(Figs. 20 and 21, panel C). CD and AO (L) extracts were slightly more toxic for
these cells than OA and TM (Fig. 20, panel C), though this was not apparent from the
time-dependent graphs (Fig. 21, panel C).
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Figure 21: Comparative effect of different plant extracts on normal and cancerous
human cell lines with time.
A) MCF-10A, B) MCF-7, C) MDA-MB231, and D) HeLa cell lines using the MTT
assay in a time-dependent manner. * indicates statistically significant differences
between the control and treated samples (* = p<0.05; ** p<0.01; *** = p<0.001).
This figure shows replotting of data shown in Figs. 15-19.
Finally, the cervical cancer cell line HeLa was found to be most sensitive to
the anti-proliferative effects of CD and AO (L) followed by TM, similar to the
normal and cancerous MCF-7 mammary cells; however, it was barely sensitive to the
cytotoxic effects of OA (Fig. 20, panel D). AO (S) was the most effective at killing
HeLa cells among the four cell lines tested, though only to a limited extent by about
20-25% (Fig. 20, panel D). It thus could be termed as an extract that affects HeLa
cells primarily compared to the mammary gland cell lines tested, but does not seem
to have the level of cytotoxicity observed with the other extracts.
The variable effects of the tested extracts on the four cell lines suggests that
each plant extract has a different set of bioactive components in different
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concentrations, resulting in variable effects on the cell lines tested, making them a
valuable source of biomolecules as anticancer compounds.
3.10 Effect of Medicinal Plant Extracts on Cell Morphology
We also studied the ability of the extracts to induce morphological changes in
the breast cancer cells, MCF-7 compared to untreated cells. Differences in cell
morphology were observed by light microscopy after 29 hours of treatment, as
shown in Figure 22. The changes observed included cell rounding, shrinkage, and
detachment from other cells as well as the plate. Interestingly, each extract showed
different types of morphological changes. Some of these changes are reminiscent of
apoptotic cell death, which was absent in untreated cells, suggesting that MCF-7 may
partly be dying by the process of apoptosis.

Figure 22: All effective plant extracts could induce cytopathic effects in MCF-7
breast cancer cell line.
Photomicrographs of MCF-7 cells treated with 250 µg/ml of the effective extracts
including CD (Cleome droserifolia), TM (Teucrium muscatensis), OA (Orchadenus
arabicus), AO Acredocarpus orientallus leaf (L) and stem (S), 29 hours after
treatment. All panels show 400X magnification.
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3.11 Effect of Medicinal Plant Extracts on Apoptosis
To explore the potential mechanism of action of the effective extracts, the
ability of the various extracts to induce apoptosis was explored since apoptosis is the
most widely induced type of cell death pathway observed. Towards this end, as with
the Boswellia sacra , the ability of the effective plant extracts to affect cell viability
as well as induce enzymatic activity of the caspase 3/7, 8, and 9 enzymes, the key
regulators of the process of apoptosis were determined using the Promega glo
assays.
Two independent experiments were carried out, as shown in Figure 23, in
which MCF-7 cells were treated with four of the effective extracts (CD, TM, OA,
and AO (L)) for 48 hours. AO (S) was tested in the HeLa cells only (Fig. 23) since
our data suggested that this extract was more HeLa-cell specific for inducing cell
death. As can be seen from Experiment 1 (Fig. 23), CD and TM induced the most
potent anti-proliferative effects in MCF-7 cells (> 80% in Experiment I and > 98% in
Experiment II), and were also able to induce the highest levels of caspase 3/7, 8 and
9 in a statistically significant manner (Fig. 23).

This observation correlated well

with the results of the MTT assays that were obtained earlier. All results obtained
for the induction of caspases were normalized to the number of viable cells in culture
(see Materials & Methods). Since MCF-7 cells do not express caspase 3 [432], any
induction of caspase 3/7 in this system is most likely due to the induction of
caspase7.
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Figure 23: The tested medicinal plant extracts are able to induce various caspase
enzymes in MCF-7 cells.
MCF-7 cells were treated with 250 µg/ml of the stated plant extracts for 48 hours and
then assayed for cell viability and induction of different caspase enzyme activities
(3/7, 8, and 9). CD (Cleome droserifolia), TM (Teucrium muscatensis), OA
(Orchadenus arabicus), AO Acredocarpus orientallus leaf (L). * indicates
statistically significant differences between the control and treated samples (* =
p<0.05; ** = p<0.01; *** = p<0.001).
OA was observed to induce high levels of cytotoxic effects as well in the
MCF-7 cells (~85-95% of DMSO control); however, it was less efficient in the
induction of the caspases compared to CD and TM, especially caspase 8, which was
statistically not significant in Experiment II (Fig. 23). The reason for the increased
cytopathicity observed by OA in the glo assays is not clear, but it was consistently
observed in two independent experiments. Much lower levels of cytopathicity were
observed for this extract in the MCF-7 cells by the MTT assays (Figs. 20 and 21).
The fact that lower levels of caspase induction was also observed suggests that the
cell viability readings may be over reported by the Promega Glo assays. This
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observation is being investigated further to determine which assay is more accurate
to determine cell viability.
AO (L), was less efficient in inducing cell death compared to the other
extracts overall, leading to a much lower induction of caspases in the two
experiments consistently. It was able to activate caspase 8 and 9 in a statistically
significant manner; however, induction of caspase 3/7 was inconsistent with
statistically significant levels in the first experiment and no induction in the second
experiment (Fig. 23).

The inconsistent results observed regarding activation of

certain caspases by OA and AO (L) extracts is probably due to the low levels of
caspases induced, especially by AO (L), which may be at the threshold of detection
of these assays.
Overall, these results suggest that extracts CD and TM primarily contain
bioactive molecules that induce apoptosis as their main mechanism of cell death,
while OA and AO (L) can induce apoptosis, but probably contain other bioactive
molecules that may activate other cell death pathways as their primary deathinducing mechanism.
Finally, the AO (S) extract was tested in the HeLa cells to study its
mechanism of action since it could cause significant cell death only in this cervical
cancer cell line and not the mammary cells. As observed in Figure 24, AO (S) was
able to induce death of HeLa cells; however, it was unable to induce either caspase 3
or 7 enzymatic activities. Interestingly, it was able to activate caspases 8 and 9 in a
statistically significant, but less efficiently when compared to CD or TM and more
like OA and AO (L). This suggests that even though AO (S) can stimulate apoptosis,
similar to AO (L) in MCF-7 cells, AO (S) is probably activating other cell death
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mechanism(s) for its cytotoxic effects in HeLa cells. Once again, AO (S) was able to
induce higher toxicity for HeLa cells as assessed by the glo assay compared to MTT
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Figure 24: Acredocarpus orientallus stem (S) is able to induce caspase 8 and 9 in
HeLa cells.
HeLa cells were treated with 250 µg/ml of the effective extract for 48 hours and then
assayed for cell viability and induction of different caspase enzyme activities (3/7, 8,
and 9). * indicates statistically significant differences between the control and treated
samples (* = p<0.05; ** = p<0.01; *** = p<0.001). This experiment was conducted
once.
3.12 Effect of Medicinal Plant Extracts on Key Apoptotic Proteins
To confirm whether the extracts tested in the Promega glo enzyme assays for
caspase activation could indeed induce apoptosis, our next aim was to confirm the
activation of caspases associated with apoptosis using western blot analyses. MCF-7
or HeLa cells were treated with 250 µg/ml of the appropriate extracts for various
time points, cell lysates were prepared and tested for the expression and cleavage of
various caspases and Poly ADP-ribose polymerase (PARP). PARP is one of the
enzymes that is cleaved during the execution phase of apoptosis by activated
caspases [433]. Thus, activation of caspases and PARP are two major hallmarks of a
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cell undergoing apoptosis. Cell lysates (40 µg protein) from the treated cell cultures
were separated by 10-12% SDS-PAGE, immunoblotted onto nitrocellulose
membranes, and incubated with the appropriate antibodies. The western blots for
each extract were conducted multiple times (2-3 times) using different time points to
ensure that cleavage of the apoptotic proteins could be observed efficiently in at least
one instance, if not all.
Figure 25 shows the western blot analysis of CD, TM, OA, and AO (L)
extracts on MCF-7 cells 24 hours post treatment. Treated cell lysates were tested for
the expression of caspase 7, 8, 9, and PARP proteins and actin was used as a loading
control. As can be seen, we could not detect a cleaved band for any of the caspase
proteins and in fact, the antibody reactivity for caspase 8 and 9 was very poor for
these proteins from MCF-7 cells; however, diminished amounts of procaspases 7, 8,
and 9 could be observed at 24 hours, suggesting that the cleavage reaction had taken
place (Fig. 25, panels A-D). Test of the PARP protein revealed that a cleaved
product could be observed for OA and CD (Fig. 25, panels A and C), while the full
length PARP band intensity had slightly reduced in AO (L)-treated cultures, once
again suggesting the activation of PARP (Fig. 25, panel D). The PARP band had
completely disappeared in TM-treated cultures as well (Fig. 25, panel B), also
suggesting PARP activation, but lack of actin band more likely suggests either
protein degradation, or most likely complete cell death.
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Figure 25: All effective exracts could induce cleavage of one or more proteins of the
apoptotic pathway.
Test of the ability of extracts of Orchadenus arabicus (OA), Cleome droserifolia
(CD), Teucrium muscatensis (TM), and Acredocarpus orientallus (AO) leaf (L) to
induce caspase-dependent apoptosis in MCF-7 cells. MCF-7 cells were treated with
250 µg/ml of the specified extracts for 24 hours. Western blots were carried out on
the untreated, DMSO-treated, and extract-treated cellular lysates for the specified
caspases or poly ADB ribose polymerase (PARP) proteins. Actin antibody was used
as a loading control. FL PARP, full length PARP.
To verify the results, MCF-7 cells were once again treated with the four
extracts, but for shorter time periods. Figure 26 shows the results for MCF-7 cells
treated for < 15 mins, 12hrs, and 24 hrs with OA and CD. Both extracts were able to
induce the cleavage of caspase 7 and PARP starting from around 15 minutes to 12

97
hours. The cleaved product decreased or disappeared by 24 hours, as had been
observed earlier (Fig. 25). No such cleavage or reduced proteins were observed in
either the untreated or DMSO-treated cell lysates. This observation confirms that
these two plant extracts have the potential to induce apoptosis in MCF-7 cells. We
also tested for the expression and cleavage of caspase 8 and 9 proteins; however,
unfortunately, we were unable to detect even the uncleaved bands in the MCF-7 cell
lysates with these antibodies.

Figure 26: Orchadenus arabicus (OA) and Cleome droserifolia (CD) induce caspasedependent apoptosis in MCF-7 cells.
MCF-7 cells were treated with 250 µg/ml of the specified extract for the time frame
indicated. Western blots were carried out on the untreated, DMSO-treated, and
extract-treated cellular lysates for the specified caspases or poly ADB ribose
polymerase (PARP) proteins. Actin antibody was used as a loading control.
To ensure that the results we were getting were truly due to the ability of
these extracts to cause apoptosis, we took one of the CD extracts (ethyl acetate
extract, E) that had shown an inability to cause cell death in MCF-7 cells (Table 8)
and treated the cells in a similar manner (Fig. 27). Results of the western blot
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analysis of these extracts revealed a complete lack of either cleavage of the
procaspases 7, 8, and 9, or PARP, or decrease in their expression in these extracts,
confirming that the cleavage of the procaspases or PARP was truly due to the ability
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< 15 mins

DMSO-treated

Untreated

of these extracts to induce apoptosis.

- Pro-caspase 7
- Pro-caspase 8
- Pro-caspase 9

- Full length PARP
- Cleaved PARP
Figure 27: Cleome droserifolia (CD) ethyl acetate extract (E) is unable to induce
caspase-dependent apoptosis in MCF-7 cells.
MCF-7 cells were treated with 250 µg/ml of CD E for the time frame indicated.
Western blots were carried out on the untreated, DMSO-treated, and extract-treated
cellular lysates for the specified caspases or poly ADB ribose polymerase (PARP)
proteins. Actin antibody was used as a loading control.
Since the test of the TM extract suggested complete degradation of cellular
proteins, we tested the TM extract using the early time points as shown in Figures 26
and 27; however, we observed similar results with complete degradation of the cell
lysates (data not shown). Therefore, we changed our strategy to determine whether
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TM could induce cleavage of procaspases and PARP. Figure 28 reveals the results
of the test of TM extract on MCF-7 cells. In the new design, different concentrations
of the extract were tested at one time; thus a dose-responsive approach was used
rather than a time-dependent approach. As can be seen in Figure 28, using this
methodology, we were able to successfully detect the expression and cleavage of
caspase 7 and PARP proteins, confirming that TM extract has the potential to induce
apoptosis in MCF-7 cells via a caspase-dependent mechanism.

Figure 28: Teucrium muscatensis (TM) induces caspase-dependent apoptosis in
MCF-7 cells.
MCF-7 cells were treated with various concentrations of the extract for 24 hours.
Western blots were carried out on the untreated, DMSO-treated, and extract-treated
cellular lysates for the specified caspases or poly ADB ribose polymerase (PARP)
proteins. FL PARP, full length PARP. Actin antibody was used as a loading control.
Finally, Figure 28 shows the results of the test of Acredocarpus orientalis
(AO) stem (S) and leaf (L) extracts on HeLa cells. As can be seen, both extracts
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were able to induce cleavage of PARP in a time-dependent manner. However, we
could not observe cleavage of caspase 7, but only a time-dependent disappearance of
the full length band (Fig. 28). Based on the previous results obtained, this can be
considered as an indication of activation of the caspases. In the HeLa cell lysates,
the pro-caspase 8 band was weakly detectable, similar to how it was being observed
in the MCF-7 cells; however, pro-caspase 9 could be detected much more strongly
(Fig. 29). Yet, the cleavage of neither pro-caspase 8 or 9 could be clearly observed
and only a decrease in the pro-caspase band with time could be detected. Together
with a clear cleavage of PARP, we take these observations as suggestive of the
induction of apoptosis in these cell lysates.

Figure 29: Acredocarpus orientalis (AO) stem (S) and leaf (L) extracts induce
caspase-dependent apoptosis in HeLa cells.
HeLa cells were treated with 250 µg/ml of the specified extract for the time frame
indicated. Western blots were carried out on the untreated, DMSO-treated, and
extract-treated cellular lysates for the specified caspases or poly ADB ribose
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polymerase (PARP) proteins. FL PARP, full length PARP. Actin antibody was used
as a loading control.
Medicinal plants and their metabolites have an important role in cancer
treatment [462] and their synthetic derivatives could play an important role in
preventing, slowing, or reversing cancer development [463, 464]. In the last part of
this thesis, we screened two purified compounds isolated from the organic extracts as
well as their synthetic derivatives provided by our collaborators to determine their
anticancer activity.
3.13 Description of Purified Compounds and their Derivatives for their Antiproliferation Activity against Cancer Cells
Table 9 lists the description and characteristics of each compound. As can be
seen, the two purified compounds included FTZ from Acridocarpus orientalis (AO)
and IM-60 from Teucrium mascatensis (TM). Screening of the stem (S) and leaf (L)
extracts from AO had revealed divergent effects on normal and cancer cell lines.
While AO (L) was observed to be cytotoxic for all four cell lines tested, the AO (S)
extract was found to have mitogenic activity for the normal MCF-10A cells, minor to
none for the MCF-7 and MDA-MB-231 cells, and intermediate cytotoxic effects for
HeLa cervical cancer cells (Figs. 21 and 22). The TM extract was similar to AO (L)
and observed to be cytotoxic for all four cell lines (Figs. 21 and 22). In addition to
the purified compounds, three synthetic derivatives of FTZ were also obtained as
shown in Table 9: F-OTF-1, F-OTF-SS1, and FTZ-SM3 (Table 9).
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Table 9: List of compounds from the plant extracts and their derivatives
Name

Source (Plant or Synthetic)

Molecular Formula
(MW)

FTZ

Isolated from Acridocarpus orientalis

C21H20O12 (464.376)

F-OTF-1

Synthetic derivative of FTZ

C20H5F15O17S5 (962.550)

F-OTF-SS1

Synthetic derivative of FTZ

C26H12F12O15S4 (920.609)

FTZ-SM3

Synthetic derivative of FTZ

C50H40O7 (752.848)

IM-60

Isolated from Teucrium muscatensis

C15H26O (222.366)

The anti-proliferative potential of the listed compounds was tested by
performing the MTT assays, as described earlier, using the MCF-7 breast cancer cell
line. Figure 30 reveals the results of IM-60 and FTZ. As can be seen, IM-60,
initially showed a spike in cell proliferation, but this was followed by > 90% cell
death at the highest concentration tested (1.7 mM), compared to the DMSO-treated
cells at all the three time points tested (24, 48, and 72 hours; Fig. 30). On the other
hand, FTZ showed a statistically significant proliferative effect on MCF-7 cells
throughout the concentrations tested, similar to what has been observed in its mother
extract AO (S) (Figs. 21, 22 compared to Fig. 30).
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Figure 30: IM-60 induces cytotoxic effects in MCF-7 cells.
MTT assay was used to test different concentrations of purified compounds A and B)
FTZ and C & D) IM-60 on MCF-7 at 24, 48, and 72 hours post treatment. Analysis
of the effect on cell viability of the purified compounds in a dose-dependent manner
at 72 hours post treatment. * indicates statistically significant differences between
the control and treated samples (* = p<0.05; ** p<0.01; *** = p<0.001). These
compounds were tested 2 times in the MTT assay.
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Next we tested the ability of the various molecular derivatives of FTZ to
induce cell death in MCF-7 cells. As can be seen in Figure 31, none of the three
derivatives of FTZ, F-OTF-1, F-OTF-SS1, TZ-SM3, showed any cytotoxic effect on
MCF-7 cell proliferation, and if at all, like the original compound FTZ, demonstrated
a slight proliferative effect at the tested doses (Fig. 31).

Figure 31: FTZ derivatives do not affect viability of MCF-7 cells.
Effect of different concentrations of FTZ derivatives on MCF-7 cells at 24, 48, and
72 hours post treatment. using the MTT assay. A) F-OTF-1, B) F-OTF SS1, C) TZSM3. D) Comparative analysis of the three FTZ derivatives on MCF-7 cell viability
at 72 hours post treatment. * indicates statistically significant differences between the
control and treated samples (* = p<0.05; ** p<0.01; *** = p<0.001). The derivatives
were tested only once in the MTT assay.

105
The cytotoxic effects of IM-60 observed in Figure 30 were at only one
concentration which was also the highest dose tested, suggesting toxic effects of the
compound rather than a specific mechanistic effect on cell proliferation.

To

determine whether a more dose-dependent response could be observed, the MTT
assay was repeated using different dilutions closer to the effective dose and an earlier
time point. Figure 32 shows the results of the MTT assay on MCF-7 cells 6 and 24
hours post treatment. As can be seen, a more effective dose response could be
observed of the IM-60 cell killing. The compound was quite effective, killing > 90%
of the MCF-7 cells by six hours post treatment at concentrations starting with 425
µM.

Figure 32: IM-60 is highly efficient in killing MCF-7 cells in a dose-dependent
manner within six hours of treatment.
Test of IM-60 using MTT assay on MCF-7 A) 6 and B) 24 hours post treatment. C)
Dose-dependent effect of IM-60 on cell viability as a percentage of untreated cells. *
indicates statistically significant differences between the control and treated samples
(* = p<0.05; ** p<0.01; *** = p<0.001). IM-60 was tested twice in the MTT assay.
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3.14 Effect of IM-60 on Cell Morphology
Next, we analyzed the morphological changes being induced by IM-60 on
MCF-7 cells compared to DMSO-treated and untreated cells (Fig. 33). Differences in
cell morphology could be observed by light microscopy as early as 3 hours post
treatment. The changes noticed included cell shrinkage and detachment of the cells
from other cells. These changes suggest apoptotic cell death could be a possible
mechanism used by this purified compound which was isolated from TM. The crude
extract of TM itself was observed to induce these changes as well in MCF-7 cells
(Fig. 22).

Figure 33: IM-60 induces cytopathic effects in MCF-7 cells within 3 hours post
treatment.
Photomicrographs of MCF-7 cells treated with IM-60 compound at 0.425 mM 3
hours post treatment (Magnification 400X).
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3.15 IM-60 can Activate Caspases
To confirm whether IM-60 had the potential to induce apoptosis, the Promega
Cell Titer and caspase glo assays were used to study its ability to activate caspase
enzymes, as shown previously, on MCF-7 cells using 425 µM concentration for six
hours.

Figure 34 reveals the effects of IM-60 on cell viability as well as the

activation of caspase enzymes. As can be seen, > 90% effect on cell viability was
observed in a statistically significant manner (p value < 0.002), confirming the
cytotoxic effects of IM-60 on MCF-7 observed by the MTT assay earlier on (Figs. 30
and 32). Among the four caspase enzymes tested (3/7, 8 and 9), no significant
activation of the initiator caspases 8 or 9 was observed (Fig. 34).
However, a statistically significant activation of caspase 3/7 was observed (p
value <0.03). This data suggests that IM-60 has the ability to induce caspase-3/7
enzymes, thereby leading to caspase-dependent apoptosis in MCF-7 cells. Studies
are in progress to confirm these results and study the mechanism of action of this
compound further.
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Figure 34: IM-60 purified compound is able to induce caspase 3/7 in MCF-7 cells.
MCF-7 cells were treated with 425 µM of the compound for 6 hours and then
assayed for cell viability and induction of different caspase enzyme activities (3/7, 8,
and 9). * indicates statistically significant differences between the control and treated
samples (* = p <0.05; ** = p <0.01; *** = p <0.001). This experiment was
conducted once.
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Chapter 4: Discussion and Future Directions
4.1 Discussion
The aim of this thesis was to characterize the anticancer potential of select
medicinal plants from the Arabian Peninsula. Towards this end, 32 organic extracts
were obtained from five medicinal plants from the University of Nizwa, Oman along
with one essential oil that has already been shown to have anticancer potential (Table
1). Specifically, a breast (MCF-7) and cervical cancer cell line (HeLa) were used for
the initial screening. The extracts were tested for their anticancer potential by first
conducting cell proliferation assay, MTT, to determine whether anti-proliferation
activity could be observed (Table 8). This was followed by confirming this activity
in a select group of extracts chosen from each plant in a wider panel of breast (MCF10A, MCF-7, and MDA-MB-231) and cervical (HeLa) cell lines (Figs. 15-22), where
MCF-10A normal breast cell line served as a control to determine the effect of the
extracts on normal cells. Once confirmed, enzyme activity and western blot assays
were conducted to determine the apoptosis-inducing potential of the short-listed
extracts from each plant, revealing that apoptosis could be induced by them in a
caspase-dependent manner (Figs. 23-29). However, it was apparent that in some
extracts, the primary cell death mechanism may be other than apoptosis, such as
necrosis, necroptosis, autophagy, or a combination thereof (Figs. 23-24).
Furthermore, a few isolated compounds and derivatives were obtained from these
extracts from our collaborators and tested for their anti-proliferation effect on the
MCF-7 cell line (Table 7). One of these isolated compounds was found to be
effective in inducing inhibition of MCF-7 cell proliferation (Figs. 30 and 32), and
activation of caspases (Fig. 34), suggesting that it has specific anticancer activity that
uses a caspase-dependent pathway of apoptotic cell death (Fig. 31). Thus, this work

110
has resulted in the characterization of the anticancer potential of five indigenous
medicinal plants and led to the identification of a possible novel isolated compound
with good apoptotic activity against breast cancer cells. Together, this work reveals
that medicinal plants provide a valuable source for the search of new anticancer
agents since we were able to observe such activity in all the five plants tested in this
study.
An additional outcome of this study was that it shed light on the effectiveness
of various organic solvents in successfully extracting the anticancer activity within
the plant extracts. Briefly, the 32 plant extracts tested used five different organic
solvents, including hexane, chloroform, ethyl acetate, butanol, and methanol, that
were used in a sequential manner [425].

The aim of this type of exhaustive

sequential extraction was to separate the active constituents of plants in a selective
manner based on polarity (charge). The products of these extractions consist of
complex mixtures of metabolites such as alkaloids, glycosides, terpenoids,
flavonoids, lignans, etc. [429, 434]. Thus, this process allows one to start with the
crude plant parts and finally to get the desired portion of various metabolites, while
excluding the unwanted material when treated with selective solvents.
The quality of the extract is influenced by many variables, such as the origin
of the plant and the season of harvest, the plant part used, the solvent, and the
extraction procedure used [435]. Additionally, other variables affecting the quantity
and type of secondary metabolites of the extract depend upon the temperature of
extraction, the nature, concentration, type and polarity of solvent [435].
Furthermore, the choice of the solvent has a direct effect on the quantity of
phytochemicals of the extract, the rate of extraction, variety of compounds extracted,
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ease of the handling procedure of the extracts, toxicity of the solvent for cells, and
the health hazard associated with the extraction [436].
During the extraction, the solvents are diffused into the solid plant part and
the active biological components solubilized through similar polarity. There is a
strong relationship between the biological activity observed and the solvent used in
the extraction process, resulting in the extraction of different potential biological
activities with different polarities [437]. Table 10 shows the type of biologically
active molecules that can be preferentially extracted using different types of solvents.
As can be seen, methanol seems to have the most versatile ability to extract different
types of biological molecules, while chloroform and acetone seem the most limited.
Different solvents can extract the same biological molecules as well. For example,
terpenoids can be extracted by nearly all the solvents listed in Table 10 other than
acetone, while alkaloids can be extracted only by ethanol and ether, and polypeptides
are water soluble only due to their polar nature.
Table 10: Solvents used for active component extraction [438]
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Interestingly, we observed that chloroform was the most effective solvent for
the isolation of anti-proliferation activity for cancer cells among the five organic
solvents tested. Figure 35 plots the number of different types of extracts tested and
whether they could induce anti-proliferation activity in the MTT assay against cancer
cells. As can be seen, 100% of the chloroform extracts were effective for inducing
cell death in either MCF-7 or HeLa cancer cell line, and this activity was not due to
any residual chloroform remaining in the effective extracts (Fig. 14 and NMR data
not shown). Ethyl acetate and methanol were the next best solvents, followed by
hexane, and butanol. The aqueous content remaining, on the other hand, was devoid
of any anti-proliferation activity, suggesting that the biochemical molecules that
induce anti-proliferation are primarily non-polar (hydrophobic) in nature.
Chloroform has been reported to be effective in the extraction of anticancer activity
of several medicinal and other plants, such as Nepeta deflersiana [439], Solanum
nigrum [440], Angelica archangelica [435]. As can be seen from Table 10, it
primarily purifies terpenoides and flavonoides, compounds that have been shown to
have anticancer activity in cell lines [441].

This suggests that some of the

compounds in our extracts may be either terpenoides and/or flavonoids. Thus, the
nature of the solvent is critical for the successful extraction of anticancer activity
from plants and chloroform seems the best among the ones tested in our study.
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Figure 35: Chloroform is the best solvent for the successful extraction of antiproliferation activity from plant extracts.
The graph shows the percent of extracts that were effective in inducing cell death in
MCF-7 or HeLa cell lines based on the solvents that were used for their extraction.
4.1.1 Boswellia sacra essential oil and extracts
Boswellia sacra essential oil is known for its medicinal properties locally and
its anticancer activity has been tested by other research groups [265, 328, 329]. We
confirmed these observations and have shown that the anti-proliferative effect of
Boswellia sacra essential oil was the highest on MDA-MB-231 cell line compared to
the other breast cell line tested, MCF-7, the cervical cancer cell line HeLa, or even
the normal breast cells, MCF-10A. This observation suggests that Boswellia sacra
essential oil may be a good candidate for the treatment of triple negative types of
cancers that are much harder to treat than the hormone responsive breast cancers due
to their resistance to the treatment options. Thus, cancer cell sensitivity to the
essential oil opens up new strategies (such as combined therapy with classical
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chemotherapeutics drugs) to reduce their side effects for treating cancer, even the
types where their normal cells are sensitive to the essential oil.
In addition to the distilled essential oil of Boswellia sacra resin, we also
tested a number of extracts (both organic and aqueous) of the Boswellia sacra resin
and showed that they could also induce death of cancer cells like the essential oil
(Figs. 10 and 11), except for the aqueous extract that showed no such activity. This
observation suggests that the biomolecules responsible for the anticancer activity of
these extracts are hydrophobic in nature and can be successfully extracted using
either chloroform, methanol, or hexane solvents. Furthermore, the chloroform and
methanol extracts induced nearly identical cell death profiles in a dose-dependent
manner in the two cell lines; however, MCF-7 cells were more sensitive to the
hexane extract than HeLa cells as observed by the reduction in cell death with
increasing dilutions of the extract in HeLa but not MCF-7 cells (Fig. 10). This
observation suggests that the constituents of the hexane extract are different from
those of the chloroform and methanol extracts which seem to be more similar. The
residual aqueous extract, on the other hand, led to a proliferation of both cancer cell
lines in a significant manner, suggesting that most of the anti-proliferation activity
from the resin had been successfully removed by the sequential extraction procedure.
4.1.2 Anticancer activity of Cleome droserifolia, Teucrium muscatensis,
Orchadenus arabicus, and Acredocarpus orientalis crude organic extracts
We also screened 28 organic extracts from four regional medicinal plants,
including Cleome droserifolia, Teucrium muscatensis, Orchadenus arabicus, and
Acredocarpus orientalis. We observed Cleome droserifolia to be the most cytotoxic
of the four plants tested in the four cell lines tested, with similar cytotoxic activities
for both normal and cancer cell lines (Figs. 20 and 21).
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As mentioned in the Introduction, Cleome droserifolia has anti-diabetic, antipyretic, analgesic, antimicrobial, liver protective, anti-rheumatic fever, and antiinflammatory properties, and has been shown to have high levels of antioxidants and
many phytochemicals (see Introduction for references).

In terms of anticancer

effects, Cleome gynandra has been observed to have therapeutic effects in the Swiss
albino mouse model off Ehlrich’s ascites carcinoma as well [361, 362]. An extensive
literature search while writing this thesis found one study from Egypt (published in a
German journal) that has shown that aqueous and ethanolic extracts of Cleome
droserifolia variety from Egypt and its four subfractions (hexane, chloroform, ethyl
acetate, and butanol fractions) could induce significant cytotoxic effects on MCF-7
and HCT116, a human colon carcinoma cell line [442]. They isolated six terpenoids
and two flavonol glycosides from the more active chloroform and ethyl acetate
fractions and observed some of these isolated compounds to have cytotoxic effects
similar to those observed with the anticancer drug, doxorubicin [442]. Similarly, in
another recent study, the triterpene from Cleome arabica has been shown to have
cytotoxic effects against the mouse leukemia cell line, P388 [443]. These studies
confirm our findings that Cleome droserifolia has strong anticancer activity. Even
though as a crude extract, Cleome droserifolia has cytotoxic effects against normal
cells, one may be able to isolate bioactive molecules that may have differential
ability to kill normal verses cancer cells, making this medicinal plant valuable for the
exploration of novel anticancer agents.
Test of Teucrium muscatensis extracts overall showed a more moderate antiproliferative activity against cancerous than normal cells of the four plants tested
(Fig. 10). Similar to Cleome droserifolia, the genus Teucrium has been shown to
have anti-bacterial, anti-inflammatory, analgesic, anti-pyretic, hypolipidemic, anti-
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diabetic, and many other activities [419]. Not much is known about the anticancer
potential of Teucrium muscatensis. Most of the scientific studies on this plant have
been done on Teucrium polium. In one early study from 2008, Teucrium polium has
been shown to be an effective and safe chemosensitizing agent for cancer therapy, as
demonstrated by potentiating the anti-proliferation and apoptotic potential of several
chemotherapeutic drugs [444]. It may have anticancer properties due to the presence
of flavonoids and diterpenoids [445-446]. A recent study using decoctions of
Teucrium polium in rats has shown significant anticancer activity in rats against
hepatocellular carcinomas [447].

Teucrium species secondary metabolites have

toxicity against cancer [420-422].
Interestingly, the one effective pure compound identified in this thesis, IM60, was isolated from Teucrium muscatensis crude extracts. It was not only able to
induce anticancer cell proliferation (Figs. 30 and 32), but also activate caspase 7
activity in MCF-7 cells, suggesting that it has the potential to cause caspasedependent cell death (Fig. 34). Further tests of IM-60 revealed that it could induce
rapid cell death (within 3 hours) with morphological changes reminiscent of
apoptosis as observed by microscopy at a concentration of 425 μM (Fig. 33). We
would like to investigate IM-60 further once more product has been made available
to us.
Like Teucrium muscatensis, the Ochradenus arabicus extracts were observed
to have a more moderate anti-proliferation activity on breast cancer cells (Figs. 20
and 21). However, HeLa cells were quite resistant with only ~20% of the cells
sensitive to this plant (Figs. 20 and 21). A recent paper from our collaborators has
analyzed the types of biological activities present in Ochradenus arabicus extracts
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and were shown have a rich source of many different types of bioactivities, including
antibacterial and antifungal activities [448].

These extracts included methanol,

hexane, ethyl acetate, chloroform, butanol, and water. They were further analyzed
for their anticancer activities by another laboratory in Korea on several different cell
lines, including human colon adenocarcinoma cell lines HT29 and HCT116, human
liver cancer cell line HepG2, and MCF-7. In these analyses, only the ethyl acetate,
butanol, and aqueous extracts were observed to cause suppression of the growth of
these cancer cell lines, except HegG2 cells [448]. Interestingly, we got very different
results where we observed anti-proliferation activity primarily with the chloroform
extract in both MCF-7 and HeLa cell lines, and some activity against HeLa cells with
the ethyl acetate extract. In contrast to the anti-proliferation activity observed in the
butanol and aqueous extracts, we did not observe cell death with the butanol or
aqueous extracts in our cell line system (Table 8). In fact none of the aqueous
extracts tested by us, including those from Boswellia sacra, showed any cytotoxic
effects (Table 8).
A closer look at the data presented in the paper suggests that proper controls
were not included in the analysis to compare the rate of proliferation of the treated
cells with cells when exposed to the test extracts [448]. For example, in our case, all
treated samples were compared to the cells treated with the same amount of DMSO
to ensure that the cytotoxic effect of the solvent used to solubilize the extracts was
taken into account. In the published study, no information is provided about how the
extracts were solubilized before addition to the cells. Furthermore, no dose-response
is observed in the treated cells whether 1 μg or 100 μg/ml of the extract is used (Fig.
36). In fact, based on the data provided, not much cytotoxicity is observed in any of
the cell lines since the cell viability rates were well above 80% for all the treated
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cells (Fig. 36). Finally, no details are given as to how the percent of viable cells
were calculated. Thus, based on these observations, we believe that their conclusions
regarding these extracts may not be reflective of what the data suggests.

Figure 36: Reproduction of data claiming to show induction of cell death in various
human cancer cell lines using AO extracts.
Anticancer activities of various concentrations of the extracts against HT29,
HCT116, HepG2 and MCF-7 cell lines. The error bars shows the standard deviation
of the mean values. Figure copied from reference [448].
Finally, the last plant tested was Acredocarpus orientalis for which we tested
the leaf and stem extracts separately. Interestingly, most of the cytotoxic activity of
the plant was observed in its leaf extracts (Figs. 20, 21, and Table 8). In fact, the AO
(S) extracts led to increased proliferation of the breast cancer and normal breast cells
(Figs. 20 and 21, panels A-C). The AO (L) extracts, on the other hand, resulted in
nearly 80-90% decrease in cell viability of all the four cell lines tested (Figs. 20 and
21). Of the four effective AO extracts (ET and CH for AO (L) and BT and CH for
AO (S)), only one (AO (L) CH) was able to kill both MCF-7 and HeLa cell lines,
while the rest showed cytotoxic effects for HeLa cells only (Table 8). This suggests
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that metabolites from Acredocarpus orientalis are more efficient at targeting HeLa
than breast cancer cells.
We further tested one isolated compound from Acredocarpus orientalis, FTZ,
and three of its derivatives for effects on cancer cell proliferation using the MTT
assay. However, FTZ and its derivatives in fact induced cell proliferation (Figs. 30
and 31). In retrospect, being an AO isolate, a plant that showed a more HeLaspecific cell death activity, it is possible that we may have missed observing its
anticancer potential by using MCF-7 cells. Thus, it would be interesting to test FTZ
in HeLa cells to determine if some anti-proliferative effects can be observed. Two
different flavonoids have recently been isolated from Acredocarpus orientalis that
have been tested for cytotoxic activity against three cancer cell lines HT29, HCT116,
and HepG2 [449]. Though the MTT cell viability assay has been conducted by the
same laboratory that tested the Ochradenus arabicus extracts above [448], these
results are more convincing since a control is shown against which the comparison is
being made.

One of the flavonoids isolated, morin, seems to have a 40-55%

inhibitory effect on the three cell lines mentioned, while the other compound, morin3-O-β-D glucopyranoside, has a more drastic effect with 60-90% effect on control
cell viability [449]. These compounds were isolated from the “aerial” part of the
plants. Thus, it is possible that they came from the leaves and our data shows that
leaves have more anticancer activity than the stems. This may also explain why we
did not find FTZ or its derivatives to have any anti-proliferation activity. In fact,
since they were observed to be causing “cell proliferation” just like our AO (S)
extracts, they may represent isolates from the stem part of the plant.
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Overall, these results suggest that Acredocarpus orientalis has compounds
that can both inhibit and activate cancer cell proliferation, and its active anticancer
activity may be more concentrated in the leaves of the plant.
4.1.3 Assessment of apoptosis induced by the crude extracts
Once the anti-proliferation profile of the effective extracts had been
confirmed, multiple assays were used to determine whether these extracts were able
to induce apoptosis. These included: 1) morphological observation of the treated
cells, 2) enzymatic activity analysis of specific caspase enzymes using Promega Glo
assays, and 3) analysis of the cleavage of the procaspase and other apoptosis-related
protein PARP. The morphological analysis of the treated cells revealed that the
various extracts could lead to cell shrinkage and detachment of the treated cells as
well as their rounding off, which are characteristics of apoptotic cells (Figs. 11 and
22). Analysis of different caspase enzyme activities revealed that many of the
caspases were significantly activated by the test extracts (Figs. 13, 23, and 24).
Boswellia sacra essential oil had the most robust activation of the caspases (Fig. 13)
compared to the other extracts (Figs. 23 and 24) with nearly a 10-20-fold higher
activation than that induced by the extracts. This may reflect the concentration of the
anti-apoptotic biological activity in the essential oil compared to the complex
composition of the crude extracts. Additionally, BS, TM, and CD could activate all
the caspases tested (3/7, 8, and 9) significantly (Figs. 13 and 23). OA showed better
activation in the first experiment compared to the second, while AO (L) and AO (S)
were both more limited in their activation of the caspase enzymes, suggesting that
different combination of cell death activities were present in the various crude
extracts and apoptosis is probably not the main cell killing mechanism being
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induced, leaving the room open for the exploration of the activation of other cell
death pathways by these extracts.
Next, western blotting was used to determine whether cleavage of procaspase
proteins could be observed as well as PARP, which are hallmarks of apoptosis
induction. Indeed, cleavage of both caspase 7 and PARP could be detected by OA,
CD, and TM in MCF-7 cells in a reproducible manner (Figs. 26 and 28). However,
OA (L) could only reduce the levels of procaspase 7 in MCF-7 cells, while in HeLa
cells, OA (L) and OA (S) extracts showed only cleavage of PARP with a similar
reduction of procaspase 7 observed in MCF-7 cells, suggesting activation of
procaspase 7. Overall, these results suggest that the tested extracts have the ability to
kill cancer cells by enhancing apoptosis in MCF-7 and for some, in HeLa cells.
4.2 Conclusions
In summary, our work has resulted in the characterization of the anticancer
potential of one essential oil and 32 crude extracts from five medicinal plant species
that have traditionally been used by the locals of the Arabian Peninsula for therapy.
Many of the tested extracts were able to induce suppression of breast and cervical
cancer cell lines and induce apoptosis, which is the most common cell death
mechanism observed in successful anticancer drugs. Furthermore, we were able to
identify one lead compound from Teucrium muscatensis, IM-60, with promising
anticancer activity for breast cancer cells. Thus, active biomolecules from these
plants, such as IM-60, could be a source of promising treatments for various types of
cancers in near future. Overall, our results reveal that traditional medicinal plants
could be an excellent source of natural anticancer agents available to fight cancer.
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4.3 Future Directions
Based on the work outlined above, several lines of investigations can be carried
out in the future. They range from characterizing the extracts further for their
mechanism of action, to exploring the anticancer potential of IM-60 further. Some
of the future experiments that can be conducted are listed below:


Characterize IM-60 and FTZ further to determine their effect on normal cells as
well as other cancer cell lines, especially the effect of FTZ on HeLa cells



Explore the mechanism of action of IM-60. Only caspase 7 was induced without
affecting levels of caspase 8 or 9. Could it be inducing necrotopsis?



Test the derivatives of IM-60 to see if lower concentrations can be used along
with lower toxicity for normal cells (if it has any toxicity for normal cells)



Expand the cell lines to be tested with the essential oil and the effective
extracts (ovarian cancer cell line, for example because of connections between
breast and ovarian cancer )



Test other purified compounds from these effective extracts for anticancer
activity and mechanism of action, and compare different extracts from the same
plant to determine if different mechanism of cell death can be observed that could
suggest the presence of different types of bioactive molecules alters the potential
of the extracts for various biochemical processes



Test the essential oil and select effective isolated compounds directly in animal
model system such as mice to determine their efficacy and toxicity in animals.
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Explore other cell death pathways activated by the crude extracts, especially
extracts which are not clearly showing apoptosis, such as autophagy



Test the potential anticancer activity of isolated compounds from these extracts in
combination with chemotherapeutics drugs being used clinically to reduce their
side effects in treating cancer



Conduct phytochemical screening of the effective extracts to determine the
phytochemical constituents and antioxidant capacity within the effective extracts
which is strongly associated with anticancer activity

4.4 Manuscripts in preparation
1. Induction of caspase-dependent apoptosis by Boswellia sacra essential oil and its
organic extracts in human cancer cells.
2. Cleome droserifolia can induce apoptosis in a caspase-dependent manner in a
human cancer cell lines.
3. Anticancer potential of Teucrium muscatensis for human breast and cervical
cancer cell lines: induction of caspase-dependent apoptosis.
4. Organic extracts of Orchadenus arabicus exhibit potent anticancer activity in
human cancer cell lines.
5. Organic extracts of Acridocarpus orientalis can induce cell death in human breast
and cervical cancer cells, but this activity lies primarily in its leaves and not
stems.
6. Chloroform is a robust solvent for the extraction of anticancer activity from
medicinal plants.

124

References
1.

Farnsworth N. The role of ethnopharmacology in drug development. Ciba
Found Symp. 1990;154:2-11.

2.

Farnsworth N. Ethnopharmacology and drug development. Ciba Found Symp.
1994;185:42-51.

3.

Msonthi J. Traditional Medicine and Health Care Coverage: a reader for health
administrators and practitioners edited by Robert H. Bannerman, John Burton,
and Chen Wen-Chieh Geneva, World Health Organization, 1983. Pp. 342.
Sw.F.35.00. The Journal of Modern African Studies. 1984;22(04):695.

4.

Farid M. Journal of Ethnopharmacology, Edited by L. Rivier & J. G. Bruhn,
Elsevier Sequoia, Lausanne, Switzerland: Volume 1, No. 1, pp. 1–97+, illustr.,
24 × 16 × 0.8 cm, 01 1979. Envir Conserv. 1979;6(02):168.

5.

Solecki R. Shanidar IV. A Neanderthal Flower Burial in Northern Iraq.
Science. 1975;190(4217):880-881.

6.

Rates S. Plants as source of drugs. Toxicon. 2001;39(5):603-613.

7.

Phillipson J. Phytochemistry
2001;56(3):237-243.

8.

Farnsworth N, Akerele O, Bingel A, Soejarto D, Guo Z. Medicinal plants in
therapy. Bull WHO. 1985;63:965-981.

and

medicinal

plants.

Phytochemistry.

9. Fabricant D Farnsworth N. The Value of Plants Used in Traditional Medicine for
Drug Discovery. Environ Health Perspect. 2001;109(s1):69-75.
10.

Prance G. Endangered Plants of the USA Endangered and Threatened Plants of
the United States Edward S. Ayensu Robert A. DeFilipps. BioScience.
1978;28(9):598-598.

11.

Verpoorte R. Pharmacognosy in the New Millennium: Lead finding and
Biotechnology. Journal of Pharmacy and Pharmacology. 2000;52(3):253-262.

12.

Hamburger M, Hostettmann K. 7. Bioactivity in plants: the link between
phytochemistry and medicine. Phytochemistry. 1991;30(12):3864-3874.

13.

Vagelos P. Are prescription drug prices high?. Science. 1991;252(5009):10801084.

14.

Almeida C, Barry S. Cancer. Chichester, UK: Wiley-Blackwell; 2010.

15.

W S, P W. World Cancer Report 2014. Geneva: World Health Organization;
2014.

125
16.

American Cancer Society. Cancer Facts and Figures 2015. Atlanta, GA:
American Cancer Society; 2015.

17.

Altekruse SF, Kosary CL, Krapcho M. Cancer Statistics, Trends, and Multiple
Primary Cancer Analyses from the Surveillance, Epidemiology, and End
Results (SEER) Program Review,1975-2007. National Cancer Institute, 2010.

18.

ohnson A, Shekhdar . Breast cancer incidence: what do the figures mean .
Journal of Evaluation in Clinical Practice. 2005 11(1):2 -31.

19.

Globocan 2012: Estimated cancer incidence, mortality and prevalence
worldwide in 2012 [Internet]. 2012 [cited 10 August 2016]. Available from:
http:// globocan.iarc.fr/pages/fact_sheets_cancer.aspx.

20.

Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646-674.

21.

Goodwin P, Phillips K, West D. Breast cancer prognosis in BRCA1 and
BRCA2 mutation carriers: an international prospective breast cancer family
registry population-based cohort study. Clinical Oncology. 2012;30(1):19-26.

22.

Mavaddat N, Barrowdale D, Andrulis L. Pathology of Breast and Ovarian
Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).Cancer
Epidemiol Biomarkers Prev. 2012;21(1):134-147.

23.

Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S et
al. A strong candidate for the breast and ovarian cancer susceptibility gene
BRCA1. Science. 1994;266(5182):66-71.

24.

Futreal P, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S et
al. BRCA1 mutations in primary breast and ovarian carcinomas. Science.
1994;266(5182):120-122.

25.

Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N et al.
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome
13q12-13. Science. 1994;265(5181):2088-2090.

26.

Colditz G, Rosner B, Speizer F. Risk factors for breast cancer according to
family history of breast cancer. For Nurses Health study research group.
Journal of National Cancer Institute. 1996;88(6):365-371.

27.

Andrieu N. Effect of chest x-rays on the risk of breast cancer among BRCA1/2
mutation carriers in the international BRCA1/2 carrier cohort study: a report
from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS collaborators'
group. Journal of Clinical Oncology. 2006;24(21):3361-3366.

126
28.

Bhatia S, Robison L, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F et al.
Breast cancer and other second neoplasms after childhood Hodgkin's disease.
New England Journal of Medicine. 1996;334(12):745-751.

29.

Breast cancer and hormone replacement therapy: collaborative reanalysis of
data from 51 epidemiological studies of 52 705 women with breast cancer and
108 411 women without breast cancer. The Lancet. 1997;350(9084):10471059.

30.

Wolin K, Carson K, Colditz G. Obesity and cancer. Oncologist.
2010;15(6):556-565.

31.

Morimoto L, White E, Chen Z. Obesity, body size, and risk of postmenopausal
breast cancer: the women's Health Initiative (U.S). Cancer Causes Control.
2002;13(8):741-751.

32.

Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data
from 53 epidemiological studies, including 58 515 women with breast cancer
and 95 067 women without the disease. Br J Cancer. 2002;87(11):1234-1245.

33.

Shu Y. Recent Natural Products Based Drug Development: A Pharmaceutical
Industry Perspective. J Nat Prod. 1998;61(8):1053-1071.

34.

Norleena P G, A. R. M R, Soley B, John M P, Dong M S, Fadlo R K et al.
Cancer prevention with natural compounds. Seminars in Oncology.
2010;37(3):258-281.

35.

Kaur G, Verma N. Nature curing cancer – review on structural modification
studies with natural active compounds having anti-tumor efficiency.
Biotechnology Reports. 2015;6:64-78.

36.

Wang Z, Huang M, Ferraro T. Inhibitory effect of green tea in the drinking
water on tumorigenesis by ultraviolet light and 12-O-tetradecanoylphorbol-13acetate in the skin of SKH-1 mice. Cancer Research. 1992;52:1162-1170.

37.

Hara , Matsuzaki S, akamura . Anti-tumor activity of tea catechins.
Journal of apan Society of utrition and Food Science. 1989 42(1):39-45.

38.

Liu J, Chen S, Lin C, Tsai S, Liang Y. Inhibition of melanoma growth and
metastasis by combination with-epigallocatechin-3-gallate and dacarbazine in
mice. Journal of Cellular Biochemistry. 2001;83(4):631-642.

39.

Kuroda Y, Hara Y. Anti mutagenic and anti carcinogenic activity of tea
polyphenols. Mutat Res. 1999;436:69-97.

40.

Jung Y, Ellis L. Inhibition of tumour invasion and angiogenesis by
epigallocatechin gallate (EGCG), a major component of green tea. International

127
Journal of Experimental Pathology. 2001;82(6):309-316.
41.

Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature. 1999;398:381.

42.

Heilbrun L, Nomura A, Stemmermann G. Black tea consumption and cancer
risk: a prospective study. Br J Cancer. 1986;54(4):677-683.

43.

Kinlen L, Willows A, Goldblatt P, Yudkin J. Tea consumption and cancer. Br J
Cancer. 1988;58(3):397-401.

44.

Inoue M, Tajima K, Mizutani M, Iwata H, Iwase T, Miura S et al. Regular
consumption of green tea and the risk of breast cancer recurrence: follow-up
study from the Hospital-based Epidemiologic Research Program at Aichi
Cancer Center (HERPACC), Japan. Cancer Letters. 2001;167(2):175-182.

45.

Bharti A, Donato N, Singh S, Aggarwal B. Curcumin inhibits constitutive NFkB, IkBa kinase, inhibits proliferation, and induces apoptosis in human
multiple myeloma cells. Blood. 2003;101:1053-1062.

46.

Anto R, Mukhopadhyay A, Denning K, Aggrawal B. Curcumin induces
apoptosis through activation of caspase-8, BID cleavage and cytochrome C
release. Carcinogenesis. 2002;23:143.

47.

Mehta K, Pantazis P, McQueen T, Aggarwal B. Antiproliferative effect of
curcumin (diferuloylmethane) against human breast tumor cell lines.
Anticancer Drugs. 1997;8(5):470-481.

48.

Aggarwal B, Shishodia S. Curcumin suppresses metastasis in a human breast
cancer xenograft model: association with suppression of nuclear factor-kB,
cyclooxygenase-2 and matrix metalloproteinases. U.S. Army Medical Research
and Material Command and Cancer Center Core Grant. US.

49.

Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal B.
Curcumin downregulates cell survival mechanisms in human prostate cancer
cell lines. Oncogene. 2001;20(52):7597-7609.

50.

Dorai T, Cao Y, Dorai B, Buttyan R, Katz A. Therapeutic potential of curcumin
in human prostate cancer. III. Curcumin inhibits proliferation, induces
apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.
The Prostate. 2001;47(4):293-303.

51.

Shishodia S, Potdar P, Gairola C, Aggarwal B. Curcumin (diferuloylmethane)
down-regulates cigarette smoke-induced NF- B activation through inhibition of
I B kinase in human lung epithelial cells: correlation with suppression of COX2, MMP-9 and cyclin D1. Carcinogenesis. 2003;24(7):1269-1279.

52.

Xu G, Chu Y, Jiang N, Yang J, Li F. The three dimensional quantitative

128
structure activity relationships (3D-QSAR) and Docking Studies of Curcumin
Derivatives as Androgen Receptor Antagonists. IJMS. 2012;13(12):6138-6155.
53.

Perry M, Demeule M, Régina A, Moumdjian R, Béliveau R. Curcumin inhibits
tumor growth and angiogenesis in glioblastoma xenografts. Molecular
Nutrition & Food Research. 2010;54:1192-1201.

54.

Huang M, Lou Y, Ma W, Newmark H, Reuhl K, Conney A. Inhibitory effects
of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in
mice. Cancer Research. 1994;54(22):5841-5847.

55.

Kawamori T, Lubet R, Steele V. Chemopreventive effect of curcumin, a
naturally occurring anti-inflammatory agent, during the promotion/ progression
stages of colon cancer. Cancer Research. 1999;59:597-601.

56.

Conney A. Enzyme induction and dietary chemicals as approaches to cancer
chemoprevention: the seventh De-Witt S. Goodman Lecture. Cancer Research.
2003;63(21):7005-7031.

57.

Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary
antioxidants: progress and promise. Antioxidants & Redox Signaling.
2008;10(3):475-510.

58.

Surh Y, Chun K. Cancer chemopreventive effects of curcumin. Adv Exp Med
Biol. 2007;595:149-172.

59.

Li M, Zhang Z, Hill D, Wang H, Zhang R. Curcumin, a dietary component, has
anticancer, chemosensitization, and radiosensitization effects by downregulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
Cancer Research. 2007;67(5):1988-1996.

60.

Kuttan G, Kumar K, Guruvayoorappan C, Kuttan R. Antitumor, anti-invasion,
and anti-metastatic effects of curcumin. Adv Exp Med Biol. 2007;595:173-184.

61.

Verma S, Salamone E, Goldin B. Curcumin and genistein, plant natural
products, show synergistic inhibitory effects on the growth of human breast
cancer MCF-7 cells induced by estrogenic pesticides. Biochemical and
Biophysical Research Communications. 1997;233(3):692-696.

62.

Khafif A. Quantitation of chemopreventive synergism between (-)epigallocatechin- 3-gallate and curcumin in normal, premalignant and
malignant human oral epithelial cells. Carcinogenesis. 1998;19(3):419-424.

63.

Sreepriya M, Bali G. Effects of administration of embelin and curcumin on
lipid peroxidation, hepatic glutathione antioxidant defense and hematopoietic
system
during
N-nitrosodiethylamine/Phenobarbital-induced
hepatocarcinogenesis in Wistar rats. Molecular and Cellular Biochemistry.

129
2006;284(1-2):49-55.
64.

Pezzuto J. Resveratrol as an inhibitor of carcinogenesis. Pharm Biol.
2008;46:443-573.

65.

Sengottuvelan M, Nalini N. Dietary supplementation of resveratrol suppresses
colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating
biotransforming enzymes and aberrant crypt foci development. British Journal
of utrition . 2006 96(01):145.

66.

Waffo-Téguo P, Hawthorne M, Cuendet M, Mérillon J, Kinghorn A, Pezzuto J
et al. Potential Cancer-Chemopreventive Activities of Wine Stilbenoids and
Flavons Extracted From Grape (Vitis vinifera) Cell Cultures. Nutrition and
Cancer. 2001;40(2):173-179.

67.

Aggarwal B, Shishodia S. Resveratrol in health and diseases. Boca Raton: CRC
Press; 2005.

68.

A.J.Gescher. Resveratrol from red grapes-pedestrain polyphenol or miraculous
anticancer agent?. UK: The University of Manchester; 2010.

69.

Jang M. Cancer chemopreventive activity of resveratrol, a natural product
derived from grapes. Science. 1997;275(5297):218-220.

70.

Athar M, Back J, Tang X, Kim K, Kopelovich L, Bickers D et al. Resveratrol:
A review of preclinical studies for human cancer prevention. Toxicology and
Applied Pharmacology. 2007;224(3):274-283.

71.

Li Z. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced
esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis.
2002;23(9):1531-1536.

72.

Ma X, Tian X, Huang X, Yan F, Qiao D. Resveratrol-induced mitochondrial
dysfunction and apoptosis are associated with Ca2+ and mCICR-mediated
MPT activation in HepG2 cells. Molecular and Cellular Biochemistry.
2007;302(1-2):99-109.

73.

Kubota T, Uemura Y, Kobayashi M, Taguchi H. Combined effects of
resveratrol and paclitaxel on lung cancer cells. Anticancer Research.
2003;23:4039-4046.

74.

Shimoi K, Saka N, Kaji K, Kinae R. Metabolic fate of luteolin and its
functional activity at focal site. BioFactors. 2000;12(1-4):181-186.

75.

Yang S, Yang W, Chang H, Chu S, Hsieh Y. Luteolin induces apoptosis in oral
squamous cancer cells. Journal of Dental Research. 2008;87(4):401-406.

76.

Zhang Q, Zhao X, Wang Z. Flavones and flavonols exert cytotoxic effects on a

130
human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest
and inducing apoptosis. Food and Chemical Toxicology. 2008;46(6):20422053.
77.

Ju W, Wang X, Shi H, Chen W, Belinsky S, Lin Y. A critical role of luteolininduced reactive oxygen species in blockage of tumor necrosis factor-activated
nuclear factor- kappaB pathway and sensitization of apoptosis in lung cancer
cells. Molecular Pharmacology. 2007;71(5):1381-1388.

78.

Lim D, Jeong Y, Tyner A, Park J. Induction of cell cycle arrest and apoptosis in
HT-29 human colon cancer cells by the dietary compound luteolin. AJP:
Gastrointestinal and Liver Physiology. 2007;292(1):G66-G75.

79.

Selvendiran K. Luteolin Promotes Degradation in Signal Transducer and
Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the
Antitumor Potential of Flavonoids. Cancer Research. 2006;66(9):4826-4834.

80.

Chiu F, Lin J. Downregulation of androgen receptor expression by luteolin
causes inhibition of cell proliferation and induction of apoptosis in human
prostate cancer cells and xenografts. The Prostate. 2008;68(1):61-71.

81.

Wu B, Zhang Q, Shen W, Zhu J. Anti-proliferative and chemosensitizing
effects of luteolin on human gastric cancer AGS cell line. Molecular and
Cellular Biochemistry. 2008;313(1-2):125-132.

82.

Manju V, Nalini N. Protective role of luteolin in 1,2-dimethylhydrazine
induced experimental colon carcinogenesis. Cell Biochemistry and Function.
2007;25(2):189-194.

83.

Jurenka J. Therapeutics applications of pomegranate (Punica granatum L): a
review. Alternative Medicine Rev. 2008;13:128-144.

84.

Heber D. Multitargeted therapy of cancer by ellagitannins. Cancer Letters.
2008;269(2):262-268.

85.

Chaturvedi P, Bhui K, Shukla Y. Lupeol: Connotations for chemoprevention.
Cancer Letters. 2008;263(1):1-13.

86.

Ye B, Aponte M, Dai Y, Li L, Ho M, Vitonis A et al. Ginkgo biloba and
ovarian cancer prevention: Epidemiological and biological evidence. Cancer
Letters. 2007;251(1):43-52.

87.

DeFeudis F, Papadopoulos V, Drieu K. Ginkgo biloba extracts and cancer: a
research area in its infancy. Journal of Fundamental & Clinical Pharmacology.
2003 1 (4):405-41 .

88.

Ognjanovic B, Markovic S, Pavlovic S, Zikic R. Effect of chronic cadmium

131
exposure on antioxidant defense system in some tissues of rats: protective
effect of selenium. Physiological Research. 2008;57:403-411.
89.

Ghosh T, Maity K, Sengupta P, Dash K, Bose A. Antidiabetic and in vivo
antioxidant activity of ethanol extract of Bacopa monnieri Linn. aerial parts: a
possible mechanism of action. Iranian Journal of Pharmacology and Research.
2008;7:61-68.

90.

Rattanachitthawat S, Suwannalert P, Reingrojpitak S, Chaiyasut C,
Pantuwatana S. Phenolic content and antioxidant activities in red unpolished
Thai rice prevents oxidative stress in rats. Journal of Medical Plants.
2010;4(9):796-801.

91.

Zulkhairi A, Khairunnuur S, Hafipah N, Azrina A, Rasadah A, Kamilah K. An
aqueous extract of citrus mitis possesses antioxidative properties and improves
plasma lipid profiles in rat induced with high cholesterol diet. Journal of
Medical plant Research. 2010;4(1):49-57.

92.

Chiang L, Teik L, Chaiang W. Immunomodulatory activities of flavonoids,
monoterpenoids, triterpenoids, iridoid glycosides and phenolic compounds of
plantago species. Planta Med. 2003;69(7):600-604.

93.

Ali Ghasemzadeh. Flavonoids and phenolic acids: Role and biochemical
activity in plants and human. Journal of Medicinal Plants esearch .
2011 5(31): 669 -6 03.

94.

Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food
sources and bioavailability. American Journal of Clinical Nutrition.
2004;79:727-747.

95.

Dahan A, Altman H. Food–drug interaction: grapefruit juice augments drug
bioavailability—mechanism, extent and relevance. European Journal of
Clinical Nutrition. 2004;58(1):1-9.

96.

Tolonen M, Taipale M, Viander B, Pihlava J, Korhonen H, Ryhänen E. PlantDerived Biomolecules in Fermented Cabbage. Journal of Agricultural and Food
Chemistry. 2002;50(23):6798-6803.

97.

Austin M, Noel J. The Chalcone Synthase Superfamily of Type III Polyketide
Synthases. Journal of Natural Product Reports. 2003;20:79-110.

98.

Seigler D. Plant secondary metabolism. Boston: Kluwer Academic; 1998.

99.

Luk’yanova L, Storozheva Z, Proshin A. Corrective effect of flavonoidcontaining preparation extra life on the development of Parkinson’s syndrome.
Bulletin of Experimental Biology and Medicine. 2007;144(1):42-45.

100. Fimognari C, Berti F, Cantelli Forti G, Hrelia P. In vitro Antitumor Activity of
cyanidin-3-O-&beta;-Glucopyranoside. Chemotherapy. 2005;51(6):332-335.

132
101. Zhang Y, Seeram N, Lee R, Feng L, Heber D. Isolation and Identification of
Strawberry Phenolics with Antioxidant and Human Cancer Cell
Antiproliferative Properties. Journal of Agricultural and Food Chemistry.
2008;56(3):670-675.
102. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S
et al. Potent inhibitory action of red wine polyphenols on human breast cancer
cells. Journal of Cellular Biochemistry. 2000;78(3):429-441.
103. Weisburg J, Weissman D, Sedaghat T, Babich H. In vitro cytotoxicity of
epigallocatechin gallate and tea extracts to cancerous and normal cells from the
human oral cavity. Journal of Pharmacological and Toxicological Methods.
2004 95(4):191-200.
104. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Antiproliferative activity
of flavonoids on several cancer cell lines. Bioscience, Biotechnology and
Biochemistry. 1999;63(5):896-899.
105. Manthey J, Guthrie N, Grohmann K. Biological properties of citrus flavonoids
pertaining to cancer and inflammation. Journal of Current Medicinal
Chemistry. 2001;8(2):135-153.
106. Meiyanto E, Hermawan A, Anindyajati A. Natural products for cancer targeted
therapy: citrus flavonoids as potent chemopreventive agents. Asian Pacific
Journal of Cancer Prevention. 2012;13(2):427-436.
107. Ogasawara M, Matsunaga T, Suzuki H. Differential effects of antioxidants on
the in vitro invasion, growth and lung metastasis of murine colon cancer cells.
Journal of Biological and Pharmaceutical Bulletin. 200 30(1):200-204.
108. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer
chemoprevention. The Journal of Nutritional Biochemistry. 2007;18(7):427442.
109. Luo H, Rankin G, Liu L, Daddysman M, Jiang B, Chen Y. Kaempferol inhibits
angiogenesis and VEGF expression through both HIF dependent and
independent pathways in human ovarian cancer cells. Nutrition and Cancer.
2009;61(4):554-563.
110. Tang F, Chiang E, Shih C. Green tea catechin inhibits ephrin-A1-mediated cell
migration and angiogenesis of human umbilical vein endothelial cells. The
Journal of Nutritional Biochemistry. 2007;18(6):391-399.
111. Chen G, Heilbrun L, Venkatramanamoorthy R, Maranci V, Redd J, Klurfeld D
et al. Effects of low-fat and/or high fruit-and-vegetable diets on plasma levels
of 8-Isoprostane-F 2α in the nutrition and breast health study. utrition and
Cancer. 2004;50(2):155-160.

133
112. Park H, Lee S, Son H, Park S, Kim M, Choi E et al. Flavonoids inhibit
histamine release and expression of proinflammatory cytokines in mast cells.
Journal of Archives of Pharmacol esearch. 2008 31(10):1303-1311.
113. Lim J, Park J, Min D, Chang J, Lee Y, Park Y et al. NAG-1 up-regulation
mediated by EGR-1 and p53 is critical for quercetin-induced apoptosis in
HCT116 colon carcinoma cells. Apoptosis. 2006;12(2):411-421.
114. Paliwal S, Sundaram J, Mitragotri S. Induction of cancer-specific cytotoxicity
towards human prostate and skin cells using quercetin and ultrasound. British
Journal of Cancer. 2005;92:499-502.
115. Hwang H, Park H, Chung H, Min H, Park E, Hong J et al. Inhibitory effects of
caffeic acid phenethyl ester on cancer cell metastasis mediated by the downregulation of matrix metalloproteinase expression in human HT1080
fibrosarcoma cells. Journal of Nutritional Biochemistry. 2006;5:356-362.
116. Madlener S, Illmer C, Horvath Z, Saiko P, Losert A, Herbacek I et al. Gallic
acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60
promyelocytic leukemia cells. Cancer Letters. 2007;245(1-2):156-162.
117. Cheng A, Huang T, Lai C, Pan M. Induction of apoptosis by luteolin through
cleavage of Bcl-2 family in human leukemia HL-60 cells. European Journal of
Pharmacology. 2005;509(1):1-10.
118. Lee H, Wang C, Kuo H, Chou F, Jean L, Tseng T. Induction apoptosis of
luteolin in human hepatoma HepG2 cells involving mitochondria translocation
of Bax/Bak and activation of JNK. Toxicology and Applied Pharmacology.
2005;203(2):124-131.
119. Monasterio A, Urdaci M, Pinchuk I, Lopez-Moratalla N, Martinez-Irujo J.
Flavonoids induce apoptosis in human leukemia U937 cells through caspaseand caspase-calpain-dependent pathways. Nutrition and Cancer. 2004;50(1):90100.
120. Chiang C, Way T, Lin J. Sensitizing HER2-overexpressing cancer cells to
luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression
with rapamycin. Molecular Cancer Therapeutics. 2007;6(7):2127-2138.
121. Lim D, Jeong Y, Tyner A, Park J. Induction of cell cycle arrest and apoptosis in
HT-29 human colon cancer cells by the dietary compound luteolin. AJP:
Gastrointestinal and Liver Physiology. 2007;292(1):G66-G75.
122. Fang J, Zhou Q, Shi X, Jiang B. Luteolin inhibits insulin-like growth factor 1
receptor signaling in prostate cancer cells. Carcinogenesis. 2007;28(3):713-723.
123. Kandaswami C, Lee L, Lee P, Hwang J, Ke F, Huang Y et al. The antitumor

134
activities of flavonoids. In Vivo. 2005;19:895-909.
124. Bagli E. Luteolin Inhibits Vascular Endothelial Growth Factor-Induced
Angiogenesis; Inhibition of endothelial cell survival and proliferation by
targeting phosphatidylinositol 3'-kinase activity. Cancer Research.
2004;64(21):7936-7946.
125. Mancher SK, Wang LG. Promiscuous drugs compared to selective drugs
(promiscuity can be virtue). BMC. 2005;(5):3.
126. Aggarwal B, Vijayalekshmi R, Sung B. Targeting inflammatory pathways for
prevention and therapy of cancer: short-term friend, long-term foe. Clinical
Cancer Research. 2009;15(2):425-430.
127. Sethi G. TNF: A master switch for inflammation to cancer. Frontiers in
Bioscience. 2008;13:5094.
128. Luqman S, Pezzuto . FκB: a promising target for natural products in cancer
chemoprevention. Phytother Res. 2010; 24:949-963.
129. Ravindran J, Prasad S, Aggarwal B. Curcumin and cancer cells: how many
ways can curry kill tumor cells selectively?. The AAPS Journal.
2009;11(3):495-510.
130. Appella E, Anderson C. Post-translational modifications and activation of p53
by genotoxic stresses. European Journal of Biochemistry. 2001;268(10):27642772.
131. Bode A, Dong Z. Post-translational modification of p53 in tumorigenesis.
Nature Reviews Cancer. 2004;4(10):793-805.
132. Tian B, Wang Z, Zhao Y, Wang D, Li Y, Ma L et al. Effects of curcumin on
bladder cancer cells and development of urothelial tumors in a rat bladder
carcinogenesis model. Cancer Letters. 2008;264(2):299-308.
133. Schmidt F, Knobbe C, Frank B, Wolburg H, Weller M. The topoisomerase II
inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant
glioma cell lines. Oncology Reports. 2008;19(4):1061-1066.
134. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nature Cell
Biology. 2002;4(5):E131-E136.
135. Hastak K. Ablation of either p21 or Bax prevents p53-dependent apoptosis
induced by green tea polyphenol epigallocatechin-3-gallate. The FASEB
Journal. 2005;19:789-791.
136. Roy A, Baliga M, Katiyar S. Epigallocatechin-3-gallate induces apoptosis in
estrogen receptor-negative human breast carcinoma cells via modulation in

135
protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther.
2005;4:81-90.
137. Thakur V, Ruhul Amin A, Paul R, Gupta K, Hastak K, Agarwal M et al. p53Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells
from PUMA-mediated apoptosis induced by EGCG. Cancer Letters.
2010;296(2):225-232.
138. Choudhuri T, Pal S, Agwarwal M, Das T, Sa G. Curcumin induces apoptosis in
human breast cancer cells through p53-dependent Bax induction. FEBS Letters.
2002;512(1-3):334-340.
139. Kim H, Kim M, Jeong M. EGCG blocks tumor promoter-induced MMP-9
expression via suppression of MAPK and AP-1 activation in human gastric
AGS cells. Anticancer Research. 2004;24:747-753.
140. Dhandapani K, Mahesh V, Brann D. Curcumin suppresses growth and
chemoresistance of human glioblastoma cells via AP-1 and FκB transcription
factors. Journal of Neurochemistry. 2007;102(2):522-538.
141. Shimizu M, Deguchi A, Joe A, Mckoy J, Moriwaki H, Weinstein I. EGCG
inhibits activation of HER3 and expression of cyclooxygenase-2 in human
colon cancer cells. Journal of Experimental Therapeutics and Oncology.
2005 5:69- 8.
142. Korutla L, Cheung J, Medelsohn J, Kumar R. Inhibition of ligand-induced
activation of epidermal growth factor receptor tyrosine phosphorylation by
curcumin. Carcinogenesis. 1995;16(8):1741-1745.
143. Patel B, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi A et al. Curcumin
enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth
inhibition of colon cancer cells by modulating EGFR and IGF-1R. International
Journal of Cancer. 2008;122(2):267-273.
144. Zhang X, Zhang H, Tighiouart M, Lee J, Shin H, Khuri F et al. Synergistic
inhibition of head and neck tumor growth by green tea (−)‐epigallocatechin‐3‐
gallate and EGFR tyrosine kinase inhibitor. International Journal of Cancer.
2008;123(5):1005-1014.
145. Masuda M, Suzui M, Weinstein I. Effects of epigallocatechin-3-gallate on
growth, epidermal growth factor receptor signaling pathways, gene expression,
and chemosensitivity in human head and neck squamous cell carcinoma cell
lines. Clinical Cancer Research. 2001;7:4220-4229.
146. Shimizu M, Deguchi A, Hara Y, Moriwaki H, Weinstein I. EGCG inhibits
activation of the insulin-like growth factor-1 receptor in human colon cancer
cells.
Biochemical
and
Biophysical
Research
Communications.

136
2005;334(3):947-953.
147. Fang J, Zhou Q, Shi X, Jiang B. Luteolin inhibits insulin-like growth factor 1
receptor signaling in prostate cancer cells. Carcinogenesis. 2007;28(3):713-723.
148. Shankar S. EGCG inhibits growth, invasion, angiogenesis and metastasis of
pancreatic cancer. Frontiers in Bioscience. 2008;13(13):440-452.
149. Bagli E. Luteolin Inhibits Vascular Endothelial Growth Factor-Induced
Angiogenesis; Inhibition of Endothelial Cell Survival and Proliferation by
Targeting Phosphatidylinositol 3'-Kinase Activity. Cancer Research.
2004;64(21):7936-7946.
150. Lin Y, Kunnumakkara A, Nair A, Merritt W, Han L, Armaiz-Pena G et al.
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by
targeting the nuclear factor- B pathway. Clinical Cancer Research.
2007;13(11):3423-3430.
151. Gururaj A, Belakavadi M, Venkatesh D, Marmé D, Salimath B. Molecular
mechanisms of anti-angiogenic effect of curcumin. Biochemical and
Biophysical Research Communications. 2002;297(4):934-942.
152. Guo Y, Wang S, Hoot D, Clinton S. Suppression of VEGF-mediated autocrine
and paracrine interactions between prostate cancer cells and vascular
endothelial cells by soy isoflavones. The Journal of Nutritional Biochemistry.
2007;18(6):408-417.
153. Schindler R, Mentlein R. Flavonoids and vitamin E reduce the release of the
angiogenic peptide vascular endothelial growth factor from human tumor cells.
Nature. 2006;136:1477-1482.
154. Ren W, Qiao Z, Wang H, Zhu L, Zhang L. Flavonoids: Promising Anticancer
Agents. Medicinal Research Reviews. 2003;23(4): 519-534.
155. Fisher B, Fisher E, Redmond C, Brown A. Tumor nuclear grade, estrogen
receptor, and progesterone receptor: Their value alone or in combination as
indicators of outcome following adjuvant therapy for breast cancer. Breast
Cancer Res Tr. 1986;7(3):147-160.
156. Thor A, Berry D, Budman D, Muss H, Kute T, Henderson I et al. erbB-2, p53,
and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal
National Cancer Institute. 1998;90(18):1346-1360.
157. Paik S, Bryant J, Park C. erb-B-2 and response to doxorubicin in patients with
axillary lymph node-positive, hormone receptor-negative breast cancer. Journal
National Cancer Institute. 1998;90(18):1361-1370.

137
158. Simpson J, Gray R, Dressler L. Prognostic value of histologic grade and
proliferative activity in axillary node-positive breast cancer: results from the
Eastern Cooperative Oncology Companion Study, EST 4189. Clinical
Oncology. 2000;10(18):2059-2069.
159. Hutchins L. Randomized, Controlled trial of cyclophosphamide, methotrexate,
and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with
and without tamoxifen for high-risk, node-negative breast cancer: treatment
results of intergroup protocol INT-0102. Journal of Clinical Oncology.
2005;23(33):8313-8321.
160. Lingos T, Recht A, Vicini F, Abner A, Silver B, Harris J. Radiation
pneumonitis in breast cancer patients treated with conservative surgery and
radiation
therapy.
International
Journal
of
Radiation
Oncology*Biology*Physics. 1991;21(2):355-360.
161. Højris I, Overgaard M, Christensen J, Overgaard J. Morbidity and mortality of
ischaemic heart disease in high-risk breast-cancer patients after adjuvant
postmastectomy systemic treatment with or without radiotherapy: analysis of
DBCG 82b and 82c randomised trials. The Lancet. 1999;354(9188):1425-1430.
162. Nixon A, Manola J, Gelman R. No long term increase in cardiac-related
mortality after breast conserving surgery and radiation therapy using modern
techniques. Clinical Oncology. 1998;16(4):1374-1379.
163. Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury:
follow-up of two different fractionation schedules. Radiotherapy and Oncology.
1990;18(3):213-220.
164. Fraass B, Roberson P, Lichter A. Dose to the contralateral breast due to
primary breast irradiation. International Journal of Radiation Oncology.
1985;11(3):485-497.
165. Inskip P, Stovall M, Flannery J. Lung cancer risk and radiation dose among
women treated for breast cancer. Journal National Cancer Institute.
1994;86(13):983-988.
166. Effects of radiotherapy and of differences in the extent of surgery for early
breast cancer on local recurrence and 15-year survival: an overview of the
randomised trials. The Lancet. 2005;366(9503):2087-2106.
167. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence
and 15-year breast cancer death: meta-analysis of individual patient data for 10
801 women in 17 randomised trials. The Lancet. 2011;378(9804):1707-1716.
168. Pritchard K, Paterson A, Paul N. Increased thromboembolic complications with
concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant

138
therapy for women with breast cancer. National Cancer Institute of Canada
Clinical trials group breast cancer site group. Clinical Oncology.
1996;14(10):2731-2737.
169. Chapiro C, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is
associated with rapid bone loss in women with early-stage breast cancer.
Clinical Oncology. 2001;19(14):3306-3311.
170. Komen S. Facts for life: Research on breast cancer treatment. 1st ed. U.S:
Running Ribbon; 2014.
171. Cos P, Vlietinck A, Berghe D, Maes L. Anti-infective potential of natural
products: how to develop a stronger in vitro ‘proof-of-concept’. ournal of
Ethnopharmacology. 2006;106(3):290-302.
172. Venugopal R, Liu R. Phytochemicals in diets for breast cancer prevention: the
importance of resveratrol and ursolic acid. Food Science and Human Wellness.
2012;1(1):1-13.
173. Azwaida NN. Review on the extraction methods use in medicinal plants,
principle, strength and limitation. Medicinal & Aromatic Plants. 2015;04(03):16.
174. Handa S, Khanuja S, Longo G. Extraction technologies for medicinal and
aromatic plants. United Nations Industrial Development Organization and the
International Centre for Science and High Technology. 2008;66:1-260.
175. Trusheva B, Trunkova D, Bankova V. Different extraction methods of
biologically active components from propolis: a preliminary study. Chemistry
Central Journal. 2007;1(1):13.
176. Jain T, Jain V, Panday R, Vyas A, Shukla S. Microwave assisted extraction for
polyconstituents- an overview. Asian Journal of Research and Chemistry.
2009;2:19-25.
177. Kaufmann B, Christen P. Recent extraction techniques for natural products:
microwave-assisted extraction and pressurised solvent extraction. Journal of
Phytochemical Analysis. 2002;13(2):105-113.
178. Xu H, Zhang Y, He C. Ultrasonically assisted extraction of isoflavones from
stem of pueraria lobata (Wild.) Ohwi and its mathematical model. Chinese
Journal of Chemical Engineering. 2007;15(6):861-867.
179. Tonthubthimthong P, Chuaprasert S, Douglas P, Luewisutthichat W.
Supercritical CO2 extraction of nimbin from neem seeds – an experimental
study. Journal of Food Engineering. 2001;47(4):289-293.

139
180. Li H, Wu J, Rempel C, Thiyam U. Effect of operating parameters on oil and
phenolic extraction using supercritical CO2. Journal of the American Oil
Chemists' Society. 2010;87(9):1081-1089.
181. Ahuja S, Diehl D. Comprehensive Analytical Chemistry. Oxford, UK: Elsevier
(Wilson & Wilson); 2006.
182. Schnaubelt K. Biology of essential oils. San Rafael, CA: Terra Linda Scent;
2002.
183. Basic principles of steam distillation [Internet]. Fao.org. 1995 [cited 18 August
2005]. Available from: http://www.fao.org/docrep/V5350e/V5350e13.htm.
184. Cory S, Adams J. The Bcl2 family: regulators of the cellular life-or-death
switch. Nature Reviews Cancer. 2002;2(9):647-656.
185. Cory S, Huang D, Adams J. The Bcl-2 family: roles in cell survival and
oncogenesis. Oncogene. 2003;22(53):8590-8607.
186. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between
apoptosis, necrosis and autophagy. Biochimica et Biophysica Acta (BBA) Molecular Cell Research. 2013;1833(12):3448-3459.
187. Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alternative
mechanisms. Nature Reviews Molecular Cell Biology. 2001;2(8):589-598.
188. Schweichel J, Merker H. The morphology of various types of cell death in
prenatal tissues. Teratology. 1973;7(3):253-266.
189. Los M. Activation and caspase-mediated Inhibition of PARP: a molecular
switch between fibroblast necrosis and apoptosis in death receptor signaling.
Molecular Biology of the Cell. 2002;13(3):978-988.
190. Zong W. Necrotic death as a cell fate. Genes & Development. 2006;20(1):1-15.
191. Iyer S, Pulskens W, Sadler J, Butter L, Teske G, Ulland T et al. Necrotic cells
trigger a sterile inflammatory response through the Nlrp3 inflammasome.
Proceedings National Academy of Sciences. 2009;106(48):20388-20393.
192. Kerr J, Wyllie A, Currie A. Apoptosis: A basic biological phenomenon with
wide ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239-257.
193. Wyllie A, Kerr J, Currie A. Cell death: the significance of apoptosis.
International Review of Cytology. 1980;68:251-306.
194. Bibel M. Neurotrophins: key regulators of cell fate and cell shape in the
vertebrate nervous system. Genes & Development. 2000;14(23):2919-2937.

140
195. Adams J. Ways of dying: multiple pathways to apoptosis. Genes &
Development. 2003;17(20):2481-2495.
196. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization
in cell death. Physiological Reviews. 2007;87(1):99-163.
197. Green D. Apoptotic pathways: ten minutes to dead. Cell. 2005;121(5):671-674.
198. Boujrad H, Gubkina O, Robert N, Krantic S, Susin S. AIF-mediated
programmed necrosis: a highly orchestrated way to die. Cell Cycle.
2007;6(21):2612-2619.
199. Jäättelä M, Tschopp J. Caspase-independent cell death in T lymphocytes.
Nature Immunology. 2003;4(5):416-423.
200. Lorenzo H, Susin S. Mitochondrial effectors in caspase-independent cell death.
FEBS Letters. 2004;557(1-3):14-20.
201. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell.
2008;132(1):27-42.
202. Mizushima N, Levine B. Autophagy in mammalian development and
differentiation. Nature Cell Biology. 2010;12(9):823-830.
203. Mizushima N, Levine B, Cuervo A, Klionsky D. Autophagy fights disease
through cellular self-digestion. Nature. 2008;451(7182):1069-1075.
204. He C, Klionsky D. Regulation mechanisms and signaling pathways of
autophagy. Annu Rev Genet. 2009;43(1):67-93.
205. Kroemer G, Mariño G, Levine B. Autophagy and the Integrated Stress
Response. Molecular Cell. 2010;40(2):280-293.
206. Glucksmann A. Cell Deaths in normal vertebrate ontogeny. Biological Reviews.
1951;26(1):59-86.
207. Lockshin R, Zakeri Z. Programmed cell death and apoptosis: origins of the
theory. National Reviews Molecular Cell Biology. 2001;2(7):545-550.
208. Lockshin R, Williams C. Programmed cell death—II. Endocrine potentiation of
the breakdown of the intersegmental muscles of silkmoths. Journal of Insect
Physiology. 1964;10(4):643-649.
209. Saraste A. Morphologic and biochemical
Cardiovascular Research. 2000;45(3):528-537.

hallmarks

of

apoptosis.

210. Hengartner M. The biochemistry of apoptosis. Nature. 2000;407:770-776.
211. Cohen G. Caspases: the executioners of apoptosis. Biochemical Journal.

141
1997;326(1):1-16.
212. Rai N. Apoptosis: a basic physiologic process in wound healing. The
International Journal of Lower Extremity Wounds. 2005;4(3):138-144.
213. Nemes Z, Friis R, Aeschlimann D, Saurer S, Paulsson M, Fesus L. Expression
and activation of tissue transglutaminase in apoptotic cells of involuting rodent
mammary tissue. European Journal of Cell Biology. 1996;70:125-133.
214. Bortner C, Oldenburg N, Cidlowski J. The role of DNA fragmentation in
apoptosis. Trends in Cell Biology. 1995;5(1):21-26.
215. Chaurio R, Janko C, Muñoz L, Frey B, Herrmann M, Gaipl U. Phospholipids:
Key Players in Apoptosis and Immune Regulation. Molecules.
2009;14(12):4892-4914.
216. Bratton D, Fadok V, Richter D, Kailey J, Guthrie L, Henson P. Appearance of
phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific
flip-flop and is enhanced by loss of the aminophospholipid translocase. Journal
of Biological Chemistry. 1997;272(42):26159-26165.
217. Arur S, Uche U, Rezaul K, Fong M, Scranton V, Cowan A et al. Annexin I is
an endogenous ligand that mediates apoptotic cell engulfment. Developmental
Cell. 2003;4(4):587-598.
218. Kaufmann S, Earnshaw W. Induction of apoptosis by cancer chemotherapy.
Experimental Cell Research. 2000;256(1):42-49.
219. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev.
2001;15(22):2922-2933.
220. Kroemer G, Reed J. Mitochondrial control of cell death. National Medicine.
2000;6(5):513-519.
221. Kroemer G, Zamzami N, Susin S. Mitochondrial control of apoptosis.
Immunology Today. 1997;18(1):44-51.
222. Bernardi P, Scorrano L, Colonna R, Petronilli V, Di Lisa F. Mitochondria and
cell death. Mechanistic aspects and methodological issues. Eur J Biochem.
1999;264(3):687-701.
223. Loeffler M, Kroemer G. The mitochondrion in cell death control: certainties
and incognita. Experimental Cell Research. 2000;256(1):19-26.
224. Susin S, Lorenzo H, Zamzami N, Snow I. Molecular characterization of
mitochondrial apoptosis-inducing factor. Nature. 1999;397(6718):441-446.
225. Li L, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released

142
from mitochondria. Nature. 2001;412(6842):95-99.
226. Verhagen A, Ekert P, Pakusch M, Silke J, Connolly L, Reid G et al.
Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by
Binding to and Antagonizing IAP Proteins. Cell. 2000;102(1):43-53.
227. Verhagen A, Silke J, Ekert P, Pakusch M, Kaufmann H, Connolly L et al.
HtrA2 Promotes Cell Death through Its Serine Protease Activity and Its Ability
to Antagonize Inhibitor of Apoptosis Proteins. Journal of Biological Chemistry.
2002;277(1):445-454.
228. Salvesen G, Renatus M. Apoptosome: the seven-spoked death machine. Dev
Cell. 2002;2(3):256-257.
229. Denault J, Salvesen G. Caspases: Keys in the Ignition of Cell Death. Chemical
Reviews. 2002;102(12):4489-4500.
230. Earnshaw W, Martins L, Kaufmann S. Mammalian Caspases: structure,
activation, substrates, and functions during apoptosis. Journal of Annual
Review of Biochemistry. 1999;68(1):383-424.
231. MacFarlane M, Williams A. Apoptosis and disease: a life or death decision.
EMBO Rep. 2004;5(7):674-678.
232. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis
factor superfamily. Nature Reviews Cancer. 2002;2(6):420-430.
233. Naismith J, Sprang S. Modularity in the TNF-receptor family. Trends in
Biochemical Sciences. 1998;23(2):74-79.
234. Scaffidi C. Two CD95 (APO-1/Fas) signaling pathways. The EMBO Journal.
1998;17(6):1675-1687.
235. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl-2 interacting
protein, mediates cytochrome c release from mitochondria in response to
activation of cell surface death receptors. Cell. 1998;94(4):481-490.
236. Acehan D, Jiang X, Morgan D, Heuser J, Wang X, Akey C. Three-dimensional
structure of the apoptosome: implications for assembly, procaspase-9 binding,
and activation. Molecular Cell. 2002;9(2):423-432.
237. Slee E. Ordering the cytochrome C-initiated caspase cascade: hierarchical
activation of caspases-2, -3,-6,-7,-8, and -10in a caspase-9-dependent manner.
The Journal of Cell Biology. 1999;144(2):281-292.
238. Searle J, Lawson T, Abbott P, Harmon B, Kerr J. An electron-microscope study
of the mode of cell death induced by cancer-chemotherapeutic agents in
populations of proliferating normal and neoplastic cells. Journal of Pathology

143
1975;116(3):129-138.
239. Dive C, Hickman J. Drug-target interactions: only the first step in the
commitment to a programmed cell death? British Journal of Cancer.
1991;64(1):192-196.
240. Kaufmann S. Induction of endonucleolytic DNA cleavage in human acute
myelogenous leukemia cells by etoposide, camptothecin and other cytotoxic
anticancer drugs: a cautionary note. Cancer Research. 1989;49:5870-5878.
241. Eastman A. Activation of programmed cell death by anticancer agents:
cisplatin as a model system. Cancer cells. 1990;2:275-280.
242. Schmitt C, Lowe S. Apoptosis and therapy. Journal of Pathology.
1999;187:127-137.
243. Wong . Apoptosis in cancer: from pathogenesis to treatment. Journal of
Experimental and Clinical Cancer esearch. 2011 30(1):8 .
244. Lowe S, Ruley H, Jacks T, Housman D. p53-dependent apoptosis modulates
the cytotoxicity of anticancer agents. Cell. 1993;74(6):954-967.
245. Schmitt C, McCurrach M, de Stanchina E, Wallace-Brodeur R, Lowe S.
INK4a/ARF mutations promote lymphomagenesis and chemoresistance by
disabling p53. Genes & Development. 1999;13(20):2670-2677.
246. Lowe S, Bodis S, McClatchey A, Remington L, Ruley H, Fisher D et al. p53
status and the efficacy of cancer therapy in vivo. Science. 1994;266(5186):807810.
247. Wallace-Brodeur R, Lowe S. Clinical implications of p53 mutations. Cellular
and Molecular Life Sciences CMLS. 1999;55(1):64-75.
248. Fujiwara T, Grimm E, Mukhopadhyay T, Zhang W, Owenschaub L, Roth J.
Induction of chemosensitivity in human lung cancer cells in vivo by
adenovirus-mediated transfer of the wild type p53 gene. Cancer Research.
1994;54:2287-2291.
249. Nikiforov M, Hagen K, Lowe S, Connor T, Ossovskaya V. p53 modulation of
anchorage independent growth and experimental metastasis. Oncogene.
1996;13:1709-1719.
250. Barrington R, Subler M, Rands E, Omer C, Miller P, Hundley J et al. A
Farnesyltransferase inhibitor induces tumor regression in transgenic mice
harboring multiple oncogenic mutations by mediating alterations in both cell
cycle control and apoptosis. Molecular and Cellular Biology. 1998;18(1):85-92.
251. Bunz F, Hwang P, Torrance C, Waldman T, Zhang Y, Dillehay L et al.

144
Disruption of p53 in human cancer cells alters the responses to therapeutic
agents. Journal of Clinical Investigation. 1999;104(3):263-269.
252. Brown J, Wouters B. Apoptosis, p53 and tumor cell sensitivity to anticancer
agents. Cancer Research. 1999;59:1391-1399.
253. Lowe S, Schmitt E, Smith S, Osborne B, Jacks T. p53 is required for radiationinduced apoptosis in mouse thymocytes. Nature. 1993;362(6423):847-849.
254. Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M et al. Thymocyte
apoptosis induced by p53-dependent and independent pathways. Nature.
1993;362(6423):849-852.
255. Lotem J, Sachs L. Regulation by bcl-2, c-myc and p53 of susceptibility to
induction of apoptosis by heat shock and cancer chemotherapy compounds in
differentiation competent and defective myeloid leukemic cells. Cell Growth
Differ. 1993;4:41-47.
256. Clarke A, Gledhill S, Hooper M, Bird C, Wyllie A. p53 dependence on early
apoptotic and proliferative responses within the mouse intestinal epithelium
following gamma-irradiation. Oncogene. 1994;9:1767-1773.
257. Merritt A, Potten C, Kemp C, Hickman J, Balmain A, Lane D et al. The role of
p53 in spontaneous and radiation-induced apoptosis in gastrointestinal tract of
normal and p53 deficient mice. Cancer Research. 1994;54:614-617.
258. Pritchard D, Potten C, Hickman J. he relationships between p53-dependent
apoptosis, inhibition of proliferation and 5-fluorouracil-induced histopathology
in murine intestinal epithelia. Cancer Research. 1998;58:5453-5465.
259. Gross A, McDonnell J, Korsmeyer S. Bcl-2 family members and the
mitochondria in apoptosis. Genes & Development. 1999;13(15):1899-1911.
260. Fulda S. Evasion of apoptosis as a cellular stress response in cancer.
International Journal of Cell Biology. 2010;2010:1-6.
261. Boeckler F, Joerger A, Jaggi G, Rutherford T, Veprintsev D, Fersht A.
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.
Proceedings of the National Academy of Sciences. 2008;105(30):10360-10365.
262. Kuball J, Schuler M, Antunes E, Herr W, Neumann M. Generating p53-specific
cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination
in mice, but not man. Gene Therapy. 2002;9(13):833-843.
263.

ai , Moore , Wu , ovick S, O’ Brien S. Effect of the addition of
oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for patients who
achieve CR/nPR: Five year follow up from randomized phase III study.

145
Clinical Oncology. 2008;26:7008.
264. Abou-Nassar K, Brown J. Novel agents for the treatment of chronic
lymphocytic leukemia. Clinical Advanced Hematology and Oncology.
2010;8(12):886-895.
265. Suhail M, Wu W, Cao A, Mondalek F, Fung K, Shih P et al. Boswellia sacra
essential oil induces tumor cell-specific apoptosis and suppresses tumor
aggressiveness in cultured human breast cancer cells. BMC Complementary
and Alternative Medicine. 2011;11(1):129.
266. Maloney G. Gold, frankincense, and myrrh: an introduction to eastern Christian
spiritulaty. New York: Crossroads Pub; 1997.
267. Banno N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y et al.
Anti-inflammatory activities of the triterpene acids from the resin of Boswellia
carteri. Journal of Ethnopharmacology. 2006;107(2):249-253.
268. Langmead L, Rampton D. Review article: complementary and alternative
therapies for inflammatory bowel disease. Alimentary Pharmacology and
Therapeutics. 2006;23(3):341-349.
269. Chevrier M, Ryan A, Lee D, Zhongze M, Wu-Yan Z, Via C. Boswellia carterii
extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clinical
and Vaccine Immunology. 2005;12(5):575-580.
270. Sharma M, Khajuria A, Kaul A, Singh S, Singh G, Atal C. Effect of salai
guggal ex-Boswellia serrata on cellular and humoral immune responses and
leucocyte migration. Agents and Actions. 1988;24(1-2):161-164.
271. Singh G, Atal C. Pharmacology of an extract of salai guggal ex-Boswellia
serrata, a new non-steroidal anti-inflammatory agent. Agents and Actions.
1986;18(3-4):407-412.
272. Weckesser S, Engel K, Simon-Haarhaus B, Wittmer A, Pelz K, Schempp C.
Screening of plant extracts for antimicrobial activity against bacteria and yeasts
with dermatological relevance. Phytomedicine. 2007;14(7-8):508-516.
273. Huang M, Badmaev V, Ding Y, Liu Y, Xie J, Ho C. Anti-tumor and anticarcinogenic activities of triterpenoid, β-boswellic acid. BioFactors. 2000;13(14):225-230.
274. Winking M, Sarikaya S, Rahmanian A, Jodicke A, Boker D. Boswellic acids
inhibit glioma growth: a new treatment option? Neurooncology. 2000;46:97103.
275. Hostanska K, Daum G, Saller R. Cytotoxic and apoptosis-inducing activity of

146
boswellic acids toward malignant cell lines in vitro. Anticancer Research.
2002;22:2853-2862.
276. Flavin D. A lipoxygenase inhibitor in breast cancer brain metastases. Journal of
Neuro-Oncology. 2007;82(1):91-93.
277. Celiktas O, Kocabas E, Bedir E, Sukan F, Ozek T, Baser K. Antimicrobial
activities of methanol extracts and essential oils of Rosmarinus officinalis,
depending on location and seasonal variations. Food Chemistry.
2007;100(2):553-559.
278. Ozkan A, Erdogan A. A comperative evaluation of antioxidant and anticancer
activity of essential oil from origanum unites (lamiaceae) and its two major
phenolic components. Turkish Journal of Biology. 2011;35(6):735-742.
279. Stenhouse J. Zusammensetzung des Elemi- und Olibanumöls. Annalen der
Chemie und Pharmacie. 1840;35(3):304-306.
280. Eichhorn T, Greten H, Efferth T. Molecular determinants of the response of
tumor cells to boswellic acids. Pharmaceuticals. 2011;4(12):1171-1182.
281. Snatzke G, Vertesy L. ber die neutralen Sesqui- und Triterpene des
Weihrauchs. Monatshefte for Chemie. 1967;98(1):121-132.
282. Evans W, Evans D, Trease G. Trease and Evans' pharmacognosy. Edinburgh:
WB Saunders; 2002.
283. Büchele B, Zugmaier W, Simmet T. Analysis of pentacyclic triterpenic acids
from frankincense gum resins and related phytopharmaceuticals by highperformance liquid chromatography. Identification of lupeolic acid, a novel
pentacyclic triterpene. Journal of Chromatography. 2003;791(1-2):21-30.
284. Gulioli G, Mathe C, Archier P, Viellescazes C. A lupine triterpene from
frankinscence. Phytochemistry. 2003;62:537-541.
285. Mikhaeil B, Maatooq G, Badria F, Amer M. Chemistry
Immunomodulatory Activity of Frankincense Oil. Zeitschrift
Naturforschung C. Journal of Bioscinces. 2003;58(3-4):230-238.

and
für

286. Hamm S, Bleton J, Connan J, Tchapla A. A chemical investigation by
headspace SPME and GC–MS of volatile and semi-volatile terpenes in various
olibanum samples. Phytochemistry. 2005;66(12):1499-1514.
287. Kubmarawa D, Ogunwande I, Okorie D, Olawore N, Kasali A. Constituents of
the Essential Oils of Boswellia dalzielii Hutch. from Nigeria. Journal of
Essential Oil Research. 2006;18(2):119-120.
288. Mathe C, Culioli G, Archier P, Vieillescazes C. Characterization of

147
archaeological frankincense by gas chromatography–mass spectrometry.
Journal of Chromatography A. 2004;1023(2):277-285.
289. Frank A, Unger M. Analysis of frankincense from various Boswellia species
with inhibitory activity on human drug metabolising cytochrome P450 enzymes
using liquid chromatography mass spectrometry after automated on-line
extraction. Journal of Chromatography A. 2006;1112(1-2):255-262.
290. Lancelle H, Giordano O, Sosa M, Tonn C. Chemical composition of four
essential oils from Eupatorium spas: biological activities toward Tribolium
castaneum (Coleopatra: Tenebrionidae). Revista de la Sociedad Entomologica
Argentina. 2009;68(3-4):329-338.
291. Yu J, Lei J, Zhang X, Yu H, Tian D, Liao Z et al. Anticancer, antioxidant and
antimicrobial activities of the essential oil of Lycopus lucidus Turcz. Var,
hirtus Regel. Food Chemistry. 2011;126(4):1593-1598.
292. Tepe B, Donmez E, Unlu M, Candan F, Daferera D, Vardar-Unlu G et al.
Antimicrobial and antioxidative activities of the essential oils and methanol
extracts of Salvia cryptantha (Montbret et Aucher ex Benth.) and Salvia
multicaulis (Vahl). Food Chemistry. 2004;84(4):519-525.
293. Lu M, Han Z, Yao L. In vitro and in vivo antimicrobial efficacy of essential
oils and individual compounds against Phytophthora parasitica var. nicotianae.
Journal of Applied Microbiology. 2013;115(1):187-198.
294. Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential
oils – A review. Food and Chemical Toxicology. 2008;46(2):446-475.
295. Boukhris M, Bouaziz M, Feki I, Jemai H, El Feki A, Sayadi S. Hypoglycemic
and antioxidant effects of leaf essential oil of Pelargonium graveolens L’Hér in
alloxan induced diabetic rats. Lipids Health Disease. 2012;11(1):81.
296. Perry N, Houghton P, Sampson J, Theobald A, Hart S, Lis-Balchin M et al. Invitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of
Alzheimer's disease. Journal of Pharmacy and Pharmacology.
2001;53(10):1347-1356.
297. Lawless J. The IIIustrated Encyclopaedia of Essential oils. London: Element
Books; 1996.
298. Rayman D. Aromatherapy, the encyclopaedia of plants and oils. London: Judy
Piatkus Publishers Ltd; 1997.
299. Umezu T. Behavioral Effects of Plant-Derived Essential Oils in the Geller Type
Conflict Test in Mice. The Japanese Journal of Pharmacology. 2000;83(2):150153.

148
300. Sharma M, Khajuria A, Kaul A, Singh S, Singh G, Atal C. Effect of salai
guggal ex-Boswellia serrata on cellular and humoral immune responses and
leucocyte migration. Agents and Actions. 1988;24(1-2):161-164.
301. Singh G, Atal C. Pharmacology of an extract of salai guggal ex-Boswellia
serrata, a new non-steroidal anti-inflammatory agent. Agents and Actions.
1986;18(3-4):407-412.
302. Ali A, Wurster M, Arnold N, Teichert A, Schimidt J, Lindequist U et al.
Chemical composition and biological activities of essential oils from the oleo
gum resins of three endemic soqotraen boswellia species. RecNatProd.
2008;2:6-12.
303. Wahab S, Aboutabl E, El-Zalabani S, Fouad H, De Pooter H, El-Fallaha B. The
Essential Oil of Olibanum. Journal of Planta Medica. 1987;53(04):382-384.
304. Ammon H, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory
actions of curcumine and boswellic acids. Journal of Ethnopharmacology.
1993;38(2-3):113-119..
305. Ammon H, Mack T, Singh G, Safayhi H. Inhibition of Leukotriene B 4
Formation in Rat Peritoneal Neutrophils by an Ethanolic Extract of the Gum
Resin Exudate of Boswellia serrata. . Journal of Planta Medica.
1991;57(03):203-207.
306. Gupta I, Parihar A, Malhotra P, Singh G, Ludtke R, Safayhi H et al. Effects of
Boswellia serrata gum resin in patients with ulcerative colitis. European Journal
for Medicine and Research. 1997;2:37-43.
307. Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Ammon H et al. Effects of
Boswellia serrata gum resin in patients with bronchial asthma: results of a
double-blind, placebo controlled, 6-week clinical study. European Journal of
Medicine and Research. 1998;3:511-514.
308. Safayhi H, Mack T, Sabieraj J, Anazodo M, Subramanian L, Ammon H.
Boswellic acids: Novel, specific, non redox inhibitors of 5-lipoxygenase.
Journal of pharmacology and Experimental Therapeutics. 1992;261:1143-1146.
309. Safayhi H, Sailer E, Ammon H. Mechanism of 5-lipoxygenase inhibition by
acetyl-11-keto-boswellic acid. Molecular Pharmacology. 1995;47:1212-1216.
310. Shao Y, Ho C, Chin C, Badmaev V, Ma W, Huang M. Inhibitory activity of
boswellic acids from Boswellia serrata against human leukemia HL-60 cells in
culture. Journal of Planta Medica. 1997;64(04):328-331.
311. Ota M, Houghton P. Boswellic acid with acetylcholinesterase inhibitory
properties from frankincense. 53rd Annual congress organized by society of

149
medicinal plants. Florence: Societa Italiana di Fitochimica Florence; 2005. p.
339.
312. Akihisa T, Tabata K, Banno N, Tokuda H, Nishihara R, Nakamura Y et al.
Cancer chemopreventive effects and cytotoxic activities of the triterpene acids
from the resin of Boswellia carteri. Journal Biological and Pharmaceutical
Bulletin. 2006;29(9):1976-1986.
313. Verhoff M, Seitz S, Paul M, Noha S, Jauch J, Schuster D et al. Tetra- and
pentacyclic triterpene acids from the ancient anti-inflammatory remedy
frankincense as inhibitors of microsomal prostaglandin E 2 synthase-1. Journal
of Natural Products. 2014;77(6):1445-1451.
314. Anthoni C. Mechanisms underlying the anti-inflammatory actions of boswellic
acid derivatives in experimental colitis. AJP: Gastrointestinal and Liver
Physiology. 2006;290(6):G1131-G1137.
315. Mitoshi M, Kuriyama I, Nakayama H, Miyazato H, Sugimoto K, Kobayashi Y
et al. Effects of essential oils from herbal plants and citrus fruits on DNA
polymerase inhibitory, cancer cell growth inhibitory, antiallergic, and
antioxidant activities. Journal of Agriculture and Food Chemistry.
2012;60(45):11343-11350.
316. Park Y, Lee J, Bondar J, Harwalkar J, Safayhi H, Golubic M. Cytotoxic action
of Acetyl-11-keto-β-Boswellic Acid (AKBA) on meningioma cells. Journal of
Planta Medica. 2002;68(5):397-401.
317. Liu J, Nilsson A, Oredsson S, Badmaev V, Duan R. Keto- and acetyl-ketoboswellic acids inhibit proliferation and induce apoptosis in HepG2 cells via a
caspase-8 dependent pathway. International Journal of Molecular Medicine.
2002;10:501-505.
318. Zhao W, Entschladen F, Liu H, Niggemann B, Fang Q, Zaenker K et al.
Boswellic acid acetate induces differentiation and apoptosis in highly
metastatic melanoma and fibrosarcoma cells. Cancer Detection and Prevention.
2003;27(1):67-75.
319. Liu J. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8
activation but independent on Fas/Fas ligand interaction in colon cancer HT-29
cells. Carcinogenesis. 2002;23(12):2087-2093.
320. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X et al. Acetyl-11-Keto- Boswellic Acid inhibits prostate tumor growth by suppressing vascular
endothelial growth factor receptor 2-mediated angiogenesis. Cancer Research.
2009;69(14):5893-5900.
321. Lu M, Xia L, Hua H, Jing Y. Acetyl-Keto- -Boswellic acid induces apoptosis

150
through a death receptor 5-mediated pathway in prostate cancer cells. Cancer
Research. 2008;68(4):1180-1186.
322. Syrovets T, Gschwend J, Buchele B, Laumonnier Y, Zugmaier W, Genze F et
al. Inhibition of IB kinase activity by acetyl-boswellic acids promotes apoptosis
in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. Journal
of Biological Chemistry. 2005;280(7):6170-6180.
323. Liu J. Pharmacology of oleanolic acid and ursolic acid. Journal of
Ethnopharmacology. 1995;49(2):57-68.
324. Estrada A, Syrovets T, Pitterle K, Lunov O, Buchele B, Schimana-Pfeifer J et
al. Tirucallic acids are novel pleckstrin homology domain-dependent Akt
inhibitors inducing apoptosis in prostate cancer cells. Molecular Pharmacology.
2010;77(3):378-387.
325. Yadav V, Prasad S, Sung B, Gelovani J, Guha S, Krishnan S et al. Boswellic
acid inhibits growth and metastasis of human colorectal cancer in orthotopic
mouse model by downregulating inflammatory, proliferative, invasive and
angiogenic biomarkers. International Journal of Cancer. 2011;130(9):21762184.
326. Park B, Prasad S, Yadav V, Sung B, Aggarwal B. Boswellic acid suppresses
growth and metastasis of human pancreatic tumors in an orthotopic nude mouse
model through modulation of multiple targets. PLoS ONE. 2011;6(10):e26943.
327. Frank M, Yang Q, Osban J, Azzarello J, Saban M, Saban R et al. Frankincense
oil derived from Boswellia carteri induces tumor cell specific cytotoxicity.
BMC Complementary and Alternative Medicine. 2009;9(1):6.
328. Fung KM, Suhail MM, McClendon B, Woolley CL, Young DG, and Lin HK.
Management of basal cell carcinoma of the skin using frankincense (Boswelia
sacra) essential oil: a case report. University of Oklahoma Health Sciences
Centre, Oklahama City Veterans Medical Centre, Ayub Research in Oman, and
Young living essential oils in USA. London: OA Alternative Medicine
2013;1(2):14.
329. Ni X, Suhail M, Yang Q, Cao A, Fung K, Postier R et al. Frankincense
essential oil prepared from hydrodistillation of Boswellia sacra gum resins
induces human pancreatic cancer cell death in cultures and in a xenograft
murine model. BMC Complementary and Alternative Medicine.
2012;12(1):253.
330. Nadeem M, Al Qurainy F, Khan S, Tarroum M, Ashraf M. Direct shoot
multiplication in ochradenus arabicus, an endemic medicinal plant of Saudi
Arabia. Pakistan Journal of Botany. 2012;44(1):345-347.

151
331. Miller A. A revision of Orchradenus. Notes RBotGradEdinb. 1984;41:491-594.
332. Khan S, Al-Qurainy F, Nadeem M, Tarroum M. Development of genetic
markers for Ochradenus arabicus (Resedaceae), an endemic medicinal plant of
Saudi Arabia. Genetics and Molecular Research. 2012;11(2):1300-1308.
333. Khan S, Al-Qurainy F, Nadeem M, Tarroum M. Effect of some chemical
treatments on seed germination and dormancy breaking in an important
medicinal plant of ochradenus arabicus Pakistan Journal of Botany.
2012;44(3):1037-1040.
334. Martín-Bravo S, Meimberg H, Luceño M, Märkl W, Valcárcel V, Bräuchler C
et al. Molecular systematics and biogeography of Resedaceae based on ITS and
trnL-F sequences. Molecular Phylogenetics and Evolution. 2007;44(3):11051120.
335. Vincken J, Heng L, de Groot A, Gruppen H. Saponins, classification and
occurrence in the plant kingdom. Phytochemistry. 2007;68(3):275-297.
336. Shabana M, Mirhom Y. Study into wild Egyption plants of potential medicinal
activity. Ninth communication: hypoglycemic activity of some selected plants
in normal fasting and alloxanised rats. Archives of Experimental Veternity
Medicine. 1990;44:389-394.
337. Barakat H, El-Mousallamy A, Souleman A, Awadalla S. Flavonoids of
Ochradenus baccatus. Phytochemistry. 1991;30(11):3777-3779.
338. Ricci D, Fraternale D, Giamperi L, Bucchini A, Epifano F, Burini G et al.
Chemical composition, antimicrobial and antioxidant activity of the essential
oil of Teucrium marum (Lamiaceae). Journal of Ethnopharmacology.
2005;98(1-2):195-200.
339. Environmental Research and Wildlife Development Agency. The
comprehensive guide to the wildflowers of the United Arab Emirates. UAE,
Abu Dhabi; 2003.
340. Winbow C. The native plants of Oman. Oman: Environment Society of Oman,
Oman Printers, Stationers; 2008.
341. The Emirates: a natural history. London: Trident Press Limited; 2005.
342. Ghazanfar S, Fisher M. Vegetation of the Arabian Peninsula. Dordrecht:
Kluwer Academic Publishers; 1998.
343. Ghazanfar S. Vegetation structure and phytogeography of Jabal Shams, an arid
mountain in Oman. Journal of Biogeography. 1991;18(3):299-309.
344. Thulin M. Flora of Somalia. [Kew]: Royal Botanic Gardens, Kew; 1993.

152
345. Cullen J, Knees S, Cubey H. Dicotyledons, Resedaceae to Cyrillaceae.
Cambridge: Cambridge University Press; 2011.
346. Ghazanfar S, Al-Al-Sabahi A. Medicinal plants of northern and central Oman
(Arabia). Econ Bot. 1993;47(1):89-98.
347. Bennett B, Alarcón R. Osteophloeum platyspermum andVirola duckei
(myristicaceae): newly reported as hallucinogens from Amazonian Ecuador.
Society for Economic Botany. 1994;48(2):152-158.
348. Dalziel J, Hutchinson J. The useful plants of west tropical Africa. London:
Published under the authority of the Secretary of State for the Colonies by the
Crown agents for the colonies; 1937.
349. Watt J, Breyer-Brandwijk M. The medicinal and poisonous plants of southern
and eastern Africa. Edinburgh: Livingstone; 1962.
350. Ghazanfar S. The Arabian medicinal plant. USA: Library of Congress
cataloging in the USA; 1994.
351. Agrawal P. Carbon-13 NMR of flavonoids. Amsterdam: Elsevier; 1989.
352. Baltz T, Baltz D, Giroud C, Crockett J. Cultivation in a semi-defined medium
of animal infective forms of Trypanosoma brucei, T.equiperdum, T. evansi, T.
rhodesiense and T. gambiense. European Molecular Biology Organization.
1985;4:1273-1277.
353. Budzikiewicz H, Wilson J, Djerassi C. Mass Spectrometry in structural and
stereochemical problems. XXXII. 1 Pentacyclic Triterpenes. Journal of
American Chemical Society. 1963;85(22):3688-3699.
354. Burns D, Ellis D, March R. A predictive tool for assessing 13 C NMR chemical
shifts of flavonoids. Journal of Magnetic Resonance in Chemistry.
2007;45(10):835-845.
355. Cao S, Guza R, Miller J, Andriantsiferana R, Rasamison V, Kingston D.
Cytotoxic Triterpenoids from Acridocarpus vivy from the Madagascar rain
forest 1. Journal of Natural Products. 2004;67(6):986-989.
356. Connolly JD & Hill RA.Triterpenoids. In: Methods in plant Biochemistry. New
York, NY Academic Press; 1991;7: 331-359.
357. De-Eknamkul W, Potduang B. Biosynthesis of β-sitosterol and stigmasterol in
Croton sublyratus proceeds via a mixed origin of isoprene units.
Phytochemistry. 2003;62(3):389-398.
358. Desjardins R, Canfield C, Haynes J, Chulay J. Quantitative assessment of
antimalarial activity in vitro by a semiautomated microdilution technique.

153
Antimicrobial Agents and Chemotherapy. 1979;16(6):710-718.
359. Sarker S, Latif Z, Gray A. Methods in Biotechnology, Natural products
isolation. Totowa, N.J.: Humana Press; 2006;323-352.
360. Blois M. Antioxidant determinations by the use of a stable free radical. Nature.
1958;181(4617):1199-1200.
361. Devasagayam T, Talik J, Boloor K, Sane K, Ghaskadbi S, Lele R. Free radicals
and antioxidants in human health: current status and future prospects . Journal
of the Association of Physicians of India. 2004 52: 94-804.
362. Vivekananthan D, Penn M, Sapp S, Hsu A, Topol E. Use of antioxidant
vitamins for the prevention of cardiovascular disease: meta-analysis of
randomised trials. The Lancet. 2003;361(9374):2017-2023.
363. Shtaiwi M, Rawi S, Alshibly N, Al-Hazimi M. Chemical screening and antihyperglycemic property of cleome drosrifolia ethanol extract. Journal of
Medicinal Plant Research. 2013;7(37):2769-2776.
364. Al-shenawy N, Abdel-Nabi I. Hypoglycaemic effect of Cleome droserifolia
ethanolic leaves extract in experimental diabetes and their effect on nonenzymatic antioxidant glycogen content thyroid hormones and insulin levels.
Diabetologia Croatica. 2006;35:15-22.
365. Aparadh V, Mahamuni R, Karadge B. Toxonomy and physiological studies in
spider flower (Cleome species): A critical review. Plants Science Feed.
2012;2(3):25-46.
366. Willis J, Shaw H. A dictionary of the flowering plants and ferns. Cambridge:
Cambridge U.P.; 1966.
367. Ladhari A, Haouala R, DellaGreca M. A New Dammarane Triterpene from
Cleome arabica. Chemistry of Natural Compounds. 2014;50(4):684-686.
368. Boulos L. Flora of Egypt. Cairo, Egypt: Al Hadara Pub.; 1999.
369. Narendhirakannan R, Subramanian S, Kandaswamy M. Anti-inflammatory and
lysosomal stability actions of Cleome gynandra L. studied in adjuvant induced
arthritic rats. Food and Chemical Toxicology. 2006;45(6):1001-1012.
370. Mikhail Y. Studies on the hypoglycemic effects of cleome drosrifolia and bran
of Triticum vulgaris [M.Sc.]. Cairo University; 2000.
371. Helal I, Sharaf H, Matter F. Anti- diabetic and anti- obesity effects of plant
extract from Cleome droserifolia (samwa). The Egyption Journal of Hospital
Medicine. 2002;9:85-101.

154
372.

aggar E, Bartošíková L, Žemlička M, Švajdlenka E, abišková M, Strnadová
V et al. Antidiabetic Effect of Cleome droserifolia aerial parts: lipid
peroxidation-induced oxidative stress in diabetic rats. Acta Veterinaria Brno.
2005;74(3):347-352.

373. Abdel-Kader M, Alqasoumi S, Al-Taweel A. Hepatoprotective Constituents
from Cleome droserifolia. Chemical & Pharmaceutical Bulletin.
2009;57(6):620-624.
374. Ndamba J, Nyazema N, Makaza N, Anderson C, Kaondera K. Traditional
herbal remedies used for the treatment of urinary schistosomiasis in Zimbabwe.
Journal of Ethnopharmacology. 1994;42(2):125-132.
375. Hussein N, Ahmed A, Darwish F. Sesquiterpenes from Cleome Droserifolia.
Pharmazie. 1994;49:76-77.
376. El-Shenawy N, Abdel-Nabi I. Comparative analysis of the protective effect of
melatonin and Cleome droserifolia extract on antioxidant status of diabetic rats.
The Egyption Journal of Hospital Medicine. 2004;14:11-25.
377. Tsichritzis F, Abdel-Mogib M, Jakupovic J. Dammarane triterpenes from
Cleome africana. Phytochemistry. 1993;33(2):423-425.
378. Brouriche H, Arnhold J. Effect of Cleome arabica leaf extract treated by
naringinase on human neutrophil chemotaxis. Natural Product Communication.
2010;5:415-419.
379. Takhi D, Ouinten M, Yousfi M. Study of Antimicrobial Activity of Secondary
Metabolites extracted from spontaneous plants from the area of Laghouat,
Algeria. Advances in Environmental Biology. 2011; 5: 469-476.
380. Djeridane A, Yousfi M, Brunel J, Stocker P. Isolation and characterization of a
new steroid derivative as a powerful antioxidant from Cleome arabica in
screening the in vitro antioxidant capacity of 18 Algerian medicinal plants.
Food and Chemical Toxicology. 2010;48(10):2599-2606.
381. Bala A, Kar B, Haldar P, Mazumder U, Bera S. Evaluation of anticancer
activity of Cleome gynandra on Ehrlich's ascites carcinoma treated mice.
Journal of Ethnopharmacology. 2010;129(1):131-134.
382. Ghazanfar S. Handbook of Arabian medicinal plants. Boca Raton: CRC Press;
1994.
383. Hussein N, Ahmed A, Darwish F. Sesquiterpenes from Cleome droserifolia.
Pharmazia. 1994;49(1):76-77.
384. El-Din, A.A.S., Darwish, F.A., Abou-Donia, A. flavonoids from Cleome

155
droserifolia (Forssk.) del growing in Egypt. Journal of Pharmacological
Science. 1987;28:313-319.
385. Nagaya H, Tobita Y, Nagae T, Itokawa H, Takeya K, Halim A et al. Cytotoxic
triterpenes from Cleome africana. Phytochemistry. 1997;44(6):1115-1119.
386. DellaGreca M, Fiorentino A, Izzo A, Napoli F, Purcaro R, Zarrelli A.
Phytotoxicity of Secondary Metabolites fromAptenia cordifolia. Chemistry and
Biodevirsity. 2007;4(2):118-128.
387. Harraz F, Ulubelen A, Öksüz S, Tan N. Dammarane triterpenes from Cleome
amblyocarpa. Phytochemistry. 1995;39(1):175-178.
388. Chen X, Bai X, Liu Y, Tian L, Zhou J, Zhou Q et al. Anti-diabetic effects of
water extract and crude polysaccharides from tuberous root of Liriope spicata
var. prolifera in mice. Journal of Ethnopharmacology. 2009;122(2):205-209.
389. Atta-Ur-Rahman, Zaman K. Medicinal plants with hypoglycemic activity.
Journal of Ethnopharmacology. 1989;26(1):1-55.
390. Marles R, Farnsworth N. Antidiabetic plants and their active constituents.
Phytomedicine. 1995;2(2):137-189.
391. Ahmed A. Medical plant and human health. Biomedical Science, Engineering
and Technology. 2012;:165-190.
392. Nicola W, Ibrahim K, Mikhail T, Girgis R, Khadr M. Role of hypoglycemic
plant extract, Cleome droserifolia, in improving glucose and lipid metabolism
and its relation to insulin resistance in fatty liver. Journal of Bollettino chimico
farmaceutico. 1996;139(9):507-517.
393. Srivastava S. Stigmasta-5,24(28)-diene-3β-O-α-l-rhamnoside from Cleome
viscosa. Phytochemistry. 1980;19(11):2510-2511.
394. Qin G, Hamed A, El-Emary N, Chen Y, Wang L, Cheung K et al. A New
Trinortriterpenoid from Cleome chrysantha. Journal of Planta Medica.
2000;66(02):191-193.
395. Kjaer A, Thomsen H. Isothiocyanate-producing glucosides in species of
Capparidaceae. Phytochemistry. 1963;2(1):29-32.
396. Chauhan J, Srivastava S, Srivastava S. Kaempferide 3-glucuronide from the
roots of Cleome viscosa. Phytochemistry. 1979;18(4):691.
397. Srivastava S, Chauhan J, Srivastava S. A new naringenin glycoside from
Cleome viscosa. Phytochemistry. 1979;18(12):2057-2058.
398. Ray A, Chattopadhyay S, Kumar S, Konno C, Kiso Y, Hikino H. Structures of
cleomiscosins, coumarinolignoids of cleome viscosa seeds. Tetrahedron.

156
1985;41(1):209-214.
399. Bruno M, Piozzi F, Rosselli S, Magio A, Alania M, Lamara K et al.
Phytochemical investigation of four teucrium species. Investigación.
2004;48:137-138.
400. Tutin T, Heywood V, Burges N, Moore D, Valentine D, Waltets S et al. Flora
Europaea III. Genus Teucrium L. Cambridge: Press; 1972.
401. Josifovic M. Flora Srbije VI. Genus Teucrium L. Sanu, Beograd; 1974.
402. Zaragari A. Medicinal plants. 6th ed. Tehran: Tehran University Publications;
1994.
403. Tomás F, Nieto J, Barberán F, Ferreres F. Flavonoids from phlomis lychnitys.
Phytochemistry. 1986;25(5):1253-1254.
404. Gharaibeh M, Elayan H, Salhab A. Hypoglycemic effects of Teucrium polium.
Journal of Ethnopharmacology. 1988;24(1):93-99.
405. Suleiman M, Abdul-Ghani A, Al-Khalil S, Amin R. Effect of Teucrium polium
boiled leaf extract on intestinal motility and blood pressure. Journal of
Ethnopharmacology. 1988;22(1):111-116.
406. Stankovic M, Topuzovic M, Solujic S, Mihailovic V. Antioxidant activity and
concentration of phenols and flavonoids in the whole plant and plant parts of
teucrium chamaerdys L.var.glanduliferum Haussk. Journal of Medicinal Plants
Research. 2010;4(19).
407. Camarda I. Ricerche etnobotaniche nel comune di Dorgali (Sardegna centroorientale). Bollettino della Società sarda di scienze naturali. 1990;27:147-204.
408. Rasekh H, Khoshnood-Mansourkhani M, Kamalinejad M. Hypolipidemic
effects of Teucrium polium in rats. Fitoterapia. 2001;72(8):937-939.
409. Shahraki M, Arab M, Mirimokaddam E, Jey-Palan M. The effect of Teucrium
polium (Calpoureh) on liver function, serum lipids and glucose in diabetic male
rats. Iranian Biomedical Journal. 2006;11(1):65-68.
410. Esmaeili M, Yazdanparast R. Hypoglycaemic effect of Teucrium polium:
studies with rat pancreatic islets. Journal of Ethnopharmacology.
2004;95(1):27-30.
411. Panovska T, Kulevanova S, Gjorgoski I, Bogdanova M, Petrushevska G.
Hepatoprotective effect of the ethyl acetate extract of Teucrium polium L.
against carbontetrachloride-induced hepatic injury in rats. Acta Pharmaceutica.
2007;57(2): 241-248.

157
412. Tariq M, Ageel A, Al-Said M. Anti-inflammatory activity of T. polium.
International Journal of Tissue Reaction. 1989;11(4):185-188.
413. Heidari M, Karaminezhad R, Davvand E, Jalali S. Evaluation of the analgesic
effect of Teucrium polium extract in mice. DARU Journal of Pharmaceutical
Sciences. 2001;24(4):277-285.
414. Panovska T, Kulavanova S, Stefavo M. In vitro antioxidant activity of some
Teucrium species (Lamiaceae). Acta Pharmaceutica. 2005;55(2):207-214.
415. Hasani P, Yasa N, Vosough-Ghanbari S, Mohammadirad A, Dehghan G,
Abdollahi M. In vivo antioxidant potential of Teucrium polium, as compared to
α-tocopherol. Acta Pharmaceutica. 2007;57(11): 123-129.
416. urišić , Vladimir- nežević S, alođera Z, Grgić . Determination of
selenium in Teucrium species by hydride generation atomic absorption
spectrometry. Zeitschrift für Naturforschung C. 2003;58(1-2): 143-145.
417. Stanković M, Topuzović M, Marković A, Pavlović D, Solujić S, ićiforović N
et al. Antioxidant Activity, Phenol and flavonoid contents of different
Teucrium Chamaedrys L. extracts. Biotechnology & Biotechnological
Equipment. 2010;24(2):82-86.
418. Piozzi F. The Diterpenoids
1981;15(2):1489-1503.

of

Teucrium

Species.

Heterocycles.

419. Rudolf Pfaendler H, Piozzi F, Rodriguez B, Savona G. Advances in the
chemistry of the Furanoditerphenoids from Teucrium species. Heterocycles.
1987;25(1):807-841.
420. Piozzi F. Further researches on the furoclerodanes from Teucrium species.
Heterocycles. 1994;37(1):603-626.
421. Piozzi F, Bruno M, Rosselli S. Further furoclerodanes from Teucrium genus.
Heterocycles. 1998;48(10):2185-2203.
422. Acamovic T, Brooker J. Biochemistry of plant secondary metabolites and their
effects in animals. Proceedings of the Nutrition Society. 2005;64(03):403-412.

423. Mulabagal V, Tsay H. Plant cell cultures-an alternative and efficient source for
the production of biologically important secondary metabolites. International
Journal of Application Sciences and Engineering Technology. 2004;2:29-48.
424. Borneo R, León A, Aguirre A, Ribotta P, Cantero J. Antioxidant capacity of
medicinal plants from the Province of Córdoba (Argentina) and their in vitro
testing in a model food system. Food Chemistry. 2008;112(3):664-670.

158
425. Tiwari P, Kumar B, Kaur M, Kaur G, and Kaur H. Phytochemical screening
and extraction: a review. International Pharmaceutica Sciencia. 2011;1(1):98106.
426. Soule H, Maloney T, Wolman S. Isolation and characterization of a
spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer
Research. 1974;50:6075-6086.
427. Soule H, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a
pleural effusion derived from a breast carcinoma. Journal of National Cancer
Institute. 1973;51(5):1409-1416.
428. Cailleau R, Young R, Olive M. Breast tumor cell lines from pleural effusions.
Journal of National Cancer Institute. 1974;53:661-674.
429. Remington JGennaro A. Remington. The science and practice of pharmacy:
Lippincott Williams & Wilkins; 2006.
430. Vaux D, Silke J. Mammalian mitochondrial IAP binding proteins. Biochemical
and Biophysical Research Communications. 2003;304(3):499-504.
431. McCarthy N, Evan G. Methods for detecting and quantifying apoptosis.
Current Topics in Developmental Biology. 1998;36:259-278.
432. Jänicke R. MCF-7 breast carcinoma cells do not express caspase-3. Breast
Cancer Res Treat. 2008;117(1):219-221.
433. Chaitanya G, Alexander J, Babu P. PARP-1 cleavage fragments: signatures of
cell-death proteases in neurodegeneration. Cell Communication and Signaling.
2010;8(1):31.
434. Handa S, Khanuja S, Longo G, Rakesh D. Extraction technologies for
medicinal and aromatic plants. International centre for science and high
technology. 2008;21-25.
435. Ncube N, Afolayan A, Okoh A. Assessment techniques of antimicrobial
properties of natural compounds of plant origin: current methods and future
trends. African Journal of Biotechnology 2008;7(12):1797-1806.
436. Eloff J. Which extractant should be used for the screening and isolation of
antimicrobial components from plants. Journal of Ethnopharmacology.
1998;60(1):1-8.
437. Moure A, Cruz , Franco D, Dom nguez , Sineiro , Dom nguez H et al.
Natural antioxidants from residual sources. Food Chemistry. 2001;72(2):145171.
438. Cowan M. Plant products as antimicrobial agents. Clinical microbiology
reviews. 1999;12(4):564-582.

159

439. Farshori N, Al-Oqail M, Al-Sheddi E, Siddiqui M, Musarrat J, Al-Khedhairy
A. Anticancer activity of chloroform extract and sub-fractions of nepeta
deflersiana on human breast and lung cancer cells: an in vitro cytotoxicity
assessment. Pharmacognosy Magazine. 2015;11(44):598.
440. Kh.A H, Kh S, Y. Yaseen N. Evaluation the activity of chloroform extract of
Solanum nigrum on non Hodgkin Lymphoma cell line (SR), rat embryo
fibroblast cell line (REF) and human lymphocytes in vitro. World Journal of
Pharmacy and pharmaceutical sciences. 2015;4(11):14-22.
441. Ezzat SM, Abdel Motaal A. Isolation of New Cytotoxic Metabolites from
Cleome droserifolia Growing in Egypt. Zeitschrift für Naturforschung C.
2012;67:0266.
442. Abdullah W, Elsayed W, Abdelshafeek K, Nazif N, Singab A. Chemical
constituents and biological activities of cleome genus: A brief review.
International Journal of Pharmacognosy and phytochemical research.
2016;8(5):777-787.
443. Ladhari A, Haouala R, DellaGreca M. A New Dammarane Triterpene from
Cleome arabica. Chemistry of Natural Compounds. 2014;50(4):684-686.
444. Rajabalian S. Methanolic extract of Teucrium polium L. potentiates the
cytotoxic and apoptotic effects of anticancer drugs of vincristine, vinblastine
and doxorubicin against a panel of cancerous cell lines. Experimental
Oncology. 2008;30(2):133-138.
445. Tariq M, Ageel A, al-yahya A, Mossa J, al-said M. Anti-inflammatory activity
of Teucrium polium. International Journal of Tissue Reactions.
1989;11(4):175-188.
446. Bedir E, Tasdemir D, Çalis I, Zerbe O, Otto Sticher. Neo-clerodane
diterpenoids from Teucrium polium. Phytochemistry. 1999;51(7):921-925.
447. Movahedi A, Basir R, Rahmat A, Charaffedine M, Othman F. Remarkable
Anticancer Activity ofTeucrium polium on Hepatocellular Carcinogenic Rats.
Evidence-Based Complementary and Alternative Medicine. 2014;2014:1-9.
448. Hussain J, Rehman N, Khan A, Sang Kim J. Phytochemical and biological
assessment of medicinally important plant Ochradenus arabicus. Pakistan
Journal of Botany. 2014;46(6):2027-2034.
449. Hussain J, Ali L, Khan A, Rehman N, Jabeen F, Kim J et al. Isolation and
Bioactivities of the Flavonoids Morin and Morin-3-O-β-D-glucopyranoside
from Acridocarpus orientalis—A Wild Arabian Medicinal Plant. Molecules.
2014;19(11):17763-17772.

160

Appendix

Figure 1S: The proliferative capacity of MCF- cells.
Increasing numbers of A) MCF- and B) HeLa cells as measured by the MTT
assay. Increasing numbers of cells were plated in microtiter plates in triplicates
and allowed to grow for 2 hours followed by analyzing their proliferative
capacity in the MTT assay. As can be seen, a linear prolife could be observed for
both cell lines between 1562 and 25,000 for MCF- and and between 1562 and
50,000 cells per well for HeLa cells. Based on this data, 5,000 cells per well was
chosen to analyze cell viability of treated and untreated cells in the thesis.

Figure 2S: MDA-MB-231 is the most sensitive to the killing by Boswellia sacra essential oil.
Various dilutions of the essential oil were tested using the MTT assay on A) MCF-10A, B) MCF-7, C) MDA-MB-231, and D)
HeLa cells after 24 and 72 hours. Dose-dependent effect of Boswellia sacra on cell viability as a percentage of untreated cells
for E) the 24 hour and F) 72 hour time points for all four cell lines tested. * indicates statistically significant differences between
the control and treated samples (* = p<0.05; ** p<0.01; *** = p<0.001). The significance shown in panels A-D is between the
DMSO-control and essential oil-treated samples. The full figure is shown in Figure 8 of the thesis.
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Figure 2S: continued
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Figure 3S: Cytotoxic effects of different concentrations of Cleome droserifolia.
MTT assay on A) MCF-10A, B) MCF- , C) MDA-MB-231, and D) HeLa cells after 24, 48, and 2 hours post treatment.
* indicates statistically significant differences between the control and treated samples (* = p<0.05 ** p<0.01 *** =
p<0.001). The significance shown in panels A-D is between the DMSO-control and extract-treated groups. The full figure
is shown in Figure 15 of the thesis.

163

Figure 3S: continued
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Figure 4S: Cytotoxic effects of different concentrations of Teucrium muscatensis.
MTT assay on A) MCF-10A, B) MCF- , C) MDA-MB-231, and D) HeLa cells after 24, 48, and 2 hours post treatment. *
indicates statistically significant differences between the control and treated samples (* = p<0.05 ** p<0.01 *** = p<0.001).
The significance shown in panels A-D is between the DMSO-control and extract-treated groups. The full figure is shown in
Figure 16 of the thesis.
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Figure 4S: continued
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Figure 5S: Cytotoxic effects of different concentrations of Orchadenus arabicus.
MTT assay on A) MCF-10A, B) MCF- , C) MDA-MB-231, and D) HeLa cells after 24, 48, and 2 hours post treatment.
* indicates statistically significant differences between the control and treated samples (* = p<0.05 ** p<0.01 *** =
p<0.001). The significance shown in panels A-D is between the DMSO-control and extract-treated groups. The full figure
is shown in Figure 1 of the thesis.
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Figure 5S: continued
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Figure 6S: Cytotoxic effect of different concentrations of Acredocarpus orientalis (L).
MTT assay on A) MCF-10A, B) MCF- , C) MDA-MB-231, and D) HeLa cells after 24, 48, and 2 hours post treatment. *
indicates statistically significant differences between the control and treated samples (* = p<0.05 ** p<0.01 *** = p<0.001).
The significance shown in panels A-D is between the DMSO-control and extract-treated groups. The full figure is shown in
Figure 18 of the thesis.
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Figure 6S: continued
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Figure S: Cytotoxic effect of different concentrations of Acredocarpus orientallus (S).
MTT assay on A) MCF-10A, B) MCF- , C) MDA-MB231, and D) HeLa cells after 24, 48, and 2 hours post treatment.
* indicates statistically significant differences between the control and treated samples (* = p<0.05 ** p<0.01 *** =
p<0.001). The significance shown in panels A-D is between the DMSO-control and extract-treated groups. The full
figure is shown in Figure 19 of the thesis.
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